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Abstract 
 
The metabolic syndrome represents a state of insulin resistance, which has drawn great 
attention due to its public health importance. A quarter of the world’s adult population are 
considered to have the metabolic syndrome (Moadab et al. 2009).  
Despite having a striking phenotypic similarity with patients with Cushing’s syndrome, those 
with the metabolic syndrome have normal circulating cortisol levels. It has been proposed that 
these patients have dysregulated cortisol metabolism with either increased glucocorticoid 
activation or reduced inactivation at a tissue level.  Since this may be amenable to therapeutic 
manipulation there has been an intense focus on the microsomal enzyme 11-hydroxysteroid 
dehydrogenase type 1 (11-HSD1) which activates cortisone to cortisol in vivo.  
Through a series of in vitro and detailed translational studies, this thesis attempts to 
investigate hepatic glucocorticoid metabolism with relevance to the pathophysiology of the 
metabolic syndrome. The hepatic zonation and characterization of 11-HSD1 was defined. 
The relation between glucocorticoid metabolism and glucose homeostasis was analysed with 
relevance to body composition in normal, obese and type 2 diabetic human subjects. Glucose 
6 phosphate was identified as a novel direct link between glucose metabolism and the HPA 
axis.  Hepatic glucocorticoid metabolism and its role in the pathogenesis of alcoholic liver 
disease and non alcoholic fatty liver disease were defined.  
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1. Introduction 
1.1. Overview 
The metabolic syndrome represents a state of insulin resistance that is also known 
either as syndrome X or the dysmetabolic syndrome, which has drawn great attention 
due to its public health importance. A quarter of the world‟s adult population are 
considered to have the metabolic syndrome (Moadab et al. 2009).  
The metabolic syndrome collectively characterises a group of closely linked 
disorders, including obesity, insulin resistance, hypertension, dyslipidaemia, type 2 
diabetes and hepatic steatosis, and relates to a loss of insulin sensitivity in key target 
tissues including adipose, liver and muscle (DeFronzo and Ferrannini 1991;Roden 
2004).   Additional risk factors include polycystic ovarian syndrome (Anon 2005) and 
ethnic groups at high risk for type 2 diabetes and coronary artery disease. 
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Patients with circulating cortisol excess due to increased endogenous production 
(Cushing‟s syndrome) or exogenous corticosteroid use develop a classical phenotype 
which is remarkably similar to the obesity - metabolic syndrome, and which is 
reversible upon removal of glucocorticoid excess. However, unlike patients with 
Cushing‟s syndrome, those with the metabolic syndrome have normal circulating 
cortisol levels. At a tissue level however, it has been proposed that these patients have 
dysregulated cortisol metabolism with either increased glucocorticoid activation or 
reduced inactivation.  Since this may be amenable to therapeutic manipulation there 
has been an intense focus on the microsomal enzyme 11-hydroxysteroid 
dehydrogenase type 1 (11-HSD1) which activates cortisone to cortisol in vivo.  
This thesis attempts to investigate hepatic glucocorticoid metabolism with relevance 
to the pathophysiology of the metabolic syndrome. 
1.2. The Metabolic Syndrome 
The metabolic syndrome describes the clustering of dyslipidaemia, hypertension, 
glucose intolerance and central adiposity. It was first described by Reaven in 1988 
who postulated that insulin resistance was the cause of glucose intolerance, 
hyperinsulinaemia, increased VLDL, decreased HDL and hypertension (Ferrannini et 
al. 1997;Reaven 1988).  Since then it has been realised that obesity is the usual 
underlying cause for insulin resistance that leads to the metabolic abnormalities. 
Hyperuricemia, fatty liver (especially in concurrent obesity) progressing to non-
alcoholic fatty liver disease, polycystic ovarian syndrome (in women), and acanthosis 
nigricans are diseases all closely related to the metabolic syndrome. The metabolic 
syndrome appears in all ethnic groups, affecting young and old, males and females.  
The cardiovascular risk associated with abdominal obesity („apple‟ distribution) is 
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greater than with the gluteofemoral („pear‟) distribution of body fat seen in women.  
This may explain why obesity has a more atherogenic effect in men compared with 
women (McGill, Jr. et al. 2002;Sakkinen et al. 2000).  A recent study examining the 
association of BMI, waist circumference and waist:hip ratio with the risk of death in 
nearly 360,000 subjects found that after adjustment for BMI, waist circumference and 
waist:hip ratio were strongly associated with the risk of death (Pischon et al. 2008). 
There have been several criteria published for the diagnosis of the metabolic 
syndrome.  The most widely used are the World Health Organisation (WHO) criteria 
(Alberti and Zimmet 1998): central obesity with a waist: hip ratio above 0.9 for men 
and 0.85 for women and/or a body mass index (BMI) above 30 kg/m
2
, blood pressure 
above 140/90 mmHg, triglycerides above 1.7 mmol/L, HDL cholesterol <0.9 mmol/L 
in men and <1 mmol/L in women, glucose fasting or 2 h after a glucose load above 
7.8 mmol/L and glucose uptake during hyperinsulinaemic euglycaemic clamp in the 
lowest quartile for population. 
There have been several proposed modifications to the WHO criteria since 1998, most 
of which have been less strict and have focussed around central obesity as the most 
important and essential criterion.  Most European and American studies have found a 
prevalence of between 12 and 25% (Ford et al. 2002;Mokdad et al. 2003;Villegas et 
al. 2003).  Asian studies have found a lower prevalence of between 5 – 16% (Gupta et 
al. 2003).  All of these patients are at high risk of developing diabetes and 
cardiovascular disease (CVD) and the unifying aim is early intervention with 
intensive lifestyle modification that may ultimately prevent the progression to these 
deadly and costly diseases (Lakka et al. 2002). 
The extremely complex pathophysiology of the metabolic syndrome has only been 
partially elucidated but is largely accounted for by common factors that reinforce the 
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interactions between insulin resistance and obesity, and which are also potential 
targets for therapy.  Insulin resistance in these patients appears to be directly linked 
with ischaemic heart disease (Haffner et al. 1999).  
Patients with the metabolic syndrome commonly have a pro atherogenic 
dyslipidaemia, including low HDL and increased triglycerides and small dense LDL 
particles (Steinmetz et al. 2001).  They also have a pro thrombotic and pro 
inflammatory state with increased fibrinogen and platelet activator inhibitor (PAI-1) 
and acute phase reactants, including CRP.  These may directly increase the risk of 
coronary events.  CRP is able to destabilize atherosclerotic plaques and cause plaque 
rupture (Grundy 2002;Morrow and Ridker 2000).  PAI-1 which is released from 
abdominal adipose tissue can increase the thrombotic complications of plaque rupture 
(Sakkinen et al 2000).  The secretory activity of adipose tissue, in particular visceral 
adipose tissue, contributes to the pro thrombotic and pro inflammatory states of the 
metabolic syndrome.  Secretory products (adipokines) include pro inflammatory 
cytokines and other inflammatory markers such as TNFadiponectin, IL-6, resistin 
and leptin.  Visceral fat also shows increased lipolytic activity resulting in an increase 
in circulating free fatty acids (FFA) which promotes insulin resistance in many tissues 
and the development of reservoirs of triglycerides (TG) in liver (via increased FFA 
delivery to the liver via the portal vein) and muscle.  This also increases hepatic 
insulin resistance and the hepatic output of very low density lipoprotein (VLDL). 
1.3. Hepatic glucose and lipid metabolism in health and disease 
The liver plays a central role in carbohydrate metabolism. Disordered hepatic 
carbohydrate metabolism is critically implicated in the pathogenesis of the metabolic 
syndrome.  Hepatic glucose production through the processes of gluconeogenesis and 
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glycogenolysis represents the principal source of glucose for tissues in the fasting 
state (Roden and Bernroider 2003).  The liver also plays an important role in the 
regulation of post prandial glucose concentrations. 
The aim of hepatic glucose homeostasis is to maintain blood glucose concentrations 
within a narrow range (4 – 6 mmol/L) despite widely varying inputs from the 
gastrointestinal tract.  In health this is achieved by a precise dynamic equilibrium 
between glucose utilization and endogenous glucose production (EGP).  This involves 
a series of intracellular metabolic events which are regulated by hormones, in 
particular glucose and insulin, and metabolites such as glucose, free fatty acids (FFA) 
and carbon-3 compounds such as alanine, lactate and glycerol. 
The recent development of non invasive techniques such as isotopic tracer dilution, as 
used in this thesis, and nuclear magnetic resonance spectroscopy (NMRS), have 
allowed detailed assessment of glucose and glycogen metabolism that was previously 
not easily possible in humans (Radziuk and Pye 2002;Roden et al. 2001).  
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1.3.1. Applied liver anatomy 
  
Figure 1-1  The blood supply to and from the liver (image from medline plus online 
encyclopedia) 
Approximately 80% of the blood supply to the liver is received from the portal vein 
(formed by the superior mesenteric and splenic veins) with the remainder coming 
from the hepatic artery.  As the portal vein drains the intestinal vessels, the liver is 
well exposed to all the water soluble nutrients absorbed from the gut.  Lipid soluble 
products of digestion are delivered to the liver via the thoracic duct. The pancreatic 
vein drains into the portal vein directly immediately exposing the liver to insulin and 
glucagon released from the pancreas. Nearly 50% of the insulin secreted is cleared by 
the liver before reaching the systemic circulation via the hepatic vein.  Hence much 
higher concentrations of insulin exert an immediate effect upon hepatic cellular 
receptors than anywhere else via the systemic circulation.  This reflects the 
substantially lower systemic insulin concentration than would be expected from 
volume dilution alone. 
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Figure 1-2 A cross section of a liver lobule. Blood enters through the portal triad, 
passes through the sinusoids and exits through the central vein. (free 
access image from wikipedia website)  
Hepatocytes form plates that are only one or two cells thick separated from each other 
by large capillary spaces called liver sinusoids.  These structures form hexagonal 
functional units called „lobules‟, Figure 1-2.  There is very specific metabolic 
zonation within the liver lobules.  Periportal cells are primarily involved in 
gluconeogenesis, whereas perivenular cells (those closer to the central vein) are more 
involved with glycolysis and ketogenesis.  Each zone is able to adapt and alter the 
profile of metabolic regulation if needed.  Insulin and glucagon differentially regulate 
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gluconeogenesis and glycolyis, as well as substrate supply to maintain an appropriate 
hepatic response to blood glucose concentrations (Frayn KN 2003).  
1.3.2. Intrahepatic glucose fluxes under normal physiological conditions 
1.3.2.1. Glucose uptake 
In health the portal venous glucose concentration after a meal may approach 10 
mmol/L, much higher than in the systemic circulation.  Hepatocytes take up glucose 
independently of insulin via the low affinity GLUT-2 transporter, which facilitates 
glucose entry into cells in the presence of high sinusoidal glucose concentrations. 
Hence, hepatocytes are in a key position to buffer the hyperglycaemic effects of a 
high carbohydrate meal. It has been proposed that hepatic injury in critical illness 
leads to hyperglycaemia because of unregulated glucose uptake by the liver.  
Hepatocytes are not able to rapidly down regulate glucose uptake to protect vital 
intracellular metabolic functions.  Strict control of blood glucose concentration during 
critical illness protects from hepatic mitochondrial injury and may therefore 
contribute to improved outcomes clinically (Vanhorebeek et al. 2005). 
Once taken up by the liver, glucose is rapidly phosphorylated to glucose-6-phosphate 
(G6P), by the hepatic specific hexokinase isoform, glucokinase.  This reaction is the 
prelude to glycolysis (resulting in the production of 3-carbon compounds such as 
lactate and pyruvate). Alternatively the glucose flux can be directed towards the direct 
pathway of glycogen synthesis via uridine diphosphate (UDP)- glucose, or the pentose 
phosphate shunt, Figure 1-3. 
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Figure 1-3  The fate of glucose in the hepatocyte. 
1
glucokinase, 
2
phosphofructo-1 
kinase, 
3
pyruvate kinase, 
4
phosphoenolpyruvate carboxykinase 
(PEPCK), 
5
fructose-1,6-biphosphatase, 
6
glycogen synthase, 
7
glycogen 
phosphorylase, 
8
glucose-6-phosphatase (Roden & Bernroider 2003). 
1.3.2.2. Glycolytic flux and gluconeogenesis 
Carbon-3 compounds can enter the tricarboxlylic acid (TCA) cycle and undergo 
further oxidation or serve as substrates for de novo synthesis of glucose and glycogen 
(G6Pneogenesis and the indirect/gluconeogenic pathway of glycogen synthesis) 
(Landau 2001).   These processes form substrate cycles, a system which allows fine 
regulation of the direction and rates of flux, by changes in concentration, gene 
expression and convalent modification of effector enzymes (Dohm and Newsholme 
1983;Hue and Bartrons 1984).  Gluconeogenesis substrate cycles are controlled by the 
enzymes phosphoenolpyruvate carboxykinase (PEPCK) and fructose 1,6 
biphosphatase, while glycolytic substrate cycles are regulated by  pyruvate kinase and 
phosphofructo-1-kinase, Figure 1-3. 
1.3.2.3. Glycogen synthesis and glycogenolysis 
Glycogen synthase and glycogen phosphorylase exert another substrate cycle that can 
be active simultaneously, resulting in glycogen cycling.  The effect of this is 
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negligible in the non diabetic fasting state.  Both enzymes are regulated by 
phosphatases, kinases and allosteric effectors which are dependent on the nutrient and 
hormonal microenvironment (Bollen et al. 1998;Villar-Palasi and Guinovart 1997).  
Glycogenolysis requires the action of glycogen phosphorylase and a debranching 
enzyme to release glucose-1-phosphate which is in equilibrium with G-6-P, Figure 
1-3. 
1.3.2.4. Glucose-6-phosphatase and glucose release 
Glucose-6-phosphatase (G6Pase) catalyses the terminal step resulting in the release of 
free glucose into the hepatic veins, from either gluconeogenesis or glycogenolysis, 
Figure 1-3.  It catalyses the dephosphorylation of G6P to glucose.  G6Pase is 
expressed in liver and kidney, G6Pneogenesis can result in glucose release from these 
tissues only. In contrast, skeletal muscle is devoid of G6Pase and therefore cannot 
release glucose from glycogen despite muscle glycogen depots being four to five fold 
greater than in liver. Instead lactate is released from skeletal muscle which is shuttled 
back to the liver via the Cori cycle. G6Pase activity is deficient in patients with 
Glycogen storage disease Type 1a usually diagnosed by the detection of profound 
hypoglycaemia in infancy.  This condition and its impact upon hepatic glucocorticoid 
metabolism are further described in chapter 4. 
1.3.2.5. Insulin and glucagon 
Glucose production by the liver is regulated primarily by insulin, glucagon and 
hyperglycaemia.  Even before there is any carbohydrate induced hyperglycaemia, the 
cephalic phase of insulin secretion primes the liver to rapidly facilitate the hormonal 
responses to eating.  This coupled with the direct delivery of pancreatic hormones to 
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the liver sinusoids allows rapid control and response to nutritional stimuli.  The 
ingestion of a mixed meal also results in an increase in plasma glucagon 
concentration, although a pure glucose load can result in it being unchanged or even 
decreased.  In both situations however, the plasma insulin/glucagon ratio rises due to 
the more marked rise in plasma insulin (McMahon et al. 1989;Mitrakou et al. 1990). 
Under post prandial conditions the portal vein insulin concentration is around 180pM 
which is almost 3 fold higher than in the systemic circulation. This concentration of 
insulin is necessary to half maximally stimulate hepatic glycogen production and 
suppress EGP during periods of hyperglycaemia, much higher than the concentration 
required in the periphery to stimulate the uptake of glucose by cells (DeFronzo et al. 
1983). 
During periods of hypoglycaemia, plasma glucagon concentrations rise causing an 
immediate rise in plasma EGP. Studies using continuous glycogen infusions have 
shown that the immediate rise in EGP is accounted for by hepatic glycogenolysis.  
Following this there is a decline in EGP that is explained by a decrease in 
glycogenolysis due to decreased glycogen stores, and an increase in gluconeogenesis 
(Magnusson et al. 1995).  Glycogen stimulates PEPCK expression and pyruvate 
carboxykinase activity as well as inhibiting pyruvate kinase and phophofructo-1-
kinase (Jiang and Zhang 2003). Even small changes in the portal vein insulin and 
glucagon concentration affect hepatic glycogen synthesis and glycogenolysis, exerting 
a fine control on glucose homeostasis. 
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Figure 1-4 Brief overview of postprandial metabolism of glucose 
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Figure 1-5 Brief overview of intermediary metabolism during fasting 
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1.3.2.6. Hepatic amino acid metabolism is also linked to carbohydrate and 
lipid metabolism 
A high protein intake in humans can induce glucose intolerance as well as increasing 
EGP in the fasting state (Linn et al. 1996). Transamination of unbranched amino acids 
has also been linked to carbohydrate and lipid metabolism. Branched chain amino 
acids and alanine are often elevated in patients with obesity and insulin resistance.  
This may result from a change in the secretion of regulatory hormones and the 
stimulation of gluconeogenesis by amino acids (Felig et al. 1978).  Metabolic studies 
have shown that the rise in EGP as a result of the gluconeogenic effect of post 
prandial amino acid concentrations, is only unmasked when insulin secretion is 
impaired. Hence in subjects with normal glucose tolerance, the stimulatory effect of 
post prandial amino acid concentrations on the secretion of insulin and glucagon 
balances the increase in gluconeogenesis with no significant effect on glycaemia 
(Krebs et al. 2003). 
1.3.2.7. Hepatic carbohydrate metabolism is closely linked to lipid metabolism 
In the fasting state plasma free fatty acid (FFA) concentrations increase and energy is 
derived from fat oxidation.  In insulin resistant states, plasma FFA concentrations 
correlate with the extent of hyperglycaemia and EGP (Bogardus et al. 1984).  The 
liver is able to synthesise and oxidise fatty acids, but lacks the enzymes necessary to 
complete the metabolism of the ketone bodies resulting from mitochondrial -
oxidation.  The balance between glucose and lipid oxidation is coordinated by the 
enzyme malonyl-coenzyme A through its ability to inhibit the entry of acetylated fatty 
acid derivatives into the mitochondria.   Fatty acid synthesis is promoted by insulin.  
Insulin deficiency, with the presence of elevated glucagon levels drives ketogenesis 
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by promoting -oxidation, Figure 1-5. This is the mechanism that drives ketogenesis 
from fatty acids. 
Adipocytes act in conjunction with the liver to convert excess glucose to triglyceride 
for storage. In the liver, triglycerides are formed from glycerol-3-phosphate (from 
triose phosphate) and fatty acids (from acyl CoA), and are incorporated in VLDL, 
where they are hydrolysed by lipoprotein lipase.  The released FFA are re-esterified 
with glycerol-3-phosphate derived from glucose that has entered the tissue under the 
influence of insulin.  The resulting triglyceride is stored in adipose tissue, Figure 1-4. 
1.3.3. The liver in diabetes mellitus 
Insulinopenia in type 1 diabetes results in increased hepatic glucose production that 
correlates with the degree of fasting hyperglycaemia. Increased generation of 
gluconeogenic precursors in peripheral tissues further promote gluconeogenesis.  
Even when exogenous insulin is administered, while hepatic glucose production can 
decrease to normal, slight defects in hepatic glycogen storage persist (Roden & 
Bernroider 2003). 
In type 2 diabetes too, there is evidence for a reduction in glycogen synthesis, 
implying that the increase in hepatic glucose output is mainly a result of increased 
gluconeogenesis.  Isotopic tracer dilution studies have shown that there is a loss of 
autoregulation in patients with fasting hyperglycaemia, as hepatic glucose output rates 
are either inappropriately normal or elevated by 10-25% (Roden & Bernroider 2003). 
The increase in hepatic gluconeogenesis is further fuelled by increased rates of 
lipolysis in adipose tissue, due to impaired insulin action, releasing free fatty acids 
and glycerol which are subsequently delivered to the liver.  Increased hepatic uptake 
of non-esterified fatty acids also promotes hepatic lipid synthesis as well as increased 
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hepatic secretion of VLDL, resulting in the typical type 2 diabetic dyslipidaemic 
phenotype. 
In patients with type 2 diabetes, hepatocytes fail to respond adequately to insulin and 
with lack of suppression of hepatic glucose production. Glucagon levels are also 
inappropriately non-suppressed. This results in glucose entering the circulation from 
the intestine as well as from the liver. Defective glucose uptake by muscle and 
adipose tissue due to insulin resistance adds to the hyperglycaemia resulting in the 
post prandial elevations in serum glucose concentrations. 
1.3.4. Hepatic glucose metabolism in non alcoholic fatty liver disease 
(NAFLD) and liver cirrhosis 
Fatty infiltration of the liver in patients with diabetes was observed as long ago as the 
18
th
 century.  Before the advent of insulin treatment, marked liver enlargement was 
seen in young diabetic patients (Malins J 1968). NAFLD represents the liver 
phenotype of the metabolic syndrome, and covers a spectrum of liver disease ranging 
from simple hepatic steatosis to steatohepatitis (NASH) and eventually cirrhosis.   
NAFLD is strongly associated with visceral obesity, low HDL cholesterol and 
elevated plasma triglycerides. Hepatic steatosis has been appreciated as a mediator of 
atherogenesis and many of the factors that increase cardiovascular risk (Targher 
2007).  Liver fat content has also been shown to be correlated with insulin sensitivity 
and fasting insulin levels.  In fact studies have shown that despite normal fasting 
endogenous glucose production, patients with NAFLD show a reduction in the insulin 
stimulated utilization of glucose, similar to patients with Type 2 diabetes. There was 
also a comparable degree of impairment of insulin-dependent suppression of plasma 
FFA (Marchesini et al. 2001).  
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Hepatocellular lipid concentration, measured by 
1
H-NMRS has been shown to 
correlate with whole body and hepatic insulin resistance and the insulin dependent 
suppression of plasma FFA in non diabetic and type 2 diabetic patients.  In addition, 
prolonged infusion of insulin resulted in an increase in hepatocellular lipid 
concentration (Anderwald et al. 2002a).  These observations suggest that increased 
portal flux of FFA from visceral fat tissue as well as increased portal insulin favours 
hepatic lipid accumulation.  These two factors may be responsible for the hepatic 
steatosis seen in early NAFLD.  Cytokines such as leptin may also play a part in early 
NAFLD by promoting hepatic triglyceride synthesis and stimulating hepatic insulin 
signal transduction (Anderwald et al. 2002b). 
Cirrhosis of any cause predisposes to the development of hepatocellular carcinoma.  
This risk is significantly increased with increased BMI and diabetes.  Over a third of 
patients with obesity related cirrhosis develop hepatocellular carcinoma within 2 years 
(El-Serag et al. 2004).  Insulin resistance in patients with cirrhosis of any cause is well 
documented in the literature.  Diabetic patients with chronic liver disease have lower 
insulin requirements as the disease progresses, and patients with advanced liver 
disease can often have spontaneous fasting hypoglycaemia.  This may reflect reduced 
hepatic insulin extraction due to vascular shunting in cirrhotic patients. In liver 
cirrhosis, plasma concentrations of insulin, glucagon, lactate, FFA, and gluconeogenic 
precursors are increased.  Isotopic tracer studies using 
2
H2O show increased 
gluconeogenesis and a marginal reduction in glycogenolysis indicating a high degree 
of glycogen cycling in these patients.  The rise in plasma insulin, glucagon and free 
fatty acid concentrations may all contribute to glycogen cycling in cirrhosis (Petersen 
et al. 1998;Roden et al. 1996). 
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Treatment of NAFLD is difficult, although intensive lifestyle management and weight 
loss appear to help. Insulin sensitising thiazolidinediones such as pioglitazone, which 
stimulate hepatic nuclear proliferator-activated receptor-γ (PPAR-γ) have been shown 
to improve certain aspects of NASH histology including steatosis (Belfort et al. 2006).  
In animal models, the activation of PPAR-α by fibrates also enhances fatty acid 
oxidation and protects against steatosis.  
This thesis includes a detailed study of metabolic phenotype and steroid metabolism 
in patients with NAFLD.  The role of glucocorticoids in the pathophysiology of 
NAFLD is discussed in chapter 7. 
1.4. Adrenal Steroids 
The principal hormones secreted by the adrenal cortex in physiologically significant 
amounts are the glucocorticoids cortisol and corticosterone, the mineralocorticoid 
aldosterone, and the androgens dehydroepiandrosterone (DHEA) and 
androstenedione.  Cholesterol is the precursor for all adrenal steroid synthesis and is 
derived primarily from LDL in the circulation, and can also be synthesised de novo, in 
the liver from Acetyl-CoA via the mevalonate pathway. Cytosolic cholesterol is then 
transferred to the inner mitochondrial membrane by the steroidogenic acute regulatory 
protein (StaR), a 30kDa phosphoprotein which is the hormonally sensitive rate 
limiting step in steroid biosynthesis in all steroidogenic tissues (Clark et al. 
1994;Stocco 2000).  The importance of this step is exemplified in congenital lipoid 
adrenal hyperplasia which is caused by a homozygous mutation in the StAR gene, and 
characterised by huge lipid accumulation in steroidogenic tissues and severely 
reduced steroidogenesis (Lin et al. 1995). 
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The P450 side chain cleavage enzyme (P450scc) catalyses the initial enzymatic step 
in steroid biosynthesis by converting cholesterol to pregnelonone.  Pregnelonone is 
able to diffuse freely out of the mitochondrion and is made available in the 
endoplasmic reticulum (ER).  A range of enzymes act upon pregnelonone and its 
products in the ER or the mitochondrion, leading via intermediates to the production 
of mineralocorticoids, glucocorticoids and androgens, Figure 1-6. 
Figure 1-6 Schematic of steroid biosyntheis (open access image from wikipedia 
website) 
The ability of cells within the adrenal cortex to generate specific steroids is critically 
dependant on the expression of particular enzymes, and there is subspecialisation in 
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different zones. For example, the synthesis of cortisol and corticosterone from 
deoxycortisol and deoxycorticosterone relies on the presence of the enzyme 11β-
hydroxylase (CYP11B1), whereas the aldosterone production is dependent on the 
activity and expression of aldosterone synthase (CYP11B2).  Aldosterone synthase, 
but not 11β-hydroxylase is present in the outer zona glomerulosa, mainly responsible 
for aldosterone production.  The inner zona fasciculata and reticularis express 11β-
hydroxylase and 17α-hydroxylase and can therefore synthesize corticosteroids sex 
steroids.  In contrast there is no adrenal androgen production in the zona glomerulosa 
due to the lack of 17α-hydroxylase. 
The synthesis of glucocorticoids is regulated by adrenocorticotropic hormone 
(ACTH) released from the pituitary.  ACTH acts to cause an acute increase in the 
activity of the cholesterol ester hydrolase enzyme and the StAR transport protein. The 
long term effect of ACTH results in the up regulation of synthesis of all the enzymes 
involved in steroid biosynthesis.  Hence there is a decrease in adrenal function and 
size with prolonged ACTH deficiency as seen after hypophysectomy, and in 
conditions such as congenital adrenal hyperplasia due to 21-hydroxylase deficiency 
there is hypertrophy of the adrenal gland due to prolonged periods of elevated ACTH.  
ACTH also plays a role in the acute up regulation of aldosterone production and the 
supply of intermediate molecules for aldosterone synthesis.  Aldosterone synthase 
activity and aldosterone secretion however, is primarily regulated by angiotensin II 
(ATII) and serum potassium concentration. 
The primary glucocorticoid synthesised in humans is cortisol, with corticosterone 
produced in a lesser amount (PETERSON and PIERCE 1960).  Corticosterone is the 
predominant glucocorticoid generated in mouse and rat, due to the lack of 17α-
hydroxylase/lyase in rat adrenal cortex.  This difference must be noted when 
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extrapolating results of rodent studies to humans, as functionally significant 
differences in the metabolism of cortisol compared to corticosterone may exist. 
1.4.1. Glucocorticoid secretion 
ACTH secretion from the anterior pituitary stimulates basal glucocorticoid production 
as well as acute increases in glucocorticoid production in response to stress. ACTH is 
a single chain, 39 amino acid polypeptide hormone derived from pro-
opiomelanocortin (POMC) in the pituitary.  Pituitary ACTH production is regulated 
by the hypothalamic hormone, corticotrophin releasing factor (CRF).  Arginine 
vasopressin (AVP), another hypothalamic hormone is able to potentiate the pituitary 
ACTH response to CRF.  
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Figure 1-7 Schematic of the hypothalamo-pituitary-adrenal axis. Positive  and 
negative feedback occur at all levels of the axis 
Cortisol secretion follows a circadian rhythm in response to irregular bursts of ACTH 
secretion throughout the day, with the highest secretion rate at around 0800h and a 
nadir at around 0000h.  This circadian rhythm originates from the hypothalamus in 
response to a number of inputs from other regions of the brain including the 
suprachiasmatic nucleus (the circadian rhythm generator), from where direct 
connections to the paraventricular nucleus of the hypothalamus have been 
demonstrated (Abe et al. 1979;Vrang et al. 1995). 
ACTH release is also influenced by a number of other factors including stress and 
injury, and pro inflammatory cytokines.  Pro inflammatory cytokines appear in part to 
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mediate the stress related cortisol response. In particular, leukemia inhibitory factor 
(LIF) is needed for the stress driven response that results in pituitary POMC mRNA 
expression, increased ACTH and glucocorticoid secretion (Chesnokova and Melmed 
2000). TNFα and interleukin-6 have been shown to directly stimulate the HPA axis by 
direct action at the hypothalamic level by stimulating CRH release, as well as direct 
effects at the level of the pituitary and adrenal (Lyson and McCann 1991;Swain et al. 
1997).  In contrast, corticosteroids inhibit CRF and ACTH release via negative 
feedback, as clearly seen in cases of pharmacologic glucocorticoid excess.  When 
administered for a prolonged period there is a dose and time dependant reduction in 
the ability to generate ACTH which takes a variable amount of time to recover 
(Henzen et al. 2000), Figure 1-7.  These mechanisms allow widely ranging 
differences in cortisol production rates in response to different conditions.  Basal 
cortisol production rates are around 8-12mg/day which can increase 5-fold when the 
HPA axis is stimulated by conditions such as trauma or stress (Esteban et al. 
1991;Salem et al. 1994). 
Cortisol is bound in the circulation to an α-globulin called corticosteroid binding 
globulin (CBG).  There is also a lesser degree of binding to albumin.  As with other 
steroid hormones, only the free (non protein bound) hormone appears to have 
biological activity.  Cortisol and corticosterone are heavily protein bound, such that 
only 5-10% of these hormones are present as free in the circulation, unbound to 
protein.  CBG binding does vary between corticosteroids.  Importantly cortisone 
binding to CBG is considerably less (~50%) than circulating cortisol which is nearly 
95% CBG bound.  Of note 11β-dehydrogenated cortisol and cortisone metabolites 
have much lower binding to CBG (only around 10%).  Hence the bioavailability of 
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these steroids is likely to be significantly greater, for the same circulating level of 
glucocorticoid, then the parent compound. 
1.4.2. Mineralocorticoid secretion 
Mineralocorticoids are secreted in a different manner to that of glucocorticoids, 
Figure 1-8.  Angiotensin II (ATII) and extracellular potassium concentrations are the 
key regulators of aldosterone action.  ATII production is reliant upon the release of 
the enzyme renin from the juxtaglomerular apparatus of the kidney.  Renin release is 
stimulated by a decrease in circulating volume, and / or a reduction in sodium 
delivery to the distal tubule, which is sensed by the macula densa. A decrease in 
pressure of the major capacitance vessels also leads to renin release secondary to 
increased sympathetic stimulation of renal nerves (Gibbons et al. 1984). Renin 
catalyzes the conversion of the hepatic protein angiotensinogen to Angiotensin, which 
in turn is converted to ATII by angiotensin converting enzyme (ACE), a reaction 
which occurs in the lung.  ATII acts upon G-protein coupled cell surface receptors of 
the zona glomerulosa resulting in the stimulation of the enzyme aldosterone synthase 
and subsequent aldosterone production.  The mechanism by which potassium levels 
affect aldosterone production are not entirely clear, but may be secondary to changes 
in intracellular calcium concentrations. Low potassium levels stimulate, and high 
potassium levels inhibit, aldosterone production (Young 1985). 
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Figure 1-8 Schematic illustrating the renin-angiotensin-aldosterone system (free 
access article from wikipedia website) 
1.4.3. Glucocorticoid metabolism 
The major steps in cortisol metabolism are shown in Figure 1-9.  Cortisol can be 
inactivated by conversion to cortisone by the enzyme 11β-hydroxysteroid 
dehydrogenase (11β-HSD).  11β-hydroxysteroid dehydrogenase is one of the main 
topics of this thesis and is discussed in detail in section 1.5. Both cortisol and 
cortisone enter into two main pathways of degradation, the 5α-5β reductases and the 
20β-oxoreductase pathways. Dihydrometabolites are quickly reduced to 
tetrahydrometabolites by 3α- hydroxysteroid dehydrogenase. The tetrahydro-
derivatives are then conjugated to glucuronic acid and subsequently excreted in the 
urine (Cope 1972).  The second pathway involves the enzyme 20β-oxoreductase 
which reduces cortisol and cortisone to their 20β – dihydro derivatives.  These 
derivatives are not known to have any significant glucocorticoid activity, although 
recent preliminary work has shown that 5α-THB has anti-inflammatory properties 
similar to those of corticosterone (B) (Yang C. et al. 2009).  These reactions 
predominantly occur in the liver, but also in other tissue to a lesser extent including 
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adipose tissue, but the contribution of this overall is small compared to hepatic 
glucocorticoid metabolism (Andrew et al. 1998). 
1.4.4. Regulation of Glucocorticoid levels 
Cortisol metabolism is critically linked to the set point of the HPA axis. Circulating 
cortisol levels are maintained as a fine balance between secretion and metabolism.  
Increased cortisol clearance due to an increase in metabolism results in a 
compensatory up regulation of ACTH secretion to maintain circulating cortisol levels.  
A number of factors influence the function of these negative feedback loops (Drouin 
et al. 1993;Kovacs and Mezey 1987).  In particular a functioning glucocorticoid 
receptor (GR) appears to be essential, as animals with defective GR and GR knockout 
animals do not suppress ACTH despite chronically high circulating glucocorticoid 
levels.  While these negative feedback loops appear to control glucocorticoid levels in 
the normal state, it is apparent that central mechanisms can override these controls.  
For example, during periods of physiological and pathological stress there is an 
increase in proinflammatory cytokines such as TNFα and interleukin-1β (IL-1β) 
which cause an increase in cortisol levels via increases in CRF and subsequent 
increases in ACTH secretion.  This altered glucocorticoid negative feedback is 
imperative in mounting an adequate stress response, as illustrated in cases of adrenal 
and pituitary disease, where inability to mount a stress response can result in 
circulatory collapse unless there is pharmacological augmentation of corticosteroid 
therapy. 
Cortisol can be converted to the inactive glucocorticoid cortisone by 11β-
hydroxysteroid dehydrogenase type 1, although in vivo the oxo reductase activity of 
the enzyme predominates, generating active cortisol from inactive cortisone.  Type 2 
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11β-HSD catalyses almost exclusively the conversion of cortisol to cortisone. This 
ability to interconvert cortisol to cortisone places this enzyme as a pivotal pathway in 
controlling the local availibility of active cortisol to bind to the GR.  It is also able to 
protect the mineralocorticoid receptor from illicit occupation by cortisol. 
 
Figure 1-9 The main pathways for glucocorticoid metabolism (Tomlinson and 
Stewart 2001) 
1.4.5. Mechanism of action of corticosteroids 
The conventional view is that corticosteroids (cortisol and aldosterone) exert their 
actions through specific intracellular receptors, glucocorticoid and mineralocorticoid 
receptors (GR and MR) respectively.  More recently, evidence has been presented for 
the existence of cell surface steroid receptors, and second messengers inside cells that 
may result in steroid induced non genomic actions (Christ et al. 1999).  While there is 
molecular biological evidence of the existence of these cell surface receptors, detailed 
information about them is lacking.  Steroids are also able to facilitate the action of 
GABA receptors by binding to GABAA receptors.  
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The traditional view that steroids exert stereotyped responses for all ligands has also 
been put into question by studies that demonstrate that the oestrogen receptor is able 
to exert a range of actions often opposing, when liganded by molecules with very 
similar structures (Schaufele et al. 2000). These observations have led to the 
awareness that a key component of steroid hormone action involves interaction of the 
ligand with coactivator – corepressor molecules.   
1.4.5.1. Corticosteroid receptors 
Historically, glucocorticoids were thought to bind exclusively to GR and aldosterone 
to MR, and regulate carbohydrate and sodium homeostasis respectively. However, 
following in-vitro observations that both receptors bind to glucocorticoids with high 
affinity, they were classified as Type 1 „high affinity‟ GR (corresponding to the MR) 
and Type 2 „low affinity‟ GR (corresponding to GR).  In this thesis the traditional MR 
and GR classification will be used.  Separate receptors for glucocorticoids and 
mineralocorticoids appear to have occurred via gene duplication late in evolution, 
explaining why they behave in a similar fashion in some circumstances.  This may 
also reflect the utility of pre receptor mechanisms (section 1.4.7.1) in some tissues to 
confer further specificity to these receptors.  Both receptors have similar ligand 
binding properties.  The MR binds cortisol with an equal affinity to that of 
aldosterone (Kd for both ~ 1nM) (Arriza et al. 1987).  The GR binds cortisol and 
corticosterone with a Kd between 20 and 40 nM and aldosterone with a Kd of 25 to 65 
nM (Marver et al. 1981). 
The MR is expressed in target tissues such as epithelia of renal distal tubules, salivary 
glands and distal colon, as well as within the central nervous system (CNS), in the 
placenta and foetal tissues, and in bone cells.  The GR is widely expressed in tissues 
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involved in glucose homeostasis, such as liver, adipose tissue and muscle, as well as 
bone cells and cells in the immune system. 
There has been detailed investigation into the actions of glucocorticoid hormones.  
Steroid binding to the cytosolic GRα receptor results in the activation of the steroid 
receptor complex involving the dissociation of heat shock proteins HSP90 and HSP70 
(Hutchison et al. 1993). The initial dissociation is with HSP70 followed by two HSP 
90s.  HSP90 organising protein (hop) acts as a scaffold holding the complex together. 
Once the steroid hormone has been translocated to the nucleus, there is stimulation or 
repression of gene transcription by binding of the complexes to glucocorticoid 
response elements  in the promoter regions of target genes (Beato et al. 1996).  
Nuclear localization sequences (NLS) are obscured by chaperone proteins but are 
exposed on hormone binding which causes the chaperone proteins to dissociate.  The 
NLSs allow protein interaction at the nucleopore enabling transport into the nuclear 
compartment.  There may be additional nuclear chaperone proteins that direct the 
receptors to specific nuclear sub-compartments (DeFranco 2000).  
In addition to the classical GRα, an alternative isoform GRβ can be generated by 
alternative splicing of the human GR gene, which differs by one amino acid at the C-
turminus (Vottero 1999).  GRβ may act as a dominant negative regulator of GRα 
transactivation (Lu and Cidlowski 2004). The GRγ variant has an additional amino 
acid within the DNA binding domain of the receptor protein that may reduce GR 
transactivation (Lu & Cidlowski 2004).   Critical regions of the receptor responsible 
for binding and transactivation have been highlighted by naturally occurring 
mutations in the GR (patients with glucocorticoid resistance) and in vitro generated 
GR mutants (Hollenberg et al. 1987).  Many other coactivators and corepressors are 
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required that may confer tissue specificity of the response in addition to the many 
hundreds of glucocorticoid responsive genes that have been identified. 
Evidence suggests the GR gene expression may be under the control of more than one 
promoter.  Multiple promoters have been identified in human and rat GR resulting in 
mRNAs for GR with variable untranslated 5‟ sequences (Breslin et al. 2001).  These 
promoters respond differently to glucocorticoid treatment, and may reflect an 
additions level of control over GR expression in different tissues. 
1.4.5.2. Steroid hormone receptor structure 
The typical domains common to steroid hormone receptors are illustrated in Figure 
1-10 along with the corresponding domains in the hGR and hMR.  The DNA binding 
domain is a critical component responsible for binding to the double helix.  The N-
terminal region mediates transactivation functions, and the C-terminal is the ligand 
binding domain.  In reality this model is rather simplistic and activation functions can 
also be mediated by sequences located throughout the receptor, including NLSs and 
sequences mediating receptor dimerisation.  These features are displayed in GR and 
MR. The cDNAs encoding the proteins for human GR and MR are highly 
homologous and share a conserved DNA binding domain with 94% homology and a 
57% homology across the ligand binding domain. (Arriza et al 1987;Hollenberg et al 
1987).  This reflects the promiscuity of ligand binding of aldosterone to the GR and 
cortisol to the MR. The parts of the complex that are responsible for transrepression 
of genes are currently unclear.  Specificity upon the MR is conferred by the process of 
pre receptor metabolism of cortisol by 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2), which inactivates cortisol and corticosterone to inactive 11-keto 
metabolites, allowing aldosterone to bind to the MR (Edwards et al. 1988). 
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Figure 1-10 Schematic of steroid hormone structure with the N-terminal 
transactivation, DNA binding and steroid binding domains.  The 
corresponding regions of in the human GR and MR are shown with 
amino acid numbers. 
1.4.5.3. Transactivation of genes by corticosteroid receptors 
Transactivation of genes occurs when the GR or MR bind to glucocorticoid response 
elements (GREs) – specific regulatory sequences of DNA which are usually located 
near the promoter region of target genes (Beato et al 1996). The classic GRE 
sequence for GR binding is a partially palindromic structure with the sequence 
GGTACAnnnTGTTCT (where n is any nucleotide).  The consensus sequence for 
negatively regulated genes is less well conserved.  There has been huge investigation 
into the exact mechanism of transactivation and how the binding of the complex to 
GREs affects gene transcription. Dimerisation of the steroid-GR complex is required 
for transactivation. This has been shown in vitro and in transgenic dimerisation 
deficient transgenic animals (Reichardt et al. 1998;Touray et al. 1991).  
In addition to interaction of DNA binding and activation domains of the receptor with 
GREs, gene transcription relies on a number of other vital components. These include 
general transcription factors and coactivator or corepressors that initiate or repress 
transcription.  Coactivators are thought to be involved in the linking of the hormone 
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receptor to general transcription factors and in chromatin remodelling during 
assembly of the transcription complex (Beato et al 1996).   
There is no known classic response element for the MR.  However MR is able to bind 
to the GRE and a number of genes appear to be induced both by MR and GR e.g. 
serum and glucocorticoid inducible kinase (Sgk), a key gene of mineralocorticoid 
hormone action (Chen et al. 1999).  Some genes respond differently depending on 
whether GR or MR binds to GRE.  These differences are likely to be due to 
differences in the recruitment of coactivators and corepressors.  Studies have also 
shown that GR and MR are able to heterodimerise with each other.  These 
heterodimers appear to have different effects to GR or MR homodimers at the GREs 
of several genes.  For example corticosteroid induced gene transcription of the 
neuronal serotonin receptor was greater with GR/MR heterodimers than with GR or 
MR homodimers (Ou et al. 2001). 
1.4.5.4. Transrepression of genes by corticosteroid receptors 
Transrepression of genes is critical to restrict gene expression so only a subset of 
genes are expressed in a particular cell type and exert a degree of tissue specificity.  
The process of transrepression occurs via protein-protein interactions. GR associates 
with other transcription factors via leucine zipper interactions.  Binding of a repressor 
to the activator can mask its transactivational ability.  This type of repression is called 
quenching, an example of which is the interaction of the GR with members of the 
bZIP FOS and JUN family of transcription factors, constituting the AP-1 complex. 
GR acts as a repressor by adjacent binding to the AP-1 factors or tethering to AP-1 
factors bound to the composite element, quenching activation by AP-1 (Meyer et al. 
1993).  This process is of particular importance in the anti-inflammatory effects of 
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glucocorticoids, by negative regulation of the expression of several genes involved in 
the inflammatory cascade, by interaction with AP-1 and nuclear factor kappa B (NF-
κB). NF-κB is a key regulator of several inflammatory processes and can act as an 
amplifier of inflammatory pathways, and interaction of GR with NF-κB effects a 
significant anti inflammatory action.  MR is also able to interact with AP-1 and NF-
κB, although the relevance of this finding is unclear but may be important in the role 
of the MR in the pathogenesis of cardiovascular disease (Kolla and Litwack 2000). 
1.4.6. Glucocorticoid action 
The multiplicity of glucocorticoid function makes it difficult to unravel action at both 
the cellular and tissue level.  Some effects are permissive in nature where 
glucocorticoids allow the process to occur but do not initiate them directly.  Other 
effects which are difficult to investigate are the specifics of the glucocorticoid 
response to stress and circadian rhythm, both of which are difficult to reproduce in-
vitro.  At a cellular level glucocorticoids affect cell proliferation, differentiation and 
cell death/survival. The major effects of glucocorticoids are illustrated in Figure 1-11. 
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Figure 1-11 Diagram illustrating the effects of glucocorticoids on tissues and organ 
systems 
There is a significant attraction in the development of synthetic glucocorticoids that 
exert therapeutic effect without the undesired side effects.  The discovery of 
fludrocortisone which has salt retaining activity out of proportion with its 
glucocorticoid activity was one such achievement.  However the development of a 
steroid anti inflammatory agent devoid of the effects on intermediary metabolism is 
still awaited.  Most of our understanding of glucocorticoid action comes from 
studying the effects of glucocorticoid excess or deficiency.  Excess glucocorticoids 
leads to a constellation of signs described as Cushing‟s syndrome.  The features of 
this syndrome are similar regardless of whether the cause is from excess endogenous 
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glucocorticoid production (from an ACTH secreting pituitary adenoma or a 
glucocorticoid secreting adrenal adenoma) or exogenous use.  Some features are more 
likely to occur with endogenous Cushing‟s syndrome due to the production of adrenal 
androgens and hormones with mineralocorticoid activity (such as 
deoxycorticosterone). Cushing‟s syndrome is characterised by truncal obesity, 
supraclavicular fat pads, buffalo hump, moon face, hirsutism, dark striae, easy 
bruising, osteoporosis, hypertension and proximal myopathy.  Biochemical analysis 
reveals evidence of impaired glucose tolerance (or overt diabetes) and hypokalaemic 
alkalosis may also be present. Neutrophil leucocytosis with lymphocytopaenia with 
decreased eosinophils is also often seen.  The features of Cushing‟s syndrome are 
described in detail below. 
1.4.6.1. Effects of glucocorticoids on carbohydrate, protein and lipid 
metabolism 
The inability of adrenalectomized animals to maintain hepatic glycogen stores was 
noted in 1927 by Cori (Cori and Cori 1927). Replacement of adrenocortical steroids 
returned hepatic glycogen stores to normal and reversed hypoglycaemia.  
Glucocorticoids promote glycogen deposition in the liver by activating glycogen 
synthase (by promoting its dephosphorylation) and inactivating glycogen 
phosphorylase (involved in glycogen mobilisation) (Hornbrook et al. 1966;Stalmans 
and Laloux 1979). 
Glucocorticoids are directly able to increase hepatic glucose production.  This occurs 
by activation of key hepatic gluconeogenic enzymes such as glucose-6-phosphatase 
and PEPCK.  Interaction of the glucocorticoid receptor complex with a GRE located 
in the 5‟ flanking region of the PEPCK gene mediates glucocorticoid induced gene 
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transcription (Exton 1979;Magnuson et al. 1987).  Glucocorticoids also exert a 
secondary effect by increasing substrate availability to increase hepatic glucose 
production by promoting the release of glucogenic amino acids from peripheral 
tissues such as skeletal muscle, an effect which is particularly apparent when 
glucocorticoids are replaced in adrenalectomised animals (Exton 1979). 
Glucocorticoids also promote hepatic glucose production by exerting a permissive 
effect upon other gluconeogenic hormones such as adrenaline and glucagon, and 
increase the sensitivity of target tissues to respond to catecholamines to increase 
substrate for glucose production. For example, glucocorticoids increase sensitivity of 
catecholamines to lipolysis in target tissues (Exton 1979).  Glycerol and FFA released 
from lipolysis provides substrate and energy for hepatic glucose production.  
Glucocorticoids also increase sensitivity to glucagon action but the mechanism for 
this has not yet been elucidated (Exton 1979).  
The effects of glucocorticoids on peripheral glucose utilization further promote the 
hyperglycaemic state that can often result from glucocorticoid administration.  
Glucose transport into cells and utilisation by peripheral tissues is inhibited.  A 
decrease in glucose transporters in adipose tissue is associated with decrease in 
transporter mRNA levels (Garvey et al. 1989). 
Glucocorticoids affect lipid metabolism by directly activating lipolysis in adipose, 
increasing serum FFA, and hence FFA delivery into the circulation.  In 
adrenalectomised animals FFA levels and lipolysis are reduced, and return to normal 
2 hours after glucocorticoid administration.  The molecular mechanism for this is not 
yet known but may occur by a permissive effect upon sensitivity to lipolytic 
hormones such as human growth hormone (hGH) and catecholamines (Fain 1962).  
The chronic effects of glucocorticoids on lipid metabolism are well known, with the 
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marked redistribution of body fat.  Deposition of fat is seen over the trunk, anterior 
mediastinum and mesentery, as well as dorsocervial and supraclavicular regions, with 
sparing of the extremities.  The mechanism underlying this central predisposition is 
not understood but may be related to increased lipogenesis from the 
hyperinsulinaemia that results from the effects of (HAUSBERGER 1958).  
Glucocorticoids stimulate adipocyte differentiation and adipogenesis via key 
differentiation genes including lipoprotein lipase, glycerol-3-phosphate 
dehydrogenase and leptin (Hauner et al. 1989). Centripetal obesity and weight gain 
are extremely common in patients with Cushing‟s syndrome.  The deposition of 
visceral and central adipose tissues provides a useful discriminatory sign in the 
diagnoses of Cushing‟s syndrome (Rebuffe-Scrive et al. 1988). Generalised obesity is 
more common among the general population than in patients with Cushing‟s 
syndrome. This predisposition to visceral obesity may also relate to the increased 
expression of GR and 11β-HSD type 1 (generating active cortisol from inactive 
cortisone) in omental compared with subcutaneous tissue (Bujalska et al. 1997). 
1.4.6.2. Anti-inflammatory actions and effects on immunologic function 
Immunologic responses are suppressed by glucocorticoid excess, an observation 
which provided the stimulus to develop potent glucocorticoids for treatment of a wide 
range of inflammatory and autoimmune conditions, and organ transplantation. Latent 
infections such as tuberculosis may be reactivated by glucocorticoid administration 
(Graham and Tucker, Jr. 1984) and has been reported as a presenting feature of 
Cushing‟s disease. Wound infections and poor wound healing are also common with 
glucocorticoid excess.  Numerous effects of glucocorticoids upon the components of 
the immune and inflammatory response have been documented but the determination 
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of which are most relevant to the physiological role of glucocorticoids in 
immunomodulation is yet to be shown.  
Glucocorticoids alter the trafficking of immune cells to and from the immune system. 
Redistribution of lymphocytes from the intravascular compartment to the spleen, 
lymph nodes, and bone marrow results in an acute reduction in lymphocyte counts (T 
cells > B cells) (Yu et al. 1974).  In addition glucocorticoids act directly on T and B 
lymphocytes to inhibit immunoglobulin synthesis and stimulate lymphocyte apoptosis 
(McKay and Cidlowski 1999).  Inhibition of cytokine production from lymphocytes is 
mediated through inhibition of NF-κB by the process of transrepression (section 
1.4.5.4). Neutrophil counts increase and eosinophil counts fall rapidly, an effect that 
historically was used as a bioassay for glucocorticoids.   
In addition glucocorticoids exert anti inflammatory effects by inhibiting monocyte 
differentiation into macrophages, and macrophage phagocytosis and cytotoxic 
activity.  The local inflammatory response is also reduced by preventing the action of 
histamine and plasminogen activators.  Prostoglandin synthesis is impaired by the 
induction of lipocortins that inhibit phospholipase A2 activity. 
1.4.6.3.  Effects on skin, musculoskeletal and connective tissue and calcium 
metabolism 
Glucocorticoids cause catabolic changes in muscle, skin and connective tissue.  In 
skin and connective tissue there is inhibition of the synthesis of extracellular matrix 
components, epidermal cell division, and DNA synthesis.  The effects of 
glucocorticoids on intermediary metabolism in skeletal muscle described earlier 
(section 1.4.6.1) results in a marked catabolic effect on muscle protein, the basis of 
the profound myopathy that can result from glucocorticoid excess. 
Chapter 1  Introduction 
38 
 
With around 1% of the western population taking chronic glucocorticoid therapy, 
rising to 2.5% of adults aged 70-79 (van Staa et al. 2000), osteoporosis induced by 
glucocorticoids is a prominent health issue. Chronic glucocorticoid excess causes 
osteopenia and osteoporosis by inhibiting osteoblast function (Canalis 1996).  A 
negative calcium balance is also induced by inhibiting intestinal calcium absorption 
and increasing renal excretion of calcium.  This results in increased parathyroid 
hormone secretion.  
Patients with longstanding Cushing‟s syndrome often have loss of height due to 
osteoporotic vertebral collapse. Pathologic fractures are also not uncommon.  Rib 
fractures are often painless and heaped up callus formation is seen on radiography.  
Aseptic necrosis of the femoral and humeral heads is a known feature of high dose 
corticosteroid treatment and can occur in Cushing‟s syndrome. Hypercalciuria can 
cause renal calculi. 
1.4.6.4. Effects on salt and water homeostasis and blood pressure control 
As discussed in section 1.4.5.2 glucocorticoids have a natural affinity for MR, but the 
presence of 11β-HSD2 in mineralocorticoid target tissues minimises this action.  
Glucocorticoids however have a direct effect upon blood vessels, increasing the 
pressor response to angiotensin II (ATII).  Indeed vascular mortality is the major 
cause of death among patients with untreated Cushing‟s disease (Boscaro et al. 2001). 
Glucocorticoids are important in the ability of the kidneys to clear free water.  
Impaired free water clearance accounts for the hyponatraemia seen clinically with 
glucocorticoid deficiency (Ahmed et al. 1967;Mandell et al. 1980).  This is mediated 
by AVP- dependant and independent mechanisms.  A reduction in glucocorticoid 
levels results in increased AVP synthesis in the hypothalamus and inappropriately 
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raised plasma AVP levels for the serum osmolality (Davis et al. 1986). 
Glucocorticoids also enhance the sensitivity of the collecting ducts to AVP (Davis et 
al 1986). 
1.4.6.5. Effects on mood and the central nervous system 
The most evident effect of glucocorticoid excess in the CNS is the effect on mood 
which can range from mild euphoria to frank psychosis, as well as depression.  50% 
of patients with Cushing‟s syndrome have psychiatric abnormalities regardless of 
cause. 
1.4.6.6. Endocrine effects 
Glucocorticoids suppress the thyroid axis, via direct inhibition of thyrotropin 
secretion and inhibition of 5‟ deiodinase activity (which mediates the conversion of 
thyroxine to triiodothyronine). Growth hormone secretion is reduced as well as GnRH 
pulsatility and leutinizing hormone and follicle stimulating hormone release, 
underlying the amenorrhoea and hypogonadism seen in Cushing‟s syndrome (Saketos 
et al. 1993).  Gonadal dysfunction is very common in Cushing‟s syndrome with 
cortisol directly inhibiting the function of Leydig cells.  In females there is menstrual 
irregularity, hirsutism and acne. These effects reflect the suppression of the pituitary 
thyroid, and pituitary gonadal axis seen in Cushing‟s patients.   
1.4.6.7. Pseudo-Cushing’s Syndrome 
Pseudo-Cushing‟s syndrome represents a condition with all or some of the clinical 
features of Cushing‟s syndrome, combined with biochemical evidence of 
hypercortisolism, and disappearance of the Cushingoid-like features with resolution of 
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the underlying disorder.  Common causes include depression, alcoholism and obesity. 
Depressed patients with symptoms severe enough to require hospitalization, can have 
all the hormonal abnormalities of Cushing‟s syndrome, including the characteristic 
responses with dynamic testing of the pituitary adrenal axis.  Generally, depressed 
patients do not have the clinical signs of Cushing‟s syndrome and hence are fairly 
easy to distinguish. In addition circadian rhythm of ACTH and cortisol secretion is 
maintained.  However the ACTH pulse frequency may be increased with the resulting 
cortisol pulses being of greater amplitude and duration (Carroll et al. 1976).  Patients 
with Cushing‟s syndrome however are frequently depressed, and hence careful 
clinical and biochemical investigation is required. 
Alcoholic pseudo-Cushing‟s is rare and is seen in patients with chronic heavy alcohol 
intake with clinical and biochemical evidence of chronic liver disease.  The 
pathogenesis of this condition has remained much of a mystery. Some studies have 
shown that alcohol directly stimulates cortisol secretion. HPA axis function appears to 
vary depending on whether testing is carried out after acute alcohol consumption, 
acute withdrawal and long term abstinence (Groote and Meinders 1996). Vasopressin 
levels are also elevated with decompensated liver disease and may directly stimulate 
the HPA axis. This condition is discussed in further detail in section 1.5.3.3 and was 
part of a detailed clinical and in-vitro analysis as part of the work for this thesis, 
described in chapter 5. 
A common endocrine referral is the request to exclude an underlying endocrine cause 
in a patient with obesity.  Patients with obesity may have mildly elevated cortisol 
secretion rates secondary to HPA axis activation (Glass et al. 1981;Ljung et al. 1996). 
Urinary free cortisol concentrations are only mildly elevated and circulating cortisol 
levels are invariably normal.  This may be related to reduced hepatic cortisone to 
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cortisol conversion by 11β-HSD1 and increased cortisol clearance by hepatic A ring 
reductases, resulting in stimulation of the HPA axis (Andrew, Phillips, & Walker 
1998;Stewart et al. 1999). 
1.4.7. Determinants of tissue sensitivity to glucocorticoids 
Studies have failed to show a clear relationship between serum glucocorticoid level 
and the effect on tissues, suggesting that there are factors intrinsic to tissues that are 
important in determining tissue sensitivity to glucocorticoids.  These differences 
could occur at a number of levels, including changes in the concentration and affinity 
of GR or any of the steps involved in the formation of the steroid-receptor complex, to 
translocation to the nucleus and modulation of transactivation or transrepression of 
genes.  The action of glucocorticoid transporters may also be involved in regulating 
intracellular glucocorticoid levels.  The major part of this thesis relates to the 
expression and activity of hepatic glucocorticoid metabolising enzymes in health and 
disease related to the metabolic syndrome.  The 11β-HSD enzymes are major 
candidates for determining tissue sensitivity to glucocorticoids. 
While variation in concentration of glucocorticoid receptors may underlie differences 
in glucocorticoid sensitivity, data suggests that GR variants are not a major factor. 
Mutations in the GR gene have been associated with glucocorticoid resistance.  
Numerous GR-gene variants have been identified, as well as single nucleotide 
polymorphisms (SNP) which are relatively prevalent.  In particular, the GRβ-variant 
has been proposed to influence corticosteroid sensitivity, with evidence derived from 
the immune system and asthma.  Also of relevance are the BcII restriction fragment 
polymorphism and a Asp363Ser which have been identified to influence the 
regulation of the HPA axis and are associated with changes in metabolism and 
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cardiovascular control.  These findings further implicate cortisol in the 
pathophysiology of these disorders. Indeed, it has been proposed that a dysregulation 
of the HPA axis, especially during stress is a common underlying abnormality in these 
complex disorders (DeRijk et al. 2002). 
Post receptor variation most probably does occur but is difficult to analyse due to 
sparse knowledge of coactivators and corepressors. Of potential importance are post 
receptor factors such as AP-1 and NF-κB, and other transcription factors that directly 
interact with the GR. An example would include the increase in GR-mediated 
transcription by pro-inflammatory cytokines TNFα and IL-1β seen in several cell 
types (Costas et al. 1996). Very little is known about the impact of variation in 
coactivator/corepressors molecules in modulating glucocorticoid action. 
1.4.7.1.  Pre-receptor metabolism and steroid action 
Pre receptor metabolism as a regulator of steroid action has been seen in several 
tissues, and for several different enzymes.  Enzymatic conversion of steroid in the 
target cell cytoplasm can interconvert hormone between active and inactive forms.  
Examples of enzymes and steroid receptors involved in pre-receptor metabolism are 
shown in Table 1-1.  One clinical example where pre-receptor hormone metabolism is 
crucial relates to androgen action, and on the expression of 5α-reductase type 2 to 
convert testosterone to the more active dihydrotestosterone; lack of this enzyme is a 
cause of pseudohermaphroditism (Walsh et al. 1974).  Androgens are converted to 
oestrogens by the action of aromatase.  Aromatase deficiency has a profound effect on 
skeletal development, resulting in a eunuchoid habitus with low bone mineral density 
that is treatable with exogenous oestrogens (Carani et al. 1997).   
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Enzyme Steroid Receptor Function 
11β-HSD1 Glucocorticoid Activation 
11β-HSD2 Mineralocorticoid Inactivation 
5α - reductase Androgen Activation 
17β – HSD, aromatase Oestrogen Conversion 
1α-hydroxylase Vitamin D Activation 
24-hydroxylase Vitamin D Inactivation 
 
Table 1-1 Steroid receptors and enzymes involved in pre-receptor metabolism 
with the principle function of each enzyme shown in the final column. 
1.5. 11β-hydroxysteroid dehydrogenases 
The 11β-HSD enzymes catalyse a number of reactions, the most predominant being 
the interconversion of cortisol (F) and cortisone (E).  This activity has been described 
in a wide range of tissues (Stewart and Krozowski 1999).  Early in vitro studies 
showed significant amounts of 11β-HSD activity in placenta, kidney and liver, 
although the „set point‟ of the enzyme varied between tissues, being predominantly 
oxidative (F to E) in placenta and kidney and reductase (E to F) in liver (Bush 
1969;Jenkins 1966;Osinski PA 1960).  Subsequent in vivo isotopic studies and 
clinical studies in patients with renal disease demonstrated that the predominant 
reaction the kidney was the conversion of cortisol to cortisone (Bush 1969;Hellman et 
al. 1971;Srivastava et al. 1973). Selective venous catheterisation studies showed 
significantly lower F/E ratios in renal venous blood compared with peripheral blood.  
Hepatic venous blood however had much higher F/E ratios, indicating that in the liver 
the conversion was predominantly of cortisone to cortisol (Walker et al. 1992b).  
These observations are explained by the activity of two distinct isoenzymes of 11β-
HSD, a NADPH dependant type 1 or „liver‟ isoenzyme and a NAD dependant 
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oxidative type 2 or renal isoenzyme. 11β-HSD1 is expressed principally in liver and 
visceral adipose tissue, as well as brain, bone, muscle, gonad, muscle, eye and other 
tissues that express GR (Tomlinson et al. 2004b). This 11β-HSD type 1 enzyme was 
first cloned and sequenced in rats (Agarwal et al. 1989) and humans (Tannin et al. 
1991).  However it was subsequently realised that this enzyme did not co localise with 
MR in the kidney (Rundle et al. 1989), nor could it protect the MR from occupation 
by cortisol. The sequence for the gene of this enzyme was also found to be unchanged 
in patients suffering from a rare inborn cause of hypertension, the syndrome of 
apparent mineralocorticoid excess (AME) (Nikkila et al. 1993).  These observations 
formed the basis for the evaluation of a second 11β-HSD isoenzyme (now designated 
11β-HSD type 2) which is expressed in mineralocorticoid target tissues (Agarwal et 
al. 1994;Albiston et al. 1994), and shown to be mutated in individuals with AME 
(Mune et al. 1995;Whorwood and Stewart 1996;Wilson et al. 1995). 
1.5.1. 11β-Hydroxysteroid dehydrogenase type 2 
11β-HSD2 is a unidirectional NAD dependant enzyme that converts cortisol to 
cortisone, Figure 1-12.  It has a high affinity for cortisol with a Km of 50 nM (100 
times that for 11β-HSD1) and 5nM for corticosterone (Albiston et al 1994;Brown et 
al. 1993;Stewart et al. 1994).    
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Figure 1-12 The conversion of cortisol to cortisone by 11β-HSD2.  This reaction is 
unidierectional for endogenous glucocorticoids and prednisolone. 
The calculated molecular weight for 11β-HSD2 is 44,140 Da, but the purified protein 
migrates at 44kDa on sodium dodecyl sulphate (SDS) purified gels.  The human 11β-
HSD2 protein is 405 amino acids long and the cDNA is 5.3kb long, and the gene is 
located on chromosome 16q22, comprises 5 exons and is 6.2kb in length (Albiston et 
al 1994).  
The enzyme is highly expressed in mineralocorticoid target tissues such as kidney as 
well as surface epithelial cells in the colon, salivary epithelial cells and skin.  In the 
kidney, expression is found in the principal cells of the collecting ducts in the renal 
cortex, most of the medulla and the distal convoluted tubule (Krozowski et al. 
1995;Whorwood et al. 1995). 11β-HSD2 is also strongly expressed in the human 
placental trophoblast, which has a powerful ability to inactivate glucocorticoids.  
Enzyme expression increases to term in human, baboon and rat placenta, but in mouse 
placenta, expression decreases from day 13 (Brown et al 1993;Krozowski et al 
1995;Stewart et al. 1995).   The enzyme is also expressed in foetal tissues, and many 
malignant cell lines.  In all situations the enzyme acts as a high affinity 
dehydrogenase decreasing intracellular corticosteroid levels.  11β-HSD2 is 
Cortisol (F) Cortisone (E)
11β-HSD2
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incorporated into the ER membrane but unlike 11β-HSD1, it has a luminal N-
terminus and cytoplasmic C-terminus (Odermatt et al. 1999). 
The functional role of 11β-HSD2 in mineralocorticoid target tissues is to protect the 
mineralocorticoid receptor (MR) from cortisol, in keeping with its expression in a 
range of mineralocorticoid target tissues. Hence the enzyme has been suggested as a 
mediator of extracellular fluid volume and blood pressure.  Studies have shown a 
variation in 11β-HSD2 activity in hypertensive subjects compared with controls, with 
an increased plasma half life of cortisol and urinary (THF+alloTHF)/THE, indicative 
of decreased 11β-HSD2 activity (Soro et al. 1995;Walker et al. 1993).  Genetic 
studies have shown linkage of microsatellite markers in the 11β-HSD2 gene with salt 
sensitivity, further suggesting the possible importance of 11β-HSD2 in the regulation 
of blood pressure (Agarwal et al. 2000). The importance of 11β-HSD2 in MR 
localization was illustrated by an elegant study which showed that in the presence of 
11β-HSD2, MR is localized to the ER, whereas in its absence it is localized to the 
nucleus (Odermatt et al. 2001).  How ligand selectivity is mediated at the molecular 
level remains somewhat uncertain.  In addition, it is unclear why certain synthetic 
glucocorticoids are not substrates for the enzyme.    
1.5.1.1. Regulation of 11β-HSD2 expression and enzyme activity 
 A number of 11β-HSD2 inhibitors have been identified.  Liquorice and its derivatives 
have been widely studied.  Liquorice has been known to cause mineralocorticoid 
hypertension for many decades, and liquorice excess causes hypertension, 
hypokalaemia and low renin and aldosterone (Conn et al. 1968;Reevers 1946).  It 
became clear that liquorice itself does not possess intrinsic mineralocorticoid activity, 
as it failed to provide mineralocorticoid replacement in patients with Addison‟s 
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disease or in adrenalectomised animals (BORST et al. 1953;CARD et al. 1953).  It 
was subsequently discovered that liquorice and its derivates have extremely low 
affinity for the MR, and in fact inhibit 11β-HSD2, inducing a mild form of „apparent 
mineralocorticoid excess‟, section 1.5.1.2.  Liquorice administration results in an 
increase in urinary (THF+allo-THF)/THE ratio, with increased plasma cortisol half 
life and decreased cortisone levels (Stewart et al. 1987). Glycyrrhizic acid (GI) and its 
hydrolytic product glycyrrhetinic acid (GE) are the active components of liquorice 
that competitively inhibit 11β-HSD2 with a Ki of 5-10nM (Albiston et al 
1994;Stewart, Murry, & Mason 1994).  Carbenoxolone is the  hemisuccinate 
derivative of 18β-GE, and is also a potent 11β-HSD2 inhibitor (Stewart et al. 1990).  
Unlike GI and GE, carbenoxolone does not cause a major change in the 
(THF+alloTHF)/THE indicating that it also simultaneously inhibits 11β-HSD1 
activity. 
Decreased renal 11β-HSD2 activity has been identified as a factor in the cause of 
pregnancy induced hypertension (Heilmann et al. 2001).  This may be due to a 
placentally derived inhibitor of maternal renal 11β-HSD2, or intrinsically low 11β-
HSD2 activity seen in some patients, making them more susceptible to pregnancy 
induced hypertension. 
ACE inhibitors also appear to increase 11β-HSD2 at the enzyme level, thus providing 
an additional mechanism for the action of ACE inhibitors in reducing blood pressure 
(Ricketts and Stewart 1999). 
1.5.1.2. Syndrome of apparent mineralocorticoid excess 
The appreciation of the role of 11β-HSD2 came from the understanding of a rare 
monogenic inherited cause of hypertension, „apparent mineralocorticoid excess‟ 
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(AME).  Defective peripheral conversion of F to E in patients with AME was first 
suggested by Ulick and colleagues (Ulick et al. 1979).  Lack of 11β-HSD2 causes a 
failure of the protective mechanism preventing illicit MR activation, resulting in 
cortisol acting as a potent mineralocorticoid.  These patients however are not 
cushingoid, as normal circulating cortisol mechanisms are maintained due to normal 
negative feedback HPA axis feedback loops, causing a reduction in cortisol secretion 
rates (Stewart et al. 1988). Approximately 100 cases of AME have been identified 
worldwide (Shackleton et al. 1985;Ulick et al 1979).  AME is characterised by low 
renin, low aldosterone hypertension and hypokalaemia.  Patients present in childhood 
or adulthood with severe hypertension and hypokalaemia with suppressed aldosterone 
levels, low plasma renin activity and extended half life of cortisol. The hypertension 
in AME can be treated with the potassium sparing diuretic, spironolactone. 
 
1.5.2. 11β-Hydroxysteroid dehydrogenase type 1 enzymology and gene 
structure  
11β-HSD1 belongs to the short chain dehydrogenase/reductase SDR superfamily of 
enzymes. Members of this family have 250 to 400 residues with an N-terminal 
cofactor binding domain and a centrally located active site. 11β-HSD1 is a bi-
directional enzyme that mediates dehydrogenation or reduction at the 11β position of 
many glucocorticoids, as well as having carbonyl reductase activity (Finckh et al. 
2001;Stewart & Krozowski 1999). In contrast to dehydrogenase activity, reductase 
activity of the enzyme is unstable in vitro (Lakshmi and Monder 1988).  However in 
intact adipocytes and hepatocytes, oxoreductase activity predominates with generation 
of F from E (Bujalska, Kumar, & Stewart 1997;Kotelevtsev et al. 1997). It was 
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subsequently shown that reductase activity predominates unless intact cells are 
disrupted (Duperrex et al. 1993). 
Figure 1-13 11β-hydroxysteroid dehydrogenase type 1 interconverts cortisone and 
cortisol by modification at the 11β-position. 
Kinetic analysis in vitro showed that the enzyme has a higher affinity for E (Km
0.3µM) than F (Km 2.1 µM), in keeping with predominantly reductase activity in vivo,
(Tannin et al 1991).  In some cell types there may be predominantly 11β
dehydrogenase activity according to the physiological or developmental status of the 
particular cells type.  In human omental adipose stromal cells, there is a switch from 
dehydrogenase to reductase activity upon differentiation to adipocytes (Bujalska et al. 
2002).  In neuronal cells too, both dehydrogenase and oxoreductase activity have been 
noted (Jellinck et al. 1999). The location of the 11β-HSD1 enzyme is crucial, facing 
the inner endoplasmic reticulum lumen, which places in proximity with powerful 
generators of the reduced co-substrate NADP phosphate (NADPH). Inclusion of a 
NADPH regeneration system with the enzyme glucose 6 phosphate dehydrogenase 
allows reductase activity to be regained, suggesting that it is the high level of NADPH 
present within the ER lumen that allows reductase activity to predominate in vivo 
(Agarwal et al. 1990).  Studies have also shown that the reactions are pH dependant, 
working optimally at pH 7.0 – 7.4 (Walker et al. 2001). The critical role of providing 
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cofactor to fuel the reductase activity of 11β-HSD1 in the ER is conferred by the 
enzyme hexose-6-phosphate dehydrogenase (H6PDH) (Draper et al. 2003), as shown 
in Figure 1-14. This enzyme also constitutes a novel direct link between glucose 
homeostasis and the hypothalamo-pituitary-adrenal (HPA) axis. Studies relating to 
hepatic steroid metabolism in glycogen storage disease type 1a are described in detail 
in chapter 4, and  highlight the importance of G6P concentrations in the ER lumen in 
determining the set point of 11β-HSD1 activity.  
Figure 1-14 Schematic representation of the interaction between 11β-HSD1 and 
H6PDH in the ER lumen which provdides reductase activity to allow it 
to function as a reductase (cortisone to cortisol). G6PT, Glucose-6-
phosphate translocase; G6Pase, glucose-6-phosphatase; Glucose 6P, 
glucose-6-phosphate; 6PGluconate, 6-phosphogluconolactonate. 
The amino acid sequences of the 11β-HSD1 protein and cDNA were characterised in 
1991 (Tannin et al 1991). The gene is located on chromosome 1 and consists of 6 
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exons, 5 introns, and generates a cDNA encoding a 282 amino acid protein (Figure 
1-15).  The gene was originally thought to be 9kb long but later studies suggested that 
the gene was in fact 30kb long, due to a large intron (>25kb) (Draper et al. 2002). 
Several intronic polymorphisms in the gene have been detected but the coding region 
remains well conserved. 
Figure 1-15 Organization of the human 11ß-HSD1 gene. Open boxes indicate the 
5'- and 3'-untranslated regions, gray shaded boxes indicate coding 
exons (1–6), and intervening solid lines indicate introns (Tomlinson et 
al. 2004) . 
There is a high level of sequence homology between species in particular in the 
cofactor binding region (GASKGIG) and the catalytic site (YSASK).  The single 
hydrophobic N terminal extension preceding the cofactor binding domain anchors the 
protein in microsomes.  The greater part of the 11β-HSD1 protein was found to lie 
within the ER lumen with a short transmembrane and a five amino acid region on the 
cytosolic side.  Experiments with chimeric proteins where the N terminal regions of 
11β-HSD1 and 11β-HSD2 (a cytosolic enzyme) were exchanged, resulted in inverted 
orientation within the ER and inactive proteins (Odermatt et al 1999).  Within the N 
terminal transmembrane domain are critical charge-specific residues (2 positively 
charged lysine residues on the cytosolic side and 2 negatively charged glutamate 
residues) that are crucial to the orientation of the 11β-HSD1 protein in the ER 
membrane.  The lumen of the ER promotes the formation of specific intra-chain 
disulfide bonds in the 11β-HSD1 protein that are important in the protein structure; 
disruption of these is detrimental to enzyme activity (Moore et al. 1993;Ozols 1995).  
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While extracellular glucocorticoid levels can be measured with ease, there is 
relatively little data regarding the intracellular levels of substrates and products for 
11β-HSD1 in the cytoplasm or in the microsome. Any factors that can inhibit the 
metabolism of the 11β-hydroxyl group will increase glucocorticoid potency.  Data 
indicate the importance of the structural conformation of steroidal compounds as 
modifications to these can confer specific inhibitory properties. In addition to its 
important role in glucocorticoid metabolism, 11β-HSD1 mediates the phase 1 
biotransformation of carbonyl group bearing foreign compounds including drugs, 
xenobiotics (Maser and Bannenberg 1994;Oppermann and Maser 2000), and 
carcinogens exerting a protective detoxifying effect (Maser 1998).  
1.5.2.1. 11β-HSD1 inhibitors 
A commonly used inhibitor of 11β-HSD1 enzyme are the liquorice derivatives 
glycyrrhizic acid (GI) and glycyrrhetinic acid (GE), and the hemmisuccinate 
derivative, carbenoxolone (Jellinck et al. 1993).  GE also inhibits 11β-HSD2 with a Ki 
of 5-10nM (Stewart, Murry, & Mason 1994). These compounds act as non 
competitive inhibitors at the active site of the enzyme and can also decrease mRNA 
expression.   Studies have shown that carbenoxolone has 11β-HSD1 inhibitory effects 
in vivo (Stewart et al 1990).  Bile acids also inhibit 11β-HSD1 activity in vitro 
(Buhler et al. 1994). In particular lithocholic acid and chenodeoxyxholic acid are the 
most potent. Arylsulfonamidothiazole
 
compounds have been shown to inhibit 11β-
HSD1 both
 
in vivo and in vitro. The diethylamide derivative was shown to inhibit 
human 11β-HSD1 with an IC50 of 52 nM and an N-methylpiperazinamide form 
(BVT.2733) has been shown to be specific for the mouse 11β-HSD1 enzyme. In a 
hyperglycaemic mouse strain, BVT.2733 lowered PEPCK and G6Pase mRNA as well 
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as blood glucose and serum insulin levels raising the exciting possibility of the use of 
11β-HSD1 inhibition in the treatment of insulin resistance and diabetes (Alberts et al. 
2002).   Numerous compounds of various structural classes have since been identified 
that specifically inhibit 11β-HSD1 (Boyle and Kowalski 2009).  Recently reported 
results using INCB13979, a selective 11β-HSD1 inhibitor showed an improvement in 
HbA1c and cholesterol in patients with T2D when used in combination with 
metformin in phase IIb trial (ROSENSTOCK J 2009a).  
1.5.2.2. Regulation of expression and activity of 11β-HSD1 
11β-HSD1 activity may be regulated at a number of levels.  At the enzyme level these 
would include substrate availability, competitive and non competitive inhibition and 
allosteric regulation (by other agents or by assembly into more complex units). These 
have already been discussed in the sections above dealing with enzyme properties 
(section 1.5.2.).  Regulation may also occur at the level of expression, including 
changes in gene transcription and translation as well as the rate of clearance of the 
enzyme.  Several factors are known to regulate expression, and the most widely 
investigated include glucocorticoids and cytokines. To summarise, glucocorticoids, 
C/EBP, peroxisome proliferator-activated receptor γ agonists, and some 
proinflammatory cytokines (TNFα and IL-1ß) increase 11β-HSD1 expression, 
whereas GH (acting via IGF-I)
 
and liver X receptor agonists inhibit expression.  Other 
factors, such as sex steroids, insulin and thyroid hormone vary between tissues and 
between species (Tomlinson et al. 2004).  Some of these factors are described in 
further detail in specific chapters  
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1.5.3. Tissue expression and activity in normal physiology and 
pathophysiology of peripheral tissues 
Detailed studies have been carried out on 11β-HSD1 in a range of peripheral tissues 
including liver, adipose tissue, CNS, reproductive tissue and muscle.  There have also 
been studies on kidney, eye and pancreas.  
1.5.3.1. 11β-HSD1 in the liver, and regulatory effects on factors affecting 
insulin sensitivity 
11β-HSD1 immuno reactivity is seen in hepatocytes, being particularly intense around 
the central vein (Ricketts et al. 1998b).  In humans the activity of this enzyme 
activates orally administered cortisone to its biologically potent form.  Primary 
cultures of human and rat hepatocytes and the 2S FAZA cell line indicate exclusive 
11-oxoreductase activity (Jamieson et al. 1995;Ricketts et al. 1998a). In rat liver, but 
not mouse liver, there is a sexually dimorphic pattern of 11β-HSD1 activity and 
expression, with expression in males being higher than females, which has been 
linked to the sexually dimorphic pattern of GH secretion (Rajan et al. 1995).  In 
humans, at the age of 4-5 years 11β-HSD1 expression appears to be similar in boys 
and girls until puberty, when activity decreases in girls (Dimitriou et al. 2003).  In 
studies on elderly patients (Toogood et al. 2000) and GH deficient hypopituitary 
patients (Weaver et al. 1998), activity is generally higher in men than women.  
In clinical studies venous blood draining the liver had increased cortisone to cortisol 
ratios relative to systemic blood indicating the conversion of cortisone to cortisol in 
vivo. These studies are further supported by studies that used isolated perfused livers 
where activity was predominantly reductase.  Interestingly, while concurrent infusion 
of carbenoxolone made little difference, seven days pre treatment with carbenoxolone 
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significantly reduced oxoreductase activity (Jamieson et al. 2000;Walker et al. 
1992a).  In the rat 2S FAZA cell line reductase activity is inhibited by insulin and 
IGF-1 and stimulated by dexamethasone (Voice et al. 1996).  The promoter region of 
the rat 11β-HSD1 gene is positively regulated by C/EBPα and to a lesser extent 
C/EBPβ (Williams et al. 2000). In humans, hyperthyroidism moves the set point of F 
to E conversion towards E, but this requires a functional thyroid hormone receptor 
rather than being a function of thyroid hormone per se (Whorwood et al. 1993).   
There is currently intense research in the role of 11β-HSD1 and insulin resistance. 
The regulatory role of 11β-HSD1 can occur at the level of adipose tissue (central and 
visceral obesity), liver (hepatic gluconeogenesis) and muscle. This section focuses on 
the role of hepatic 11β-HSD1 in this process. An overview of the effect of 
glucocorticoids on hepatic carbohydrate metabolism has been detailed earlier in this 
chapter (section 1.4.6.1).  Studies on mice with targeted disruption of the 11β-HSD1 
gene showed a relative failure to express glucocorticoid-inducible genes in the liver 
indicating reduced hepatic glucocorticoid generation in these animals. These mice do 
not display fasting hypoglycaemia, but fasting glucose levels after high fat feeding are 
significantly lower than in wild type controls. While they have no difference in 
baseline expression of glucose-6-phosphatase and PECK although upon starvation 
these key enzymes of hepatic glucose induction fail to be induced (Kotelevtsev et al 
1997).  The animals also have a less atherogenic lipid profile then wild type, which is 
thought to be due to increased expression of hepatic enzymes that are involved in fat 
catabolism (Morton et al. 2001) and provided strong evidence for the role of 
glucocorticoid metabolism underlying metabolic disease.  
Administration of selective 11β-HSD1 inhibitors to rodents for seven days induced a 
decreased expression of both G6Pase and PEPCK (Alberts et al 2002).  Interestingly, 
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recent studies have shown that the administration of carbenoxolone to diet induced 
obese and insulin resistant mice, also resulted in a reduction in hepatic GR mRNA 
levels, which correlated with the suppression of H6PDH and 11β-HSD1 activity (Liu 
et al. 2008). Studies on healthy humans have supported animal data with a reduction 
in hepatic glucose production with carbenoxolone administration (Walker et al. 1995). 
Similar studies on type 2 diabetics showed that the decrease in hepatic glucose 
production may be due to decreased glycogenolysis rather than a change in hepatic 
gluconeogenesis (Andrews et al. 2003). Several selective 11β-HSD1 inhibitors are 
being developed with the aim of lowering intracellular cortisol concentrations in 
adipose and liver in patients with type 2 diabetes and obesity with promising results 
(Hughes et al. 2008) (section 1.5.2.1).   
While the impact of glucocorticoids on glucose tolerance are well known, studies on 
subjects with impaired glucose tolerance have failed to show increased hepatic 11β-
HSD1 activity when measured by cortisone generation profiles following 
dexamethasone suppression and oral cortisone acetate, and urine corticosteroid 
metabolite ratios (Andrews et al. 2002;Rask et al. 2002;Stewart et al 1999).  Studies 
on Type 2 diabetics have had varied results with no difference in 11β-HSD1 activity 
measured by urine corticosteroid metabolite ratios (Kerstens et al. 2000) and possibly 
impaired hepatic cortisol generation using cortisol generation curve analysis 
(Andrews et al. 2002). This may reflect a physiological compensatory mechanism to 
limit fasting hyperglycaemia and increase hepatic sensitivity by decreasing hepatic 
cortisol concentrations.  Interestingly, transgenic mice over-expressing 11β-HSD1 are 
hyperinsulinaemic after a glucose load and also have dyslipidaemia and hypertension 
(Paterson et al. 2004).  
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H6PDH represents a novel direct link between cellular glucose metabolism, 
glucocorticoid metabolism and the HPA axis and is described in detail in chapter 4.  
1.5.3.2. Hepatic 11β-HSD1 in non alcoholic fatty liver disease 
Non alcoholic fatty liver disease (NAFLD) is the hepatic phenotype of the metabolic 
syndrome.  Glucose metabolism in NAFLD has been detailed in section 1.3.4. The 
possible role of 11β-HSD1 in the pathophysiology of NAFLD is an exciting one as it 
raises the potential role of treatment with 11β-HSD1 inhibitors, as well as providing 
insight into the pathogenesis of this condition which remains largely unknown. Of 
note, 20% of patients with cushings syndrome have NAFLD (Rockall et al. 2003). It 
is unclear which factors are responsible for the switch from the somewhat benign 
„simple hepatic steatosis‟ to steatohepatitis which can be rapidly progressive to end 
stage liver disease and cirrhosis.  Studies on mice with transgenic overexpression of 
hepatic 11β-HSD1 (Paterson et al 2004) and adipose selective 11β-HSD1 transgenic 
mice (described in the next section) (Masuzaki et al. 2001) provided some 
background to the hypothesis that there may be a net export of cortisol from the 
omental adipose tissue to the liver via the portal circulation, which in turn would 
impact on hepatic metabolic phenotype. According to a recent study, this does not 
appear to be the case. The release of cortisol from adipose tissue and its effect on 
portal vein cortisol levels was quantified in a study using infusion of a stable isotope 
of cortisol and simultaneous sampling from the epigastric, portal and hepatic veins 
and peripheral arterialised blood.  There was evidence of significant cortisol release 
from subcutaneous adipose tissue that may contribute to whole body cortisol 
regeneration. However splanchnic release of cortisol was accounted for entirely by the 
liver, and release of cortisol from visceral tissues (gut, pancreas and spleen) into the 
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portal vein was not detected – speculating that visceral 11β-HSD1 activity is 
insufficient to influence hepatic glucocorticoid signalling (Stimson et al. 2009). 
However, an autocrine role for 11β-HSD1 in omental tissue remains a possibility 
which could still impact on hepatic metabolic phenotype by alterations in portal 
FFA/adipocytokine delivery. 
Clinical studies using healthy male volunteers showed that increased hepatic fat 
measured by abdominal magnetic imaging resonance scans was not associated with 
indices of cortisol metabolism, but importantly, these were healthy volunteers with no 
proven evidence of hepatic steatosis or NAFLD (Westerbacka et al. 2003).  Another 
clinical study did not show any difference in 11β-HSD1 mRNA expression in liver 
biopsies from different stages of NAFLD, and concluded that 11β-HSD1 gene 
expression is not involved in the pathogenesis of NAFLD (Konopelska et al. 2009).  
Detailed investigation into hepatic pre receptor cortisol metabolism in NAFLD was 
carried out as part of the work for this thesis and is described in detail in chapter 7.   
1.5.3.3. 11βHSD1 in alcoholic and other chronic liver diseases 
There is now evidence of deranged hepatic cortisol metabolism in NAFLD, alcoholic 
liver disease as well as chronic liver diseases of other causes.  Unlike results from 
human studies, rats with cirrhosis had reduced hepatic 11β-HSD1 and renal 11β-
HSD2 which could be explained by the inhibitory action of bile salts (Escher et al. 
1998). 
The alcohol-induced pseudo-Cushing's syndrome is an important differential 
diagnosis of hypercortisolism that is poorly understood (section 1.4.6.7.). In a 
previous study, urine steroid profile on patients with alcoholic liver disease and non 
alcoholic chronic liver disease showed a marked increase in urine THF+allo-
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THF/THE ratio suggesting either a reduction in renal 11β-HSD2 or an increase in 
hepatic 11β-HSD1 (Stewart et al. 1993a) suggesting a role for aberrant cortisol 
metabolism in the process.  In a further study, we have further evaluated hepatic 
glucocorticoid metabolism in patients with alcoholic liver disease (ALD) and non 
alcoholic/non fatty chronic liver disease (CLD) by measuring F and E concentrations 
through selective venous sampling of the hepatic, portal, renal and peripheral veins. 
This showed specifically increased hepatic cortisol generation in alcoholic liver 
disease.  Generation of cortisol in the liver might dampen the inflammatory response 
and thus limit tissue damage (Ahmed et al. 2008), in a similar theme to that discussed 
for NAFLD.  Indeed, the histological appearances of alcoholic and non alcoholic 
steatohepatitis are often indistinguishable and may reflect a common response in 
altered hepatic glucocorticoid metabolism in both diseases. This study formed part of 
the work for this thesis and is discussed in detail in chapter 5. 
1.5.3.4. Adipose tissue 
11β-HSD1 is also expressed in adipose tissue and in primary cultures of human 
omental and subcutaneous adipose stromal cells (Bujalska, Kumar, & Stewart 1997).  
In cell culture, 11β-HSD1 activity is higher in omental cells the subcutaneous cells 
and glucocorticoids and proinflammatory cytokines further induce activity in cells 
from both depots (Tomlinson et al. 2001).  Cortisol is essential for adipocyte 
differentiation and the autocrine generation of cortisol by 11β-HSD1 regulates this 
process. Inhibition of 11β-HSD1 prevents differentiation of adipose cells (Bujalska et 
al. 1999). In vitro enzyme expression is enough to allow differentiation of omental 
stromal cells by cortisone alone (Bujalska et al 1999) and there is enzyme induction 
with differentiation from stromal cells to adipocytes.  This appears to be related to a 
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change in the set point of the enzyme from dehydrogenase in stromal cells to 
reductase in adipocytes without a significant change in mRNA levels (Bujalska et al 
2002).  Mice over expressing 11β-HSD1 in adipocytes, by virtue of a 11β-HSD1 
cDNA linked to an adipocyte fatty-acid binding protein (aP2) promoter had enhanced 
adipose tissue differentiation (measured by increased fat cell size) (Figure 1-16) and a 
viscerally  and  centrally obese phenotype as well as other key features described later 
in this section (Masuzaki et al 2001).  In rat and human pre adipocytes, 
glucocorticoids have been seen to exert an anti-proliferative effect which is removed 
upon inhibition of 11β-HSD1 (Figure 1-16) (Tomlinson et al. 2002b).  
 
Figure 1-16  In human adipose tissue the autocrine/paracrine generation of cortisol 
through 11β-HSD1 activity promotes adipose differentiation and 
inhibits adipocyte proliferation (Tomlinson et al. 2004). 
1.5.3.5. Other tissues 
11β-HSD1 is also expressed in skeletal muscle and one study has shown that 11β-
HSD1 gene expression correlates with markers of insulin resistance, BMI and blood 
pressure (Whorwood et al. 2002).  Another more recent study showed increased 11β-
HSD1 expression in myotubes from type 2 diabetic subjects, and the cortisone 
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induced reduction in glucose uptake was reversed with carbenoxolone  (Abdallah et 
al. 2005). 
1.6. Hexose-6-phosphate dehydrogenase, ER redox and metabolic 
sensing 
The enzyme hexose-6-phosphate dehydrogenase (H6PDH) has been known for 
decades but previously received little attention until it was pushed to the forefront not 
only as a crucial component of pre receptor glucocorticoid metabolism, but also more 
recently as a link between the autocrine effects of glucocorticoids and intermediary 
metabolism. This identified H6PDH as a novel metabolic sensor of the endoplasmic 
reticulum (ER) linking intracellular hormone signalling and glucose metabolism. 
H6PDH is an autosomally linked microsomal enzyme, distinct from the cytosolic sex-
linked glucose-6-phosphate dehydrogenase. It uses its own pool of NAD(P)+ and is 
able to oxidize a variety of phosphorylated hexoses, including glucose-6-sulphate and 
galactose-6-phosphate.  In addition to oxidising G6P to 6-phosphogluconolactone 
(6PG) it is thought to also hydrolyse 6PG to 6-phosphogluconate, and therefore in 
effect catalyses the first two steps of the endoluminal pentose phosphate pathway, 
generating reduced NADPH within the ER (Bublitz and Steavenson 1988), Figure 
1-14.  The murine enzyme has been proven to have bifunctional activity but this 
remains to be shown for the human enzyme (Clarke and Mason 2003).  H6PDH has 
been shown to be ubiquitously expressed in nearly all tissues (Hewitt et al. 2005) 
implying its role as a housekeeping enzyme serving a vital role in redox homeostasis 
in the ER lumen. Highest activity is observed in steroidogenic cells, liver and renal 
cells supporting the idea that H6PDH is involved in steroid and drug metabolism.   
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The protein sequence for H6PDH was first described from rabbit liver microsomes, as 
a 90 kDa protein with 763 amino acids, unlike cytosolic G6PDH which has a 
monomer molecular mass of 56kDa (Ozols 1993).  The N-terminal region of H6PDH 
has close homology to cytosolic G6PDH, particularly at the coenzyme and G6P 
binding sites.  The C-terminal 250 amino acids show homology with the N-terminal 
regions of Plasmodium falciparum and Plasmodiem Berghei G6PDH proteins, as well 
as the human 6PGL protein (Clarke et al. 2001;Collard et al. 1999).  The human 
H6PDH gene is localised to chromosome 1p36, spanning 37kb, with 5 exons and 4 
introns, that predict a protein of 89kDa (Mason et al. 1999). 
While the redox state of the cytosolic pyridine nucleotides is determined by a number 
of different oxidoreductases, NADP
+
 reduction in the ER appears to be governed 
solely by H6PDH.  Cotransfection of mammalian cells with expression plasmids 
encoding 11β-HSD1 and H6PDH consistently increased oxoreductase activity.  
Substitution with G6PD failed to induce a similar response, demonstrating that  
NADPH must be generated in the ER lumen to access the active site of 11β-HSD1 
(Atanasov et al. 2008;Bujalska et al. 2005). H6PDH has been shown to have direct 
protein-protein interactions with 11β-HSD1 (Atanasov et al 2008).  siRNA 
experiments which decreased H6PDH expression also decreased oxoreductase activity 
in intact cells (Bujalska et al 2005).  These observations were supported by studies on 
H6PDH knockout mice. 11β-HSD1 activity in these mice is predominantly 
dehydrogenase both in vivo and in vitro (Lavery et al. 2006). 
The activity of H6PDH also appears to be governed largely by substrate supply which 
importantly is sourced via a sole ER membrane protein, the glucose-6-phosphate 
transporter (G6PT) which is selective for glucose-6-phosphate (Marcolongo et al. 
2007;Van and Gerin 2002).  This makes the G6PT-H6PDH-11β-HSD1 system an 
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ideal metabolic sensor of the ER, as minor alterations in the intraluminal [NADPH] / 
[NADP
+
] ratio in the ER lumen can cause significant changes in the set point of 11β-
HSD1 activity and in turn intracellular glucocorticoid levels.  An [NADPH] / 
[NADP
+
] ratio of around 9:1 is required for 11β-HSD1 to function as a reductase, 
implying that the in vivo set point of  the [NADPH] / [NADP
+
] redox couple is much 
more reduced in the ER lumen then the cytosol  (Diaz-Flores et al. 2006;Panten and 
Rustenbeck 2008). Further increases in ER NADPH in turn lead to dramatic increases 
in 11β-HSD1 driven glucocorticoid generation.  Furthermore, H6PDH is a lot more 
resistant to feedback inhibition by NADPH then cytosolic G6PD (Oka et al. 1981). 
The redox state of the ER lumen is therefore directly governed by cytosolic G6P 
concentrations, via the G6PT-H6PDH-11β-HSD1 system.  This was demonstrated by 
studies on patients with glycogen storage disease type 1, described in chapter 4.  
Further evidence is provided by studies on H6PDH knockout mice which showed 
fasting hypoglycaemia, low hepatic glycogen content, increased insulin sensitivity 
and decreased negative feedback on the HPA axis (Lavery et al 2006).  These results 
clearly imply the importance of the G6PT-H6PDH-11β-HSD1 system in the acute 
metabolic response to feeding with regard to the coupling between metabolic and 
hormonal responses.  Indeed, local 11β-HSD1 activation is needed for the inhibition 
of glucagon secretion in α-cells of pancreatic islets, further illustrating the direct role 
of the system in whole body metabolism (Swali et al. 2008). 
While the G6PT-H6PDH-11β-HSD1 system is able to act as a physiological 
metabolic sensor, it also plays a very likely role in the pathophysiology of metabolic 
states that induce ER stress. Its role in nutrient sensing in insulin sensitive cells has 
been elegantly illustrated in Figure 1-17 by (Banhegyi et al. 2009). A number of 
studies have shown that manipulation of the G6PT-H6PDH-11β-HSD1 system by 
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genetic or pharmacologic means leads to ER stress and UPR, and even apoptosis of 
various cell types, due to a deficiency of reducing equivalents in the ER lumen 
(Kardon et al. 2008;Lavery et al. 2008b;Leuzzi et al. 2003). ER stress results in the 
accumulation of immature proteins which in turn trigger the unfolded protein 
response (UPR). This leads to numerous downstream effects including apoptosis, 
insulin resistance and inflammation (Hotamisligil 2005;Zhang and Kaufman 2008).  
This mechanism is activated by glucose and fatty acids by an unknown mechanism, 
but may be due to excessive reducing equivalents resulting in an altered redox state in 
the ER lumen causing ER stress. The ER stress response in essence is a mechanism 
that is activated to protect the cell from apoptosis, although its activation under 
conditions chronic excesses of fatty acids and glucose can lead to cellular dysfunction 
and cell death.  Of particular relevance, saturated fatty acids disrupt ER redox 
homeostasis and cause ER stress and apoptosis in hepatocytes of rats with hepatic 
steatosis (Wang et al. 2006). 
Over-nutrition may therefore be regarded as a cause of excess reducing power in the 
ER lumen which activates H6PDH via G6PT, resulting in a high endoluminal 
[NADPH] / [NADP
+
] ratio and glucocorticoid activation by 11β-HSD1, with the 
resulting pathophysiological effects.  For example, increased 11β-HSD1 activity 
stimulates pre-adipocyte differentiation, increases expression of lipoprotein lipase, 
glycerol production and triglyceride synthesis in visceral adipose tissue, contributing 
to the development of the metabolic syndrome (Bujalska et al. 2008b;Tomlinson et al. 
2008a). Increased intracellular glucocorticoid levels results in a number of effects 
promoting insulin resistance and nearly all the effects of the metabolic syndrome, as 
detailed in previous sections.   
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Figure 1-17 The role of the G6PT–H6PD–HSD11B1 triad in nutrient sensing of 
insulin-sensitive cells. Insulin stimulates the translocation of GLUT4 
into the plasma membrane and hence enhances glucose uptake in 
muscle and adipose tissue, which results in elevated intracellular 
glucose-6-phosphate (G6P) level. On the other hand, high level of free 
fatty acids – according to Randle's ‘glucose–fatty acid cycle’ – inhibits 
glucose catabolism at several key steps, most importantly at the level of 
the pyruvate dehydrogenase (PDH) reaction. As a consequence, 
glucose-6-phosphate accumulates within the cell. Accumulation of 
glucose-6-phosphate, in turn, fuels the G6PT–H6PD–HSD11B1 
system, which leads to increased prereceptorial activation of 
glucocorticoids. Thus, oversupply of reducing equivalents – in the form 
of either carbohydrates or lipids – leads to the enhancement of 
glucocorticoid activation. Increasing concentrations are indicated by 
red arrows, and resulting enzyme inhibitions are also indicated in red. 
Abbreviations: FFA, free fatty acid; F6P, fructose-6-phosphate; 
F1,6bP, fructose-1,6-bisphosphate; Glc, glucose; G6P, glucose-6-
phosphate; GR, glucocorticoid receptor; HK, hexokinase; IR, insulin 
receptor; MT, mitochondrion; PDH, pyruvate dehydrogenase; PFK, 
phosphofructokinase; Pyr, pyruvate and OAA, oxaloacetate (Banhegyi, 
Csala, & Benedetti 2009). 
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1.6.1. Cortisone reductase deficiency 
Cortisone reductase deficiency (CRD) occurs when there is failure of regeneration of 
cortisol from cortisone via 11β-HSD1.  This causes increased cortisol clearance, 
activation of the HPA axis, and ACTH driven adrenal hyperandrogenism.  In males 
this manifests in early life with precocious pseudopuberty.  Females present in midlife 
with a PCOS phenotype with hirsutism, oligomenorrhea and infertility (Draper et al 
2003;Jamieson et al. 1999;Nikkila et al 1993;Phillipov et al. 1996).  A biochemical 
diagnosis of CRD is made by measurement of urinary corticosteroid metabolites 
reflecting 11β-HSD1 activity – the THF+5αTHF/THE ratio.  This ratio is typically 
lower than 0.1 in affected patients (Tomlinson et al 2004b). HSD11B1 was considered 
the most likely gene to be mutated in CRD, but no coding mutations directly affecting 
enzyme activity were identified.  However, as the reductase activity of 11β-HSD1 is 
crucially dependant on the availability of reduced NADPH in the ER lumen, H6PD is 
clearly also a candidate gene to explain CRD. Previously, sequence variants in H6PD 
and HSD11B1 in patients with CRD were identified (Draper et al 2003), but large 
scale population based studies showed that these were polymorphic variants, and not 
disease causing mutations.  The population frequencies of these variants could not 
explain fully the clinical picture or urinary profiles of CRD patients (Draper et al. 
2006;Smit et al. 2007;White 2005).  Recently, 4 cases of CRD were reanalysed and 
inactivating mutations in the H6PD gene were identified that were consistent with the 
steroid biochemistry.  Expression and activity assays demonstrated loss of function 
for all the reported mutations (Lavery et al. 2008a).  These data further highlighted the 
importance of redox homeostasis in the control of cortisol metabolism and the role of 
H6PDH-11β-HSD1 pathway in the activity of the HPA axis.  
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1.7. General Aims  
 
On the background presented in the preceding sections the general aim of the work 
carried out for this thesis was to investigate the impact of hepatic pre receptor 
glucocorticoid metabolism upon hepatic glucose homeostasis, and hence hepatic and 
whole body insulin sensitivity in health and disease. The overall hypothesis was that 
aberrant hepatic pre receptor glucocorticoid metabolism is implicated in the 
pathophysiology of the metabolic syndrome.   
Investigations were planned at the in vitro level, to characterise the zonation and 
expression of hepatic 11β-HSD1 in normal liver and how this compared with diseased 
liver from patients with NAFLD as well as other histologically analogous liver 
diseases including alcoholic liver diseases.  
A number of clinical investigations were planned in normal patients and those with 
increasing degrees of insulin resistance (obese non diabetic, type 2 diabetics, NAFLD, 
and alcoholic liver diseases).  The overall aim of these studies was to detect any in 
vivo differences in glucocorticoid metabolism between groups and correlating these 
differences with markers of metabolic phenotype, and hepatic glucose production by 
gluconeogenesis. 
In-vitro and clinical studies were designed in patients with glycogen storage disease 
type 1a (G6Pase deficiency) and GSD type 1b (G6P transporter deficiency) to 
investigate the concept that endoluminal G6P concentrations directly impact upon 
11β-HSD1 mediated glucocorticoid generation. 
These studies are described in the following chapters with specific aims and 
hypotheses detailed in relevant sections.  
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2. Materials and Methods 
The techniques described in this chapter are used throughout this thesis but are 
described here in detail. In each chapter any modifications will be indicated with 
specific details such as numbers of samples or subjects.  Unless otherwise stated, 
general chemicals were obtained from Sigma-Aldrich, UK, reagents for reverse 
transcription polymerase chain reactions (RT-PCR) from Applied Biosystems.  
This chapter is divided into methods that focus primarily on human tissues and 
methods used in clinical studies. 
2.1. Studies of human tissues 
Human liver tissue was obtained from the tissue archive at the Centre for Liver 
Research, University of Birmingham.  Diseased human liver tissue was obtained from 
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explanted liver from patients undergoing liver transplantation.  Normal human liver 
tissue was derived from donor liver at transplant. Liver histology of all the tissues 
used was verified from histopathology reports.  All tissues were collected with the 
informed consent of the subjects and all the clinical studies Local Research Ethics 
Committee (LREC) approval. 
2.2. Immunohistochemistry 
2.2.1. Principle 
Immunohistochemistry allows the detection of specific proteins within cells in intact 
tissue sections using antibodies specific for the protein of interest. The primary 
antibodies used are raised in a species distant from the target species allowing the use 
of labelled anti-species IgG secondary antibodies. Detection is possible via the label 
conjugated to the secondary antibody.  In the work described in this thesis the 
secondary antibodies was donkey antisheep
 
IgG peroxidase conjugate.  
Immunohistochemistry reagents were obtained from Binding Site, Birmingham , UK.  
Optimal concentrations were determined using serial antibody dilutions on standard 
tissue sections. 
2.2.2. Production of the 11β-HSD1 antibody 
Hydrophilicity profiles (Hopp 1993;Hopp and Woods 1981) were used to identify 
likely antigenic sites within the human 11β-HSD1 protein (Tannin et al 1991). One 14 
amino acid region was selected, and was synthesised into an eight-branched 
multiantigenic peptide (Binding Site, Birmingham, UK), which was mixed with 
Freund‟s adjuvant and used to immunise a single sheep.   An IgG fraction was 
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prepared from the immune serum by ammonium sulphate
 
precipitation and ion 
exchange chromatography. Purity of antisera was further enhanced by affinity 
chromatography using a column coated with the peptide used to immunise the sheep.  
The IgG fraction of the serum was run down the column to allow specific binding of 
the anti 11β-HSD1 antibody fraction.  The antibodies were then eluted from the 
column at a low pH.  A further Sephacryl S200 gel filtration purification step was 
performed, to further reduce the presence of non specific antibodies (Binding Site, 
Birmingham, UK).  Immunohistochemistry on standard tissue sections was used to 
monitor the effects of each purification step.  The validation of this antibody has been 
previously described (Ricketts et al 1998b). 
2.2.3. Preparation of tissue sections 
For immunohistochemical studies on paraffin sections, tissue was obtained from the 
Centre for Liver Research, University of Birmingham as above. Tissue was received 
fixed in 10% Formalin in H2O.  Tissues were then dehydrated through a graded series 
of ethanol washes (70%, 95% then 100%) and then transferred to xylene for 2 hours.  
Tissues were embedded in melted paraffin, and then allowed to harden and cool.  5 
μm thick sections were cut and transferred to charged microscope slides (Superfrost 
Plus, BDH, Poole, UK).  Slides were ready for use after air drying.  
Immunohistochemistry on frozen sections was carried out primarily for the study of 
NAFLD tissues described in chapter 7.  While tissue morphology in cryosections are 
somewhat inferior to paraffin sections – this method was chosen due to the ease of 
availability of frozen tissue for analysis. 
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Freshly dissected tissue had been snap frozen in liquid nitrogen prior to storage in the 
frozen tissue archive at the Centre for Liver Research, University of Birmingham.  
Small tissue blocks were received of diseased and normal livers and were transported 
in liquid nitrogen.  Tissues were stored at -80ºC until ready to section. 
The tissue sample of interest was mounted on a chuck using O.C.T. (optimal cutting 
temperature) compound (Tissue-Tek, Ted Pella Inc, USA), trimmed and allowed to 
temperature equilibrate in the cryostat for 20 minutes prior to cutting. 5μm thick 
sections were cut and mounted onto charged microscope slides (Superfrost Plus, 
BDH, Poole, UK).  Sections were then fixed in 2 exchanges of 100% acetone, 5 min 
each, and then dehydrated in 2 changes of 100% IMS for 2 min each. Slides were 
stored at -20ºC wrapped in foil till use. 
2.2.4. Reagents 
Antigen retrieval solution - Citrate buffer: 10nM citric acid, 0.05% Tween 20, pH 
6.0. 
3% methanol hydrogen peroxide: 50ml methanol in a coplin jar, containing 800μl 
30% H2O2 (for paraffin sections) 
0.1% methanol hydrogen peroxide: 50 ml 70% methanol in a coplin jar containing 
50μl of 1% H2O2 (for cryosections) 
Tris Buffered Saline (TBS) pH 7.6 (0.05M):60.5g Trizma base, 31.88g NaCl, 32.63ml 
10M HCl made up to 1L with distilled H2O. 
3,3‟-diaminobenzidine tetrahydrochloride (DAB) solution: 50mg DAB tablet 
dissolved in 20 ml TBS. 20μl 30% H2O2 added just before use and filtered through 
whatman paper. 
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2.2.5. Immunohistochemistry protocol 
2.2.5.1. Paraffin sections 
For immunohistochemical studies on paraffin sections, tissue was obtained from the 
Centre for Liver Research, University of Birmingham as above. Tissue was received 
fixed in 10% Formalin in H2O.  Tissues were then dehydrated through a graded series 
of ethanol washes (70%, 95% then 100%) and then transferred to xylene for 2 hours.  
Tissues were embedded in melted paraffin, and then allowed to harden and cool.  5 
μm thick sections were cut and transferred to charged microscope slides (Superfrost 
Plus, BDH, Poole, UK).  Slides were ready for use after air drying.  
Formalin fixed paraffin embedded liver sections were dewaxed and rehydrated (2 
changes of xylene for 2 minutes each; two changes of 100% industrial methylated 
spirit (IMS) for 2 minutes each).  A wax pen was used to draw an area around the 
section containing the tissue to allow small volumes of solution for incubation with 
primary and secondary antibody to be used. After washing in tap water the slides were 
incubated with hydrogen peroxide/methanol for 15 minutes to block endogenous 
peroxidase activity. Antigen retrieval was enhanced by incubating in an oven at 60ºC 
for 30 minutes followed by incubation in citrate buffer for 20 minutes in a microwave 
at medium power. After washing in TBS, non specific antibody binding was blocked 
with 10% normal donkey serum (NDS) in TBS for 30 min.  Sections were then 
incubated with primary antibody diluted in 10% NDS for 90 minutes at room 
temperature at a dilution of 1:50 – 1:200.  After washing in TBS, sections were 
incubated with secondary antibody (Donkey anti-sheep IgG conjugated to peroxidase) 
at a dilution of 1:25, diluted in TBS for 30 min at room temperature, and then 
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extensively washed.  Slides were developed using DAB solution (up to 10 minutes).  
DAB staining results in a brown precipitate at sites of peroxidase activity.  The 
reaction was stopped by washing in tap water.  Cellular nuclei were stained using 
Mayer‟s haematoxylin for up to 3 minutes and then washed under running water to 
remove excess haematoxylin.  Sections were then rinsed twice for 5 min in IMS, and 
then washed twice in xylene.  Sections were covered with dibutyl polystyrene, and 
xylene based mountant. 
Controls included incubating with primary antibody in the presence of an excess of 
immunising peptide (1:100) used at similar concentrations. 
2.2.5.2. Cryosections 
Slides were removed from -20ºC and allowed to equilibrate to room temperature for 
30 min before opening the foil wrapper.  Sections were re fixed in 100% acetone for 5 
minutes and then air dried.  A ring was drawn around the section using a wax pen and 
placed in a humidified chamber.  Endogenous peroxidase was blocked with 0.1% 
hydrogen peroxide for 20 min and then washed in TBS.  Non specific antibody 
binding was blocked with 10% NDS in TBS for 30 min. Sections were then incubated 
with primary antibody diluted in 10% NDS for 45 minutes at room temperature at a 
dilution of 1:50 – 1:200.  After washing in TBS, sections were incubated with 
secondary antibody (Donkey anti-sheep IgG conjugated to peroxidase) at a dilution of 
1:25, diluted in TBS for 30 min at room temperature, and then extensively washed.  
Slides were developed using DAB solution (up to 10 minutes), and then 
counterstained and mounted as described in section 2.2.5.1. 
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2.3. mRNA detection and quantification 
A number of techniques have been used in this thesis for RNA extraction, and for 
detection and quantification of mRNA. 
2.3.1. Isolation of cellular RNA 
Cellular RNA was extracted from snap frozen whole liver tissue chunks using the 
TriReagent system (Sigma, UK). The chunks were trimmed while frozen and a small 
volume (~2-3mm
3
) was used obtaining high yields of RNA. Liver samples obtained 
from biopsies of patients with NAFLD were of very small volume (<1mm
3
) and RNA 
extraction was carried out using the Genelute Mammalian Total RNA kit (Sigma). 
RNA was isolated from laser capture microdissected liver samples using the 
specialised Ambion RNAqueous-Micro Kit (Applied Biosystems) which is optimized 
for the purification of total RNA from micro sized samples of tissue. The procedure 
followed exactly as per manufacturer‟s protocol for each system used. 
2.3.1.1. Measuring RNA concentration 
RNA concentration was quantified using a Nanodrop 1000 Spectrophotometer 
(Thermo Scientific).  The quality of extracted RNA was also assessed by 
electrophoresis on 1% agarose gel with 0.15μg/ml ethidium bromide and visualised 
under UV light. Intact RNA showed clear 18S and 28S bands. 
Chapter 2  Methods 
75 
 
2.3.2. Reverse transcription Polymerase Chain Reaction (PCR) 
2.3.2.1. Principle 
Reverse transcription PCR is a sensitive technique used to detect small amounts of 
specific mRNAs within a tissue.  Cellular RNA is collected and converted to 
complimentary (cDNA) using reverse transcriptase enzymes.  The cDNA is then used 
as a template for the amplification of specific sequences. The process utilizes a pair of 
primers which are complimentary to the 5‟ end of the sequence for amplification on 
each of the two strands of cDNA.  The primers are then extended by DNA 
polymerases, with a copy of the strand made after each cycle.  The strands are 
separated by increasing the temperature above the melting point for double stranded 
DNA, so the template and the generated DNA strand become targets for further 
annealing of primers. This results in logarithmic amplification of DNA fragments of a 
size defined by the primers added.  Hence, the reaction is specific sequences of target 
DNA, with capacity for significant amplification and thus detection ability.  The DNA 
polymerases used, unlike mammalian polymerases are able to withstand the high 
temperatures required for the reaction. 
2.3.2.2. Method used for cDNA generation using reverse transcriptase 
Reverse transcription of RNA from whole liver samples was performed using a 
Promega reverse transcription system as previously described (Whorwood et al 1995).  
In summary, 1μg of total RNA and 0.5μg of random primers in a final volume of 10μl 
were incubated at 70ºC for 10 min. In a final reaction volume of 20μl made up with 
nuclease free water, the following were added: 25mM MgCl2 4μl, 10x RT buffer 2μl, 
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10mM dNTP 2μl, Ribonuclease inhibitor 0.5μl, 0.5μg/μl random hexamer primers 
1μl, 15U avian megablastoma virus reverse transcriptase.  The reaction was incubated 
at room temperature for 10 minutes, 42ºC for 60 min, 95ºC for 5 min, and then 4ºC 
for 5 min. The cDNA generated was stored at -20ºC. 
Reverse transcription of RNA from laser capture microdissected tissues was carried 
using a One Step Applied Biosystems reverse transcription kit.  In a final reaction 
volume of 20μl with a maximum of 1μg RNA the following were added: 10x RT 
buffer 1μl, 25mM MgCl2 2.2μl, 10mM each dNTPs 2μl, Random Hexamers 0.5μl, 
RNase Inhibitor 0.2μl.  The reaction was incubated at 25ºC for 10 min, 37ºC for 60 
min, 48ºC for 30 min, 95ºC for 5 min, 4ºC for 5 min, and then stored at -20ºC. 
2.3.3. PCR 
Several PCR techniques are available based on RT-PCR technology, including non 
quantitative PCR, semi quantitative PCR and or quantitative „real time‟ PCR. „Real 
time‟ PCR was the primary method used in the studies described in this thesis. 
2.3.3.1. Principle of real-time quantitative RT-PCR 
Real-time analysis is possible by the simultaneous amplification and detection of 
target RNAs.  The technique uses fluorescent dyes that are either incorporated into 
probes which bind specifically to the nucleic acids (Bustin 2000) of interest or that 
intercalate specifically with double stranded DNA.  The TaqMan assay system 
developed by Perkin-Elmer-Applied Biosystems was used for studies in this thesis.  
This system relies on the 5‟ nuclease activity of DNA polymerase to hydrolyse a 
hybridisation probe bound to the target nucleic sequence. The hybridisation probe 
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contains a fluorescent reporter dye at the 5‟ end and a quencher of fluorescence at the 
3‟ end.  Breakdown of the hybridisation probe by the nuclease activity of taq 
polymerase breaks the reporter-quencher proximity, allowing the unquenched 
emission of fluorescence that is then detected. An increase in the nucleic acid 
sequences targeted by the fluorescent probe with each PCR cycle results in a 
proportional release of fluorescence, due to breakdown of probe and release of 
reporter.  The 3‟ end of the probe is altered chemically to prevent its extension during 
PCR cycling.  A schematic of this method is illustrated in Figure 2-1. 
 
Figure 2-1 Schematic of the TaqMan assay:  Forward and reverse primers define 
the hybridisation probes that bind within the target sequences.While 
the probe is intact, emmission of fluorescence is prevented by the close 
proximity of the reporter with the quencher dye. 5’ nuclease activity of 
DNA polymerase causes displacement of the probe and cleavage of the 
reporter form the quencher dye resulting in the emission and detection 
of fluorescence. 
Real-time quantitative PCR was performed using an ABI Prism 7700 Sequence 
Detection System (Perkin-Elmer Applied Biosystems, UK).   
2.3.3.2. Validation  
For each of the primers and probes used, calibration was carried out to ensure 
linearity of amplification.  Using normal human liver cDNA as template, the 
amplification of the house keeping gene 18S (supplied by the manufacturer) was 
Chapter 2  Methods 
78 
 
examined and compared with the genes of interest.  In particular it was confirmed that 
the 18S values of normal and diseased liver samples was similar.  Primer and probe 
concentrations used were those determined previously by validation techniques in the 
group. 
2.3.3.3. Primers and probes 
Primer Express software (Perkin-Elmer Applied Biosystems, UK) had been 
previously used to design primers and probes for the 11β-HSD1 mRNA and H6PDH 
and were available for use in the group. These primers were used in the analyses of all 
whole liver samples: 
11β-HSD1 forward primer: 5’-AGGAAAGCTCATGGGAGGACTAG-3‟  
11β-HSD1 reverse primer 5’-ATGGTGAATATCATCATGAAAAAGATTC-3’ 
11β-HSD1 hybridisation probe 5’-CATGCTCATTCTCAACCACATCACCAACA-3’ 
H6PDH forward primer: 5‟-AGAACTCGGGACCTTTTTCCA-3‟ 
H6PDH reverse primer: 5‟GCGCCACAGCCTGCTT-3‟ 
H6PDH hybridisation probe: 5‟-TAAGTAATGGTCCACCCGGTACATCTCCTCC-
3‟ 
11β-HSD1 and H6PDH primers used for laser capture microdissected samples were 
the ready mixed „assay on demand‟ (Applied biosystems, UK).  Primers for all other 
genes analysed were purchased as „assay on demand‟, detailed below: 
HSD11B1: Hs00194153_m1 
H6PDH: Hs00188728_m1 
Glut-2:  Hs00165775_m1  
G6Pase-α: Hs 00609178_m1 
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G6Pase-β: Hs00292720_m1 
G6PT:  Hs00184616_m1      
GR:   Hs01005217_m1 
CYP2E1: Hs00559368_m1 
Alcohol dehydrogenase (ADHB1): Hs00913384_m1 
PEPCK1: Hs00159918_m1 
PEPCK2: Hs00388934_m1 
2.3.3.4. Reagents 
TaqMan Universal PCR Master Mix: 3mM Mn(Oac)2, 200μM dNTPs, 1.25U 
AmpliTaq Gold polymerase, 1.25U Amp Erase UNG. 
2.3.3.5. Protocol and data analysis 
Real-time PCR was performed in 25μl volumes on 96 well plates, in a reaction buffer 
containing TaqMan Universal PCR Master Mix, 100nmol TaqMan probe, 900mmol 
primers, and 25-50ng cDNA. Cycling conditions were 50 ºC for 2 min, 95 ºC for 10 
min, and then 40 cycles of 95 ºC for 15 sec and 60 ºC for 1 min. All reactions were 
compared with reactions carried out in a separate well for each sample using the 18S 
control probe (PE Biosystems, UK). Data were analyzed according to the 
manufacturer‟s guidelines and were obtained as Ct values (the cycle number at which 
logarithmic PCR plots cross a calculated threshold line) and used to determine dCt 
values (dCt=Ct of the target gene minus Ct of the internal reference, 18S). Data was 
analysed at the dCt stage and mean +/- standard error dCt values transformed through 
the equation [fold increase = 2
-ddCt
] to give fold change in relative mRNA levels. 
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results obtained. 
2.4. Enzyme Assays 
Enzyme assays are used to detect the presence of enzymes in cells and tissue as well 
as to identify and characterize particular enzymes, and investigate substrate specificity 
and regulation of enzyme activity. The assumptions involved in these experiments 
and an understanding of the theoretical aspects of enzyme behaviour are fundamental 
in the interpretation of results obtained. 
The Michaelis-Menten model of single substrate reactions was used to approximate 
the 11β-HSD1 assays used in this thesis, Figure 2-2.
Figure 2-2 Michaelis-Menten saturation curve of an enzyme reaction 
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Measurement of the initial rate of the reaction over a range of substrate concentrations 
(denoted [S]), the rate of reaction (v) is seen to increase as [S] increases.  As [S] gets 
higher, enzyme [E] saturation occurs and the rate reaches Vmax, which the maximum 
rate of the enzyme.  If catalysis occurs via rapid reversible formation of the enzyme 
substrate complex [ES] which only slowly breaks down to regenerate enzyme and 
new product, then at equilibrium a constant Km can be defined where Km=[E][S]/[ES]. 
Based on this constant, the relationship between reaction velocity, V and [S], where 
Vmax is the limiting reaction velocity, can be described as: 
 V = 
       
      
   (The Michaelis Menten equation) 
It follows that when the reaction is at half maximum reaction velocity, (V = Vmax/2), 
[S] = Km.  Also, when [S] is small compared to Km, the reaction approximates to V= 
Vmax[S]/ Km, thus the reaction would conform to first order kinetics for the enzyme. 
The Vmax and Km value are highly characteristic for different enzymes and can vary 
significantly between enzymes.  For example, enzymes that have „house-keeping‟ 
functions tend to operate closer to their Vmax concentrations, so that reaction velocity 
is not dependent on [S]. Enzymes that have a more regulatory role are more likely to 
operate such that V is dependent on [S], with the in vivo substrate concentrations 
likely to be close to the Km value. 
Values determined in-vitro for reaction velocities depend on a number of assumptions 
that may not hold true when applied to the in vivo situation.  Intracellular substrate 
concentrations in vivo are unknown and therefore the assumption that substrate 
concentration is higher than enzyme concentration may not hold true.  Also, multiple 
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factors influence enzyme and substrate interaction in vivo which cannot be translated 
to in-vitro studies where E, S and ES are in equilibrium. 
2.4.1. Generation of tritiated cortisone (3H-cortisone) for 11β-HSD1 
assay 
3
H-cortisone until very recently was not commercially available, unlike tritiated 
cortisol (
3
H-cortisol).  An in house method was used to generate 
3
H-cortisone from 
3
H-cortisol utilising the high expression and activity of 11β-HSD2 in placenta. In a 
borosilicate tube 20μl of 3H-cortisol was incubated with 250mg protein from human 
term placenta, with 500mM NAD in 500μl of 0.1M potassium phosphate buffer, pH 
7.4, for 5 hours at 37ºC.  Steroids were extracted into 7 ml dichloromethane by 
shaking the tubes horizontally for 15 min followed by centrifugation at 80 g for 15 
min to separate aqueous and organic phases.  The aqueous phase was then aspirated 
and discarded.  The organic phase was evaporated to dryness at 50ºC under air in a 
sample concentrator (Techne, UK).  100μl dichloromethane was added and vortexed 
to resuspend the steroids.  This was then spotted onto a thin layer chromatography 
(TLC) plate.  The plate was run in a TLC chamber that was pre-equilibrated with 
chloroform:ethanol in a ratio of 92:8 until the solvent front was 5 mm from the top of 
the plate. A Bioscan 3000 imaging scanner (Lablogic, Sheffield, UK) was used to 
scan the dried silica plates.  Parallel lanes containing 1mg/ml unlabelled cortisone or 
cortisol were also included on the plate. The plate was viewed under UV light and 
unlabelled steroids were localised by their fluorescence, allowing tritiated steroids on 
the plate to be identified.  The area within 0.5 cm of the location of the 
3
H-cortisone 
was cut from the plate and the steroid was eluted overnight in 300μl ethanol at 4ºC.  
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The tube was then spun at 100g for 10 min and the liquid phase removed to a new 
tube.  The silica was then resuspended in a further 300μl of ethanol and the process 
was repeated.  The purity of the 
3
H-cortisone in the ethanol was assessed by further 
TLC analysis alongside unlabelled steroids.  The amount of ethanol was adjusted with 
addition or evaporation under nitrogen in a sample concentrator to give 100 cpm/μl.   
2.4.2. 11β-HSD1 assay 
11β-HSD1 assays in this thesis were carried out primarily on liver microsomes, which 
were prepared in MOPS buffer (section 2.7). Assays were carried out with various 
concentrations of cortisol (50nM to 1μM) with tracer amounts of 3H-cortisol (specific 
activity 78.4Ci/mmol, NEN, UK) or cortisone (50nM to 0.5μM) with tracer 3H-
cortisone and incubated at 37ºC.  Steroids were then extracted from the medium into 
10 volumes of dichloromethane and separated by TLC with chloroform : ethanol 
(92:8) as a mobile phase. The percentage conversion of cortisone to cortisol and 
cortisol to cortisone was analysed on a Bioscan 3000 Imager. The protein 
concentration of microsomes added to each tube was measured as described in section 
2.5. 
2.5. Protein assay 
Total protein concentration in liver tissue homogenates were measured using the 
BioRad RC DC protein assay.  This is a colourmetric assay for protein concentration 
following detergent solubilisation.  It is a modified version of the Lowry method 
(Lowry et al. 1951) and is based on the reaction of protein with an alkaline copper 
tartrate solution and Folin reagent and the subsequent reduction of  Folin reagent by 
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the copper treated protein.  The reduction of Folin reagent can produce several 
reduced species which have a characteristic blue colour, with a maximum absorbance 
at 750 nm and a minimum absorbance at 405 nm. 
2.5.1. Method 
Protein assays were carried out in 96 well plates according to the manufacturer‟s 
protocol  (BioRad, Hemel Hempstead, Herts). 5μl of protein sample or standard per 
well was added.  The range of standards were 0, 0.25, 0.5, 1, 2 mg/ml of bovine serum 
albumin (BSA). 25μl of solution A, alkaline copper tartrate solution, was added 
followed by 200μl of solution B, Folin reagent.  The solutions were incubated at room 
temperature for 10 min and the absorbance read at 690nm on a Victor3 1420 
multilabel counter (PerkinElmer, Beaconsfield, Bucks).  
 
2.6. Western Blotting  
Western blotting is an analytical technique that allows the detection of specific 
proteins in tissue homogenate or extract (Towbin et al. 1979). Sodium docecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is by far the commonest 
method used to separate denatured proteins according to molecular weight.  The 
proteins are then transferred to a membrane, usually nitrocellulose or polyvinylidine 
difluoride (PVDF).  The membrane is then blocked with generic proteins, such as 
milk or bovine serum albumin (BSA), to prevent non specific antibody binding, 
followed by incubation with the primary antibody that binds to the protein of interest.  
A conjugated secondary antibody is then directed against the primary antibody used. 
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Secondary antibody conjugated to horseradish peroxidise (HRP) was used for the 
western blotting carried out in this thesis.  HRP allows detection by catalysing the 
oxidation of a chemiluminescent substrate producing light, which is captured on 
photographic film. 
2.6.1. Method 
SDS-PAGE and protein transfer were carried out using a BioRad protein 3 apparatus 
and a modified protocol provided with the kit. Between 10-30μg of protein was mixed 
with the appropriate amount of loading buffer and then heated at 95°C for 5 mins.  
Samples were loaded on an 8-12% SDS-PAGE gel and run at 200V for 60 – 90 min.  
Proteins were then transferred onto a nitrocellulose membrane at 100V for 60 min. To 
check for efficient transfer, membranes were incubated in Ponceau stain with 
agitation for 2 min, and then rinsed with water until protein bands were visible. Bands 
should be distinct and well spread out.   
Membranes were then blocked in 10 ml of blocking buffer for 60 min with constant 
agitation, rinsed twice with washing buffer, and incubated in primary antibody 
overnight at 4°C with constant agitation.  Membranes were washed 3 times for 15 min 
in washing buffer and then incubated with the secondary antibody for 60 min at room 
temperature, followed by three washes of 15 min each in 50 ml of washing buffer.  
Chemiluminesence was used for antibody detection; substrate A and B were mixed in 
equal quantities (0.5 ml each per membrane) and allowed to equilibrate for 5 min. 1ml 
of substrate was put on each membrane and incubated for 2 min.  Membranes were 
then placed between two sheets of clear plastic and in the dark exposed to 
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photographic film for 2 sec and 1 h.  Photographic film was developed on Compact 
X4 (Xograph Imaging Systems, Gloustershire, UK).   
2.7. Liver microsome preparation 
Microsomes are vesicle like structures formed from the endoplasmic reticulum (ER) 
when cells are broken up in the laboratory.  They are not part of the normal 
ultrastructure of eukaryotic cells.  Microsomes are concentrated and purified from 
other cellular debris by differential centrifugation. At 10,000 g nuclei, unbroken cells 
and mitochondria sediment out, while fragmented ER, and soluble enzymes remain in 
solution.  At 100, 000 g microsomes are sedimented.  Microsomes are a valuable tool 
for investigating metabolism of compounds, in particular by membrane bound 
enzymes, and for identifying drug-drug interaction by in vitro methods. 
2.7.1. Reagents 
Sucrose buffer: 0.3M (10.26g) sucrose, 10 mM (121.1 mg) TrisHCl, 0.47 g 
Hepes, made up to 100 ml with water, pH adjusted to 7.2 with potassium hydroxide.  
The solution was stored in the fridge and 10ml aliquots were used. 1 EDTA free 
protease inhibitor tablet was added per 100mls. 
MOPS buffer:  0.75 g KCl, 0.12 g NaCl, 0.02g MgCl2, 0.42 g MOPS, pH 
adjusted to 7.2 with KOH and solution made up to 100 ml with water. 
2.7.2. Method 
A small chunk (~0.5 cm
3
) of snap frozen human/mouse liver or fresh mouse liver was 
homogenised with an electric homogeniser in 4 volumes of sucrose buffer, followed 
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by 5 – 10 strokes with a hand held glass dounce homogeniser on ice.  The 
homogenate was then centrifuged at 4°C for 10 min at 1000 g to remove debris.  The 
supernatant was centrifuged at 4°C for 10 min at 12 000 g.  The supernatant was then 
removed to a fresh tube and centrifuged for 4°C for 60 min at 100 000 g (Beckman 
Ultracentrifuge).  The pellet collected contained the microsomal fraction and was 
resuspended in 1 ml MOPS and the spin was repeated.  Finally the pellet was 
resuspended in 400 – 600 μl with a plastic Pasteur pipette, gently homogenised with 4 
– 5 strokes of a hand held 2 ml Dounce homogeniser. A small aliquot was removed to 
measure protein concentration (section 2.5).  50μl aliquots were snap frozen in liquid 
nitrogen and stored at -80°C. 
2.8. Laser capture microdissection 
Laser capture microdissection (LCM) is a specialised technique for isolating highly 
pure specific cell populations from a heterogeneous tissue section, live cell culture or 
cytological preparation under direct  microscopic visualisation (Emmert-Buck et al. 
1996). A variety of downstream applications exist, including DNA genotyping, RNA 
transcript profiling, generation of cDNA libraries, proteomics, and profiling of signal 
pathways. 
2.8.1. Principle 
A number of variations on the basic technique for LCM exist, including infrared (IR) 
laser platforms, combined IR/UV laser systems and pure UV laser systems.  The 
technique used in this thesis used a UV only laser system (Zeiss P.A.L.M. 
Microbeam).  Using this system almost every kind of biological material can be 
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microdissected and catapulted directly from glass slide, including archival 
pathological sections.   Optimal performance is obtained from cryosections. 
Tissue sections are mounted on glass slides covered with a polyethylene naphthlate 
(PEN) membrane. The membrane is easily cut and acts as a stabilizing backbone 
during catapulting.  It is 1.35 μm thick and is highly absorptive in the UV-A range, 
which facilitates laser cutting.  Once the cells of interest have been indentified and a 
region of interest created, the operator activates a software controlled UV laser beam, 
which is focussed so precisely that a beam accuracy of less than 1 μm can be 
achieved.  The selected specimen is removed and catapulted by a laser pulse in to a 
collection device (The inner aspect of the cap of a microcentrifuge tube), 
microdissecting the cells of interest from the heterogeneous tissue section Figure 2-3.  
The cellular morphology as well as RNA, DNA and proteins remain intact and bound 
to the membrane.  The UV laser system may also be used to ablate unwanted tissue 
leaving the cells of interest intact. 
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Figure 2-3 Principle of UV laser-capture microdissection.  The tissue is mounted 
on a polyethylene napthalate (PEN) or polyethylene tetraphthalate 
(PET) membrane. A UV laser can be used to cut away cells of interest 
or to ablate unwanted tissue, leaving cells of interest intact on the 
substratum (Espina et al. 2006). 
One potential limitation of the UV laser system is that capture of cell with UV-
induced damage.  These cells are derived from those directly under the UV laser 
cutting path, and may contribute significantly to the final molecular signal if the 
number of cells captured at the perimeter of the region of interest is high compared to 
the total number of microdissected cells in the region of interest.  
2.8.2. Method 
LCM of normal liver sections was carried for mRNA expression analysis using real-
time PCR for 11β-HSD1 localisation studies. The method required a considerable 
amount of optimisation to ensure good quality tissue sections and a good yield of 
RNA for successful real-time PCR which has been detailed in chapter 3.  A brief 
description of the overall method is described here.  An overview of the process from 
tissue collection to mRNA expression is illustrated in Figure 2-4. 
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Figure 2-4 Schematic of LCM procedure for mRNA expression studies 
2.8.2.1. Specimen preparation 
Cryosections of snap frozen liver tissues were carried out as described in section 
2.2.3., with a number of modifications as detailed in P.A.L.M. Microlaser 
Technologies protocols, and described in brief below.  
To ensure RNase-free membrane-slides, the slides were dipped for a few seconds into 
RNase-ZAP (Ambion), followed by two washes in DEPC treated water, and drying at 
room temperature for up to two hours. To overcome the hydrophobic nature of the 
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membrane on the PEN slides, the slides were then irradiated with UV light at 254 nm 
for 30 min.  This made the membrane more hydrophilic allowing the sections to 
obtain better adherence.  In addition, irradiation of the slides sterilized and destroyed 
potentially contaminating nucleic acids which was particularly important for RNA 
preparation from the captured cells. 
Liver tissue cryosections were cut at 8 μm thickness onto PEN membrane slides, air 
dried for 20 seconds and then fixed in ice cold 100% ethanol. The slides were then 
placed in a dessicator and stored at -80°C for future use or stained for immediate use 
for LCM. As OCT media interferes with laser efficiency it was important to remove 
any remaining media from the slide prior to laser capture.  As the OCT compound is 
easily removed by gentle washing in water, the substance was „automatically‟ 
removed in aqueous staining solutions or diluted ethanol.   
RNAase free water and solutions were used for staining and steps involving aqueous 
solutions were carried out as quickly as possible to reduce the effects of endogenous 
RNAses in the tissue sections. 
Haematoxylin staining was used as recommended; ethanol fixed slides were dipped in 
distilled water and then dipped in filtered haematoxylin for 3 minutes in an RNase 
free coplin jar, washed in distilled water and dehydrated in an increasing ethanol 
series.  The stained cryosections were allowed to dry for up to 30 min at room 
temperature before use. Cresyl violet was an alternative for staining, which only 
required rehydration with 50% ethanol rather than water. 
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2.8.2.2. Laser pressure catapulting of samples 
20-25 μl of lysis buffer from the Ambion RNAqueous-Micro Kit (Applied 
Biosystems) was pipetted into the inner ring of the cap of a 0.2 ml microcentrifuge 
tube.  Microbeam Version 2.3-0103 P.A.L.M. RoboSoftware was used to draw 
regions of interest under microscopic view of the sections.  The power and focus of 
the laser was optimised for fine cutting at the desired magnification and serial regions 
of interest were cut and catapulted into the tube cap in a single step automated 
software directed mechanism.  For each cell type captured, the total area captured was 
recorded.  For downstream analysis involving RNA work with real time PCR, the 
recommended area to capture was 0.8 – 1.0 x 106 μm2.  To control the efficiency of 
catapulting it was also possible to look into the tube cap with most catapulted areas 
visualised within the small inner ring of the caps. After microdissection, the sample 
within the buffer in the tube cap was spun down on a bench centrifuge and then stored 
for later use or immediately followed by the RNA extraction protocol. 
2.8.2.3. RNA extraction from LCM samples 
The Ambion RNAqueous-Micro Kit (Applied Biosystems) was used to extract RNA 
from the LCM samples.  The technique followed exactly as per manufacturers 
protocol, and followed by reverse transcription and real time PCR as described in 
section 2.3. 
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2.9. Clinical methods 
The bulk of the methods for the clinical study are described in section 6.3.  Clinical 
analyses of whole body hepatic 11β-HSD1 activity, and biochemical assays that were 
commonly used in the clinical studies described in chapter 4-7 and are described in 
further detail here. 
2.9.1. Cortisone to cortisol generation profile 
Measurement of hepatic first pass metabolism of cortisone to cortisol in 
dexamethasone suppressed individuals was made by determining the cortisol 
generation profile (CGC). At 2300 h, subjects were given 1 mg of dexamethasone 
orally to suppress endogenous cortisol production. All subjects attended the Clinical 
Research Facility at 0900 h the following morning, and after baseline 0900 h 
measurements of cortisol and adrenocorticotropic hormone, a further 0.5 mg of 
dexamethasone and cortisone acetate (25 mg) were given orally. Serum cortisol and 
cortisone concentrations were then measured at 30-min intervals for 240 min. Serum 
cortisol was assayed as described in section in section 2.9.4.  
2.9.2. Measurement of urinary steroids 
Urine steroid metabolite analysis was carried out on 24-h urine collections from 
subjects. All samples were analyzed by gas chromatography/mass spectrometry by 
Ms Beverley Hughes (Centre for Endocrinology, Diabetes and Metabolism, 
University of Birmingham), as reported previously (Palermo et al. 1996;Shackleton 
1993), measuring free and conjugated cortisol metabolites. Urinary steroid metabolite 
ratios and total 24-h cortisol metabolite production rates were determined. The 
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THF+5αTHF/THE, the cortols/cortolones, and the 11OH-androsterone+11OH-
etiocholanolone/11-oxoetiocholanolone ratios represent acknowledged markers of 
global 11β-HSD1 activity, with a high ratio indicating increased 11β-HSD reductase 
activity. Intra and inter-assay coefficients of variation were <10% for both cortisol 
and cortisone. 
 
2.9.3. Insulin ELISA 
The Mercodia Insulin Elisa kit (Mercodia, Sweden) was used for quantitative 
determination of serum insulin levels. 
2.9.3.1. Principle 
The Mercodia Insulin ELISA is a solid phase two-site enzyme immunoassay. It is 
based in the direct sandwich technique in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule.  Insulin in 
the sample reacts with peroxide-conjugated anti insulin antibodies and anti-insulin 
antibodies bound to the microtitration well during the incubation. A washing step 
removes the unbound enzyme labelled antibody.  The bound conjugate is detected by 
a reaction with 3,3‟,5,5‟-tetramethylbenzidine (TMB).  The reaction is stopped by 
adding acid to give a colorimetric endpoint that is read spectrophotometrically. 
2.9.3.2. Sample collection 
Blood samples were collected into tubes and centrifuged to separate the serum and 
stored at -80°C. 
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2.9.3.3. Method 
The ELISA procedure was carried out exactly as per manufacturer protocol 
(Mercodia, Sweden product no. 10-1113-01). 
Each sample was analysed in duplicate.  The interassay coefficient of variation was 
3.6%.  
2.9.4. Serum cortisol measurements 
The Coat-a-count cortisol radioimmunoassay (SIEMENS) was used to determine 
serum cortisol concentrations and were kindly performed by Ms Susan Hughes 
(Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham). 
2.9.4.1. Principle 
The procedure is a solid-phase radioimmunoassay, where 
125
I-labelled cortisol 
competes for a fixed time with cortisol in the patient sample for antibody sites.  As the 
antibody is immobilized to the wall of a polypropylene tube, decanting the 
supernatant is sufficient to terminate the competition and isolate the antibody bound 
fraction of the radiolabelled cortisol.  The tube is then counted in a gamma counter 
which yields a number that converts to a measure of the cortisol present in the sample 
by way of a calibration curve.  
2.9.4.2. Sample collection 
Samples were collected by collection into plain tubes without heparin and centrifuged 
to separate the serum.  Ultracentrifugation was carried out to clear lipaemic samples.  
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2.9.4.3. Method 
The protocol was followed exactly as per manufacturer instructions. In summary: 
4 plain uncoated tubes (to measure non specific binding) and twelve cortisol Ab-
coated tubes were labelled in duplicate for calibration. Additional cortisol Ab-Coated 
tubes were labelled in duplicate for patient samples. 
25μl of the zero calibrator were pipetted into the uncoated tubes and two calibration 
tubes. 25μl of each calibrator, control and patient sample were pipetted into the 
bottom of the remaining tubes. 
1 ml of 
125
I-cortisol was added to every tube and vortexed. 
The tubes were incubated for 45 minutes at 37°C.  The contents of the tubes were then 
decanted thoroughly using a foam decanting rack and allowed to drain for 2-3 
minutes, and struck sharply on absorbant paper to shake off the all the residue 
droplets. 
A gamma counter was used to count for 1 minute. 
Intra and inter-assay coefficients of variation were between 4 and 7% 
2.9.5. Plasma free fatty acid (FFA) analysis 
Plasma FFA were analysed on a COBAS BIO semiautomatic analyser (La Roche, 
Basel, Switzerland) using a NEFA-C Kit (Alpha Laboratories, UK) as per 
manufacturer protocol. These samples were analysed by Professor Anton 
Wagenmakers (Sport and Exercise Science, University of Birmingham).  
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3. In vitro characterisation of hepatic 11β-HSD1 with 
relevance to hepatic glucose metabolism 
The bulk of the in vitro work carried out for this thesis has been detailed in relevant 
chapters underpinning clinical data described.  The work described in this chapter 
details additional in vitro work to further characterise 11β-HSD1 in the liver. 
3.1. Introduction 
3.1.1. Compartmentalised function of the liver in normal physiology 
It has become increasingly apparent over the last thirty years or more that most, if not 
all the functions of the liver are heterogeneously distributed, with the activity of each 
process varying across the acinus (the functional unit of the liver) (Gebhardt and 
Mecke 1983;Gumucio 1989), section 1.3.1.  This zonation of function is manifested 
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by phenotypic differences between cells depending on their position within the acinus 
and appears to be characteristic of all the major metabolic pathways in the liver in 
normal physiology.  Seminal studies demonstrated the acinar distribution of 
carbohydrate metabolism (Jungermann and Thurman 1992) and nitrogen metabolism 
(Haussinger et al. 1992), with both processes displaying distinct and prominent 
compartmentalisation.  Zonation of function is particularly apparent in drug 
metabolism by P450 enzymes (Traber et al. 1989), an important factor in the zonation 
of hepatocellular damage elicited by many hepatotoxins.  There is now a significant 
volume of evidence suggesting the majority of liver genes are differentially expressed 
within the acinus in upstream (periportal), or downstream (perivenous) hepatocytes, 
Table 3-1.  
 
Table 3-1 Zonation of the major metabolic pathways of the liver (Lindros 1997) 
In addition, hepatic zonation has been demonstrated at multiple cellular levels.  
Morphological studies have demonstrated that not only the number of cells, but also 
the size of the cell organelles vary along the length of the sinusoid (refer to Figure 1-2 
for basic structure of liver lobule).  In particular, periportal hepatocytes contain larger 
and fewer mitochondria whilst perivenous hepatocytes contain larger and more 
abundant endoplasmic reticulum, (ER).  This is an important observation with 
relevance to the zonation of hepatic microsomal enzymes, in particular 11β-HSD1 
expression. Sinusoidal cells such as Kuppfer cells, endothelial cells and stellate cells 
also display zonation, being more numerous in the periportal region (Sasse et al. 
General metabolism Drug metabolism General metabolism Drug metabolism
Oxidative energy metabolism Bile acid production Glycolysis Monoxygenation (P450)
Fatty acid oxidation Glutathione production Lipogenesis Glutathione conjugation
Gluconeogenesis Glucuronidation
Ureagenesis
Periportal zone Perivenous zone
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1992).  While these gradients of expression within the acinus are very well 
characterised, knowledge of the control of zonal expression is still lacking.  Many 
studies have shown that in fact, hepatic zonation is dynamic, with only a few 
exceptions, resulting from differential sinusoidal gradients of oxygen, nutrients and 
hormones (Jungermann et al. 1982), Table 3-2. Some enzymes are expressed in a 
strictly limited compartment type of expression, for example, glutamine synthetase 
which is involved in ammonia detoxification, is located specifically near the terminal 
hepatic veins and requires specific cell-cell interactions that define the position 
dependant phenotype (Kuo and Darnell, Jr. 1991), and may result from an imprinting 
process during the final differentiation and maturation of periportal liver cells 
(Gumucio 1989). 
 
Table 3-2 Suggested zone modulators of liver gene expression (Lindros 1997) 
Of particular importance, are the enzymes involved in hepatic drug metabolism.  
Indeed, hepatocytes represent 70% of liver mass, and express drug metabolising 
enzymes (well described for P450 enzymes) at high levels compared to non 
parenchymal cells.  However, depending on their position some are more involved in 
drug metabolism than others. The highest level of phase I and phase II enzymes are 
found in the perivenous cells. 
Modulator Zonation pattern
Sinusoidal oxygen tension gradient dynamic gradient
Sinusoidal gradient of hormones and/or receptors dynamic gradient
Sinusoidal gradient  of expression of transcription factors dynamic gradient
Cell lineage dependent imprinting of positional phenotype compartment-type/ dynamic
Specific cell-cell or cell-matrix interactions compartment-type
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3.1.1.1. Enzyme activation and zonation 
The question arises whether the enzymes expressed in hepatocytes are activated to the 
same extent regardless of zonation in the presence of similar concentrations of 
substrate.  Much work has been done on several P450 isoforms that are induced by 
specific compounds (for example the induction of CYP2E1 by ethanol and acetone).  
In perivenous hepatocytes expressing these enzymes, enzyme induction occurs more 
readily than in hepatocytes with low expression of the enzyme (Rich et al. 1989).  
Hence, the intrahepatic enzyme zonation, which is often attributed to differential 
expression of enzyme protein, could also result from zonal differences in enzyme 
specific activity which may be due to differences in allosteric and/or covalent 
modification.  This has been demonstrated for numerous hepatic enzymes including 
key enzymes involved in hepatic lipogenesis (Evans et al. 1990). 
3.1.1.2. Hormonal regulation of zonation 
Studies have shown that when hepatocytes are isolated from the perivenous or the 
pericentral zone and maintained in culture in the presence or absence of hormones, the 
difference in rates of gluconeogenesis and urea synthesis do not converge, suggesting 
that there are long acting mechanisms involved in the induction and maintenance of 
heterogeneity in vivo (Poso et al. 1986;Quistorff et al. 1986;Tosh et al. 1988). The 
effect of altering the endocrine state in vivo on the hepatic zonation of enzyme 
activity has also been investigated.  Hypophysectomised rats show marked reduction 
in circulating concentrations of glucocorticoids, thyroid hormone and growth 
hormone, associated with changes in the activity of a number of hepatic enzymes 
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which are known to be distributed heterogeneously within the acinus (Csanyi and 
Greengard 1968;Wong and Dunn 1977).  Another study showed that, while 
hypophysectomy caused significant changes in the activities of alanine 
aminotransferase and pyruvate kinase, the degree of heterogeneity of enzyme activity 
within the liver acinus, and of the rates of gluconeogenesis and mitochondrial redox 
state was preserved (Tosh, Alberti, & Agius 1988). Another study investigating the 
effect of hormones on the activity and zonation of specific P450 enzymes showed that 
although common hormonally acting elements appear to regulate zonation (e.g., the 
effect of growth hormone on the spatial expression of CYP2B and 3A), the zonation 
of other CYP forms appear to be regulated by thus far undefined factors.  
3.1.1.3. Hepatic zonation of 11β-HSD1 
Previously reported protein expression studies using immunohistochemistry showed 
11β-HSD1 expression in hepatocytes in a perivenous distribution, with little or no 
expression around the portal vein, hepatic artery or bile ducts (Ricketts et al 1998b). 
The physiological significance of this is not immediately apparent and is in contrast to 
both the homogeneous, ubiquitous distribution of the hepatic glucocorticoid receptor 
(Antakly and Eisen 1984), and the heterogeneity of hepatic enzyme expression related 
to gluconeogenesis (Jungermann & Thurman 1992). The predominant activities in the 
periportal zone are oxidative energy metabolism with beta-oxidation and amino acid 
metabolism, ureagenesis, gluconeogenesis, cholesterol synthesis, bile formation and 
oxidation protection. By contrast, in the perivenous zone glycolysis, lipogenesis, 
ketogenesis, glutamine formation and biotransformation are the prevalent processes, 
Table 3-1.  Hence, physiologically one would anticipate hepatic 11β-HSD1 
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expression to localise with functions known to be stimulated by glucocorticoids, 
including gluconeogenesis (periportal), glycolysis (perivenous) and lipogenesis 
(perivenous). In particular, promotion of hepatocyte de novo lipogenesis, and 
inhibition of fatty acid beta oxidation by glucocorticoids would be supported by the 
perivenous distribution of 11β-HSD1 expression, with a clear role in the pathogenesis 
of the hepatic fat deposition leading to hepatic steatosis. 
3.1.1.4. AIM -1 
On this background one of the primary aims of the in vitro work was to further 
establish the zonation of 11β-HSD1 expression in normal human liver using western 
blotting techniques to investigate protein expression and laser beam microdissection 
studies to investigate mRNA levels in hepatocytes isolated from different zones in the 
normal hepatic acinus. 
3.1.2. Hepatic 11β-HSD1 expression and activity with relevance to 
glucose signalling and carbohydrate metabolism in normal and 
diseased liver 
The association of chronic liver disease with impaired glucose metabolism has been 
recognised for over a century and led to the term „hepatogenous diabetes‟ being 
coined (Naunyn 1906).  The impairment of glucose tolerance worsens with the 
progression of chronic hepatitis to liver cirrhosis.  The prevalence of impaired glucose 
tolerance in cirrhotic patients is 60-80%, and of overt diabetes about 15%. As the term 
CLD encompasses different stages of liver dysfunction and the involvement of a 
number of intrinsic and extrinsic factors, the exact pathogenic mechanisms underlying 
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this relationship are not entirely clear. For example, continuous alcohol intake in 
alcoholic hepatitis, hepatic steatosis in NAFLD, or reduced insulin clearance in portal 
hypertension, can all directly affect glucose metabolism. Dysregulation of 
carbohydrate metabolism in non alcoholic fatty liver disease is detailed in section 
1.3.4. While alcoholic hypoglycaemia is one of the better known alterations in hepatic 
glucose metabolism (Freinkel et al. 1963), alcohol excess also induces glucose 
intolerance (Andersen et al. 1983).  The diabetogenic effect of alcohol is more likely 
to be secondary to an inhibitory effect on insulin secretion rather than effect on 
peripheral insulin sensitivity.  Reports on peripheral insulin resistance measured by 
euglycaemic clamps have been inconsistent, but studies have consistently shown that 
alcohol inhibits glucose stimulated insulin secretion (Bunout et al. 1989). 
A number of findings have suggested that common mechanisms underly insulin 
resistance in the entire spectrum of CLD regardless of the cause, and also in the stages 
heralding the onset of cirrhosis. For example, CLD is characterised by alterations in 
the growth hormone-insulin like growth factor-1 (GH-IGF-1) axis, with resistance to 
GH worsening with progressive liver disease (Picardi et al. 2003).  These alterations 
in the GH-IGF-1 axis also significantly alter blood glucose control.  In addition, as 
with other chronic inflammatory conditions, proinflammatory cytokines such as 
TNFα, IL-1 and IL-6 impair insulin action directly and impact upon the insulin 
signalling cascade through their effect on the GH-IGF-1 axis. 
Given the critical impact of glucocorticoids upon hepatic carbohydrate metabolism 
(discussed in detail in section 1.4.6.1), dysregulation of pre receptor glucocorticoid 
metabolism as a common mechanism in the pathogenesis of impaired glucose 
tolerance in chronic liver disease is an exciting and plausible possibility.  An 
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introduction to key background studies relating to 11β-HSD1 and insulin sensitivity 
and chronic liver disease are detailed in sections 1.5.3.2., and 1.5.3.3 respectively. 
3.1.2.1. AIM-2 
On this background another aim of the in vitro work was to evaluate hepatic 11β-
HSD1 expression and activity in normal liver and in chronic liver diseases (alcoholic 
liver disease, NAFLD and other non alcoholic chronic liver disease), comparing 
mRNA expression of 11β-HSD1 with key enzymes of hepatic gluconeogenesis 
(PEPCK, G6Pase, and the GLUT 2 glucose transporter), and enzymes specifically 
relating to increased oxidative stress in alcoholic liver disease (CYP2E1 and alcohol 
dehydrogenase). Current studies are ongoing to compare 11β-HSD1 reductase and 
dehydrogenase activity assays from microsomal preparations of whole liver samples 
from normal and diseased groups. 
3.2. Methods   
3.2.1. Liver samples 
Frozen human liver tissue (normal donor liver, or diseased explanted liver) was 
received from the tissue bank at the Centre for Liver Research, University of 
Birmingham as described in section 2.1. Thirty samples in total were obtained as 
follows: 5 normal livers, 9 with severe NAFLD, 7 with alcoholic liver disease, 9 with 
chronic liver disease (of which 5 had primary biliary cirrhosis, 1 had primary 
sclerosing cholangtis and one had haemachromatosis).  Histology was verified from 
histopathology reports.  The number of samples included in the final analysis for 
mRNA expression was less than the number stated because there were some livers 
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with degraded RNA and were hence unsuitable for analysis. Normal liver samples for 
paraffin sections were also obtained from the above source. 
3.2.2. 11β-HSD1 immunohistochemistry in normal and diseased liver 
Immunohistochemical analysis of 11β-HSD1 protein expression in paraffin sections 
of normal liver was carried out as described in section 2.2.  
Further immunohistochemistry for 11β-HSD1 was carried out on frozen sections of 
normal and NAFLD livers.  This study is described in detail in chapter 7. 
3.2.3. Laser capture microdissection 
Laser capture microdissection of hepatocytes from cryosections of normal liver was 
undertaken. The method is described in section 2.8 in detail and required a 
considerable amount of optimisation to ensure good quality tissue sections and a good 
yield of RNA for successful real-time PCR.  The important points essential for 
optimal results, that were not detailed in the manufacturer protocol, or required a 
change in protocol suggested by Carl Zeiss (Carl Zeiss, Germany) were as follows. 
3.2.3.1. Cryosectioning and fixation  
Cryosections of normal liver onto PALM membrane slides was associated with a 
number of difficulties compared with sectioning onto normal glass slides.  In 
particular the sections tended not stick very well onto the membrane surface of the 
slide.  After being mounted on the slide, the ethanol fixation step often resulted in the 
sections lifting off the slides completely, even when this step was reduced to only 20 
– 30 seconds.  These difficulties were optimised by altering a number of steps.  The 
slides were always treated with UV light for 30 minutes prior to use, to improve the 
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adherence of the sections onto the slides as well as reducing the presence of degrading 
RNAses.  The liver blocks were allowed to equilibrate in the cryostat for 30 minutes 
prior to cutting. Once cut, the slides were allowed to remain opposed to the cut 
section on the anti roll plate of the cryostat for a few extra seconds and lifted off 
slowly.   
The sections were not fixed in ethanol as recommended but allowed to air dry and 
then wrapped in foil and stored at -80°C till use or stained straight away prior to laser 
capture. 
3.2.3.2. Staining of cryosections mounted on membrane slides 
The staining protocols recommended a hydration step in water for staining in 
haematoxylin followed by dehydration in ethanol, prior to laser capture. This resulted 
consistently in sections with extremely poor and distorted morphology (Figure 3-1) 
that failed to yield good quality RNA, or slides where air bubbles would appear under 
the section due to the membrane lifting away from the slide and hence making cutting 
impossible.   
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Figure 3-1 Central vein (cv) and surrounding areas on normal human liver 
cryosection, stained with haematoxylin on membrane coated slide. 
Note poor distorted morphology. 
Hence it was decided to stain in cresyl violet that did not require full hydration of the 
sections as the cresyl violet stain is diluted in ethanol.  This yielded somewhat better 
results in appearance of the sections and yield of RNA, but the problems with the 
sections lifting off the slide with ethanol washes persisted. 
In collaboration with Dr Mahmood Khan (Department of Immunity and Infection, 
University of Birmingham) an optimal fixing and staining technique was devised that 
overcame all the above problems.  Sections that had been air dried on the membrane 
slides were placed on an RNAase inhibitor treated flat surface, and a wax pen was 
used to draw around the perimeter of the membrane.  300μl of cresyl violet stain was 
pipetted onto the section and allowed to stain the section over 3 minutes after which 
excess stain was drained from the slides onto a paper towel. Excess cresyl violet stain 
was removed by a quick in and out dip in 100% ice cold ethanol, in a coplin jar. The 
cv 
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slides were then allowed to completely air dry (about 5 minutes) before proceeding 
with laser capture. 
3.2.3.3. Morphology of sections on membrane coated slides 
While the above staining procedure vastly improved the morphology of the sections, 
the appearance of the sections was still sub optimal compared with sections on glass 
slides with a cover slip, Figure 3-2.   
 
Figure 3-2 Significantly improved morphology of liver tisue cryosections on 
membrane coated slide following optimisation of protocol.  The image 
is of a central vein (cv) and surrounding parenchyma.  Note effect of 
ethanol dehydration on fracturing the tissue section in multiple areas. 
While the periportal and perivenous areas were clearly visible the dehydrated sections 
showed tiny fractures throughout the field of view.  In addition the laser capture 
procedure for each slide needed to be completed within a short time frame to ensure 
the viability of the RNA. To overcome this problem, investigations were carried for 
reported techniques to improve morphology further and allow cutting time to be 
cv 
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extended to avoid wastage of slides – each slide required around 2 to 3 hours of 
cutting time. A fluid cover medium, PALM Liquid Cover Glass (LiquidCoverglass, 
PALM AG, Bernried, Germany) provides improved morphology and preserves RNA 
integrity in tissue sections for laser microdissection and pressure catapulting (Micke 
et al. 2004). This was applied by aerosol to improve morphology and to allow larger 
tissue areas to be laser pressure-catapulted, and sections were air dried for 5 minutes 
after application of the medium.   
 
Figure 3-3  Further improved tissue morphology with the optimised fixing and 
staining technique with cresyl violet and the use of PALM Liquid Cover 
Glass. Panels A area drawn around central vein, B appearance 
follwing cut and pressure catapulting of pericentral area including 
central vein, C area of periportal hepatocytes marked for cutting, D 
appearance post cut and pressure catapulting of periportal 
hepatocytes. (pv - portal vein, cv - central vein). 
A 
D 
B 
C 
pv 
cv 
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The resulting appearance of the tissue sections were much improved and RNA yields 
were improved with extended cutting times, Figure 3-3. 
After optimisation of the technique, laser capture microdissection and pressure 
catapulting was carried out on perivenous and periportal areas of 3 normal livers as 
described above.  Around 60 separate regions were captured for each area per slide 
(~10
6
 μm2).   
3.2.3.4. Sample and primers used for analysis of LCM samples 
RNA extraction, reverse transcription and real time PCR was performed as described 
in section 2.3). To determine zonation of 11β-HSD1 mRNA expression, real time 
PCR analysis of mRNA expression was carried out for 11β-HSD1 as well as other 
liver enzymes with known fixed zonation of protein and mRNA expression. CYP2E1 
was chosen on the basis of its strong perivenous expression in a „compartment-type‟ 
manner (see section 3.1.1.1) (Ingelman-Sundberg et al. 1988). In addition mRNA 
expression of the steroid A ring reductases 5α-reductase 1 and 2, and glucocorticoid 
receptor α were analysed by real time PCR with microdissected samples pooled for 
the perivenous and periportal areas retrieved from each liver. All reactions were 
carried out alongside a control reaction with primers specific for 18S rRNA (provided 
as a pre-optimized mix; Perkin-Elmer, Beaconsfield, Bucks, UK) as an internal 
reference. All target gene probes were labelled with the fluorescent label FAM, and 
the 18S probe with the fluorescent label VIC. Details of primers used are detailed in 
section 2.3.3.3. 
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3.2.4. mRNA detection and quantification of 11β-HSD1 and genes 
related to hepatic gluconeogenesis and oxidative stress in normal 
liver and diseased liver states 
Methods are described in detail section 2.3.2.3.  HSD11B1, H6PDH, and 
glucocorticoid receptor α expression was investigated in all groups.  The rate limiting 
enzyme of gluconeogenesis, PEPCK (cytosolic and mitochondrial isoforms) as well 
as key ER enzymes and proteins related to hepatic glucose output via gluconeogenesis 
and glycogenolysis: glucose-6-phosphatase (G6Pase), the glucose 6 phosphate 
transporter, and the hepatic glucose transporter GLUT 2 were analysed.  Key enzymes 
related to oxidative stress in alcoholic liver disease P450IIE1 and alcohol 
dehydrogenase (ADHB1 isoform) were also compared between groups. 
Data was analysed at the dCt stage and mean +/- standard error dCt values 
transformed through the equation [fold increase = 2
-ddCt
] to give fold change in 
relative mRNA levels. Arbitrary units were also to describe the data using the 
transformation [AU=1000*2
-dCt
] to express results obtained. 
3.2.5. Liver microsome preparation 
Microsomes were prepared from all the liver samples obtained.  The method is 
described in section 2.4.2.  
3.2.6. 11β-HSD1 assay on liver microsomes from normal and diseased 
groups 
The method is described in section 2.4.2.  At the time of writing this thesis the 
reaction conditions for 11β-HSD1 assays on liver microsomes from snap frozen 
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samples had been optimised.  The comparative assays between groups had not yet 
been performed. 
3.3. Results 
3.3.1. 11β-HSD1 immunohistochemistry on normal liver 
11β-HSD1 immunohistochemistry on paraffin sections of normal human liver showed 
a perivenous zonal distribution of staining in keeping with previously described 
results (Ricketts & Stewart 1999).  However, repeated experiments also showed a 
lesser degree of periportal staining with least staining in hepatocytes distant from 
periportal and perivenous areas.  Periportal staining was more prominent when a 
lower dilution of primary antibody was used.  Within the portal triad, hepatic artery 
staining was not seen.  Peri bile duct staining was seen in the paraffin sections but this 
was an inconsistent finding and was not seen with immunohistochemistry carried out 
on cryosections, Figure 3-4 and Figure 3-5. 
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Figure 3-4 Immunohistochemistry for 11β-HSD1 protein expression in paraffin 
sections of normal human liver(cv - central vein, pv - portal vein). A 
11β-HSD1 antibody at a dilution of 1:300 showing distinct perivenous 
staining, C perivenous staining with antibody dilution of 1:100 also 
shows staining in hepatocytes distant from vessels. B-D 11β-HSD1 
antibody at a dilution of 1:100.  B evidence of periportal staining (not 
as clearly seen with 1:100 dilution). D x40 magnification of periportal 
hepatocytes showing increased staining for 11β-HSD1. E-F 11β-HSD1 
antibody at a dilution of 1:100 in the presence of an excess 
neutralising peptide. 
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Figure 3-5 Immunohistochemcal detection of 11β-HSD1expression in cryosections 
of normal human liver (cv - central vein, pv - portal vein, bd – bile 
duct). A-C 11β-HSD1 dilution of 1:200. A low power magnification 
view showing clear perivenous zonation of 11β-HSD1 protein staining. 
B x20 view of pervinous staining. C low power magnification view 
showing a suggestion of periportal hepatocyte staining. D 11β-HSD1 
dilution of 1:100 showing clear periportal hepatocyte staining and no 
staining of bile ducts or hepatic artery within portal triad. 
3.3.2. Laser capture microdissection to determine hepatic zonation of 
11β-HSD1 mRNA expression  
Laser capture microdissection and pressure catapulting was carried out on perivenous 
and periportal areas of 3 normal livers as described in section 3.2.3.4.   
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Using 18s as an internal reference, real time PCR analysis of RNA extracted from 
perivenous and periportal hepatocytes showed significant differences in mRNA 
expression of genes related to hepatic steroid metabolism. CYP2E1 expression was 
nearly 13-fold higher in perivenous hepatocytes, supporting widely published data on 
CYP2E1 zonation. HSD11mRNA expression was 6 fold higher in perivenous 
hepatocytes compared with periportal hepatocytes. mRNA expression of the A-ring 
reductases 5α-reductase 1 and 2 (SRD5A1 and SRD5A2) were also higher in the 
perivenous areas but this achieved statistical significance only for 5α-reductase 2. 
Glucocorticoid receptor α (NR3C1) mRNA expression was similar in perivenous and 
periportal areas, in keeping with previously published data of homogenous expression 
throughout the liver parenchyma (Antakly & Eisen 1984).  
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Figure 3-6 mRNA expression (fold change) in periportal hepatocytes compared 
with perivenous hepatocytes.  ** p<0.01,* p<0.05 perivenous vs 
periportal. Table displaying dCt values and SE of mRNA expression of 
each gene in periportal (pp) and perivenous (pv) areas. 
3.3.3. Hepatic expression of HSD11B1, H6PDH and key enzymes related 
to glucose metabolism, and ER stress in normal liver and 
diseased liver states 
HSD11B1 mRNA expression in normal liver compared with diseased liver states are 
detailed in chapter 7 (non alcoholic steatohepatitis alcoholic liver disease), chapter 5, 
(other non alcoholic chronic liver diseases),and chapter 4 (glycogen storage disease). 
These are summarised collectively in Figure 3-7. 
 
Figure 3-7 HSD11B1 mRNA expression (expressed in arbitrary units +/- SE) in 
normal liver and diseased liver states. * p<0.01 compared with 
normal, ** p<0.001 compared with normal and other diseased liver 
states. (NASH non alcoholic steatohepatitis, ALD alcoholic liver 
disease, CLD other non alcoholic chronic liver diseases, GSD 
glycogen storage disease type 1a). 
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3.3.3.1. Glucocorticoid receptor α expression in normal and diseased liver 
groups 
The pattern of expression of glucocorticoid receptor mRNA expression was very 
similar to that for 11β-HSD1 and was highest in the GSD1a group compared with all 
other groups.  NASH, ALD and CLD liver groups all had higher GRα mRNA 
expression compared with normal, but statistical significance was achieved in the 
NASH and CLD groups only.  
 
Figure 3-8 GRα mRNA expression in normal and diseased liver groups;  *p < 
0.05 compared with normals, **p < 0.01 compared with normals and 
other diseased liver groups (data expressed as arbitrary units +/- SE). 
3.3.3.2. Hexose-6-phosphate dehydrogenase 
H6PDH mRNA expression was investigated in all groups with the exception of 
glycogen storage disease (the GSD1a tissue had not yet been obtained at the time of 
this investigation). H6PDH mRNA expression was notably higher in alcoholic liver 
disease compared with normal as well as NASH liver.  There was no significant 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Normal NASH ALD CLD GSD1a
G
R
α
m
R
N
A
 e
x
p
re
s
s
io
n
A
U
**
*
* 
* 
Chapter 3  In vitro characterisation of hepatic 11β-HSD1 
118 
 
difference in mRNA expression of H6PDH between NASH and other non alcoholic 
chronic liver diseases (CLD) and normal. (dCT +/- SEM: Normal 12.1 +/- 0.4, NASH 
12.7 +/- 0.4, ALD 11.3 +/- 0.4, CLD 12.4 +/- 0.5; p <0.05 ALD vs normal and 
NASH). 
 
Figure 3-9 H6PDH mRNA expression in normal liver (NASH), alcoholic liver 
disease, and other non alcoholic chronic liver diseases (CLD). Data 
expressed as arbitrary units +/- SE, *p<0.05 compared with normal 
and NASH group. 
3.3.3.3. mRNA expression of key rate limiting enzymes and proteins 
governing hepatic glucose output in normal and diseased liver 
mRNA expression of both isoforms of PEPCK, PEPCK1 (cytosolic) and PEPCK 2 
(mitochondrial) was investigated in normal and diseased liver samples.  PEPCK 2 
mRNA expression was most notably different in diseased groups compared to normal 
with significantly higher expression in NASH and ALD groups but no significant 
difference between normal and CLD groups. PEPCK1 mRNA expression was highest 
in NASH and ALD groups but the increase seen in the ALD group compared with 
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normal was not statistically significant : PEPCK1(mean dCt +/- SEM): Normal 6.24 
+/- 0.8, NASH 4.6 +/- 0.3, ALD 4.6 +/- 0.3, CLD 6.0 +/- 0.6. PEPCK2: Normal 12.9 
+/- 0.5, NASH 10.1 +/- 0.3, ALD 9.6 +/- 0.4, CLD 11.5 +/- 0.6., Figure 3-10.  
 
 
Figure 3-10 Hepatic expression of PEPCK1 (top panel) and PEPCK2 (lower panel) 
mRNA expression in normal and diseased liver groups expressed in 
arbitrary units +/- SE. PEPCK1 expression *p <0.05 NASH compared 
with normal and CLD groups. PEPCK2 expression **p <0.01 NASH 
and ALD compared with normal and CLD groups. 
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mRNA expression of the glucose 6 phosphate transporter (G6PT) was significantly 
increased in the ALD group compared with normal. Increased expression was also 
seen in the NASH group but this did not achieve statistical significance. G6PT (mean 
dCt +/- SEM): Normal 14.5 +/- 0.6, NASH 13.3 +/- 0.4, ALD 13.1 +/- 0.3, CLD 14.1 
+/- 0.6.  
Figure 3-11 G6PT mRNA expression in normal and diseased liver groups expressed 
as arbitrary units +/- SE. *p <0.05 ALD compared with normal. 
Glucose 6 phosphatase (G6Pase) α subunit mRNA expression analysis showed very 
significant induction of mRNA expression in NASH, and to a lesser degree in ALD 
liver samples.  No difference was seen in G6Pase α mRNA expression in CLD 
compared with normal.   G6Pase α (mean dCt +/- SEM): Normal 9.90 +/- 0.7, NASH 
7.9 +/- 0.4, ALD 7.7 +/- 0.3, CLD 8.7 +/- 0.5, Figure 3-12.  mRNA expression of the 
β subunit of G6Pase was similar in all groups. 
mRNA expression of the hepatic glucose transporter GLUT 2 was significantly 
increased in all diseased liver groups compared with normal. GLUT 2  (mean dCt +/- 
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SEM): Normal 10.1 +/- 0.5, NASH 7.9 +/- 0.3, ALD 7.9 +/- 0.3, CLD 8.1 +/- 0.5, 
Figure 3-13. 
 
 
Figure 3-12 G6Pase α mRNA expression in normal and diseased liver expressed as 
arbitrary units +/- SE. **p < 0.01 NASH compared with normal,*p < 
0.05 ALD compared with normal. 
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Figure 3-13 GLUT2 mRNA expression in normal and diseased liver expressed as 
arbitrary units +/- SE. * p < 0.01 for all diseased groups compared 
with normal.  
3.3.3.4. Comparative mRNA expression of cytochrome P450IIE1 and alcohol 
dehydrogenase in normal and diseased liver groups 
CYP 2E1 mRNA expression was significantly increased in the NASH liver samples 
compared with normal. Expression was similar between normal and CLD groups. In 
the ALD samples CYP2E1 expression appeared to be decreased compared with 
normal but this was not statistically significant.  CYP2E1  (mean dCt +/- SEM):
Normal 4.4 +/- 0.6, NASH 3.7 +/- 0.4, ALD 5.1 +/- 0.4, CLD 4.5 +/- 0.5, Figure 3-14. 
ADHB1 expression was significantly higher than normal in all diseased groups, and 
highest in the NASH group.  ADHB1 (mean dCt +/- SEM): Normal 6.8 +/- 0.7, 
NASH 4.0 +/- 0.3, ALD 4.6 +/- 0.3, CLD 4.8 +/- 0.6, Figure 3-15. 
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Figure 3-14 CYP2E1 mRNA expression in normal and diseased liver expressed as 
arbitrary units +/- SE. * p < 0.05 NASH compared with normal and 
ALD groups.  
 
Figure 3-15 Alcohol dehydrogenase mRNA expression in normal and diseased liver 
groups expressed as arbitrary units +/- SE. * p < 0.01 compared with 
normal for diseased group compared with normal, ** p < 0.01 NASH 
compared with normal and p < 0.05 NASH compared with ALD. 
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3.3.4. 11β-HSD1 assay on microsomes from snap frozen normal human 
liver 
Microsomes were prepared from all thirty liver samples from normal and diseased 
groups with the intention to perform comparative 11β-HSD1 assays between groups. 
At the time of writing, following the preparation of microsomes, optimisation of the 
method was carried out using microsomes from snap frozen normal liver (in triplicate) 
to determine the reaction conditions and concentration of microsomal protein  
required per assay to yield optimal results. It was decided to use 100μg of microsomal 
protein per reaction with a one hour incubation at 37°C, with which the percentage
 
of 
substrate metabolized in each experiment was 10% or less,
 
ensuring that initial rates 
of metabolism were being measured, Figure 3-16.  
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Figure 3-16 11β-HSD1 reductase activity in liver microsomes from snap fozen 
normal human liver. Upper panel: Conversion as pmol cortisol/mg 
microsomal protein/hour in preparations of assay with increasing 
concentrations of protein used per assay. Lower panel: data illustrated 
as percentage conversion of E to F with different concentrations of 
microsomal protein. 
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3.4. Discussion 
3.4.1. Hepatic zonation of steroid metabolism 
The immunohistochemistry and laser capture microdissection studies confirmed the 
perivenous zonation of 11β-HSD1 protein and gene expression in normal human 
liver.  There was a lesser degree of localisation of 11β-HSD1 to periportal 
hepatocytes, where protein expression was greater than in the parencymal cells in 
intermediate areas.  Furthermore, there was evidence of preferential perivenous 
zonation of mRNA expression of the A-ring reductase 5α-reductase 2. Glucocorticoid 
receptor α mRNA expression was similar between perivenous and periportal areas in 
keeping with previously published reports of homogenous GR protein expression 
throughout the liver parenchyma (Antakly & Eisen 1984).  The physiological 
relevance of these findings may be considered with regard to the important effects of 
glucocorticoids upon the liver.   
It has been suggested that the physiological role of hepatic 11β-HSD1 is to ensure 
adequate activation of low affinity glucocorticoid receptors by the reactivation of 
cortisone to cortisol. This may be important in maintaining optimal glucocorticoid 
induced permissive effect upon gluconeogenic hormones. There is considerable 
evidence to support this hypothesis.  Firstly, circulating cortisone concentrations in 
man are about 50nM, it is not protein bound or subject to circadian rhythm (Walker et 
al 1992a), hence there is ample cortisone availability for hepatic reactivation to 
cortisol. Secondly, 11β-HSD1 functions as a reductase in human liver, as reflected by 
cortisol/cortisone concentrations in the hepatic vein being five-fold higher than in 
peripheral arterial blood (Walker et al 1992a).  In addition, the rapid conversion of 
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oral cortisone which is delivered to the liver via the portal vein resulting in a rapid rise 
in serum cortisol levels and a negligible increase in serum cortisone levels (Stewart et 
al 1990).  Carbenoxolone inhibits the conversion of cortisone to cortisol by hepatic 
11β-HSD1 (Stewart et al 1990), and results in enhanced whole body insulin 
sensitivity without impacting on peripheral insulin sensitivity (Walker et al 1995). 
Hence, hepatic 11β-HSD1 inhibition results in an enhancement of insulin mediated 
down regulation of hepatic glucose output. In addition, transgenic deletion of 11β-
HSD1 in mice results in an absence of 11-dehydrocorticosterone to corticosterone 
conversion, despite elevated plasma corticosterone concentrations, with impairment of 
hepatic gluconeogenesis upon starvation (Kotelevtsev et al 1997). While there was 
clear evidence of hepatic 11β-HSD1 zonation, there was a significantly lesser degree 
of 11β-HSD1 protein expression throughout the liver parenchyma in intermediate 
areas.  This would support the proposed physiological role for hepatic 11β-HSD1 and 
would concur with the homogenous expression of GR, to maximise hepatic 
glucocorticoid exposure. This reflects the importance of this process and its regulation 
in the maintenance of normal hepatic metabolic phenotype. 
While the immunohistochemistry studies did show some periportal zonation of 11β-
HSD1 supporting the above observations, the primarily perivenous zonation of 11β-
HSD1 would not be entirely in line with expectations.  The hypothesis of hepatic pre 
receptor glucocorticoid activation by 11β-HSD1 impacting upon hepatic 
gluconeogenesis, and thus being involved in regulatory mechanisms to influence 
hepatic glucose output in normal physiology and diseased state would predict 
periportal localisation of hepatic 11β-HSD1 in keeping with the zonation of 
gluconeogenic enzymes.  While it is clear that hepatic 11β-HSD1 activity has an 
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influence upon hepatic gluconeogenesis, in normal physiology, the impact of hepatic 
11β-HSD1 activity upon perivenous metabolic functions may perhaps be more 
important.  Hepatic metabolic functions showing strong perivenous zonation include 
glycolysis and lipogenesis.  The effects of glucocorticoids on hepatic glucose 
metabolism reflecting the zonation of each process are summarised in Figure 3-17.  
Figure 3-17 Effects of glucocorticoids on hepatic glucose metabolism.  The 
principal metabolic fates of glucose in the liver are shown with the 
hepatic zonation of each prinicipal pathway. Actions of glucocorticoids 
(grey arrows) and insulin (striped arrows) are shown either as positive 
(up arrow)or negative (down arrow) effects.  In some respects, insulin 
and glucocorticoids oppose each others actions, particularly on 
gluconeogenesis (PEPCK) and  release of glucose from G6P .  In other 
respects, insulin and glucocorticoids do not oppose each other, 
especially in promoting oxidative glycolysis and increasing turnover 
between G6P and glycogen. Adapted from (Andrews and Walker 
1999).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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In perivenous localised processes, glucocorticoids promote the actions of insulin 
including glycolysis and lipogenesis. Importantly insulin receptors display a 
perivenous zonation in normal liver (Krones et al. 2000). In particular the rate limiting 
step of glycolysis, the conversion of fructose-1-phosphate to fructose-1-6-
bisphosphate by phosphofructokinase (PFK) and the actions of glucokinase (GK) are 
both stimulated by glucocorticoids (Loiseau et al. 1985) and insulin. However, studies 
have shown that supraphysiological doses of glucocorticoids decrease hepatic 
sensitivity to the effects of insulin and increase sensitivity to glucagon (Dirlewanger 
et al. 2000).  
The physiological importance of the high perivenous expression of 11β-HSD1 may 
reflect a physiological protective mechanism to preserve not only hepatic metabolic 
phenotype but also whole body insulin sensitivity.  Seminal work by Wu et al. showed 
that mice with hepatic over expression of the key glycolytic enzymes GK or PFK 
demonstrated increases in hepatic glycolysis and reduced adiposity and body weight 
in obese mice (Wu et al. 2005). Elevated rates of glycolysis led to a decrease in 
hepatic glucose production, with a knock-on effect on reducing plasma glucose, and a 
secondary similar reduction in plasma insulin.  This resulted in a relief of inhibition of 
hyperinsulinaemia on lipolysis in adipose tissue and fatty acid oxidation in muscle. 
Furthermore, the decrease in hepatic glucose production led to a decrease in whole 
body glucose disposal, implying a decrease in peripheral glucose utilization (i.e. 
muscle). This was compensated for by increased rates of fatty acid oxidation in 
extrahepatic tissues, in particular skeletal muscle, leading to an elevation of energy 
expenditure. While these effects were similar with either over expression of GK or 
PFK, GK over expression was also associated with increased hepatic lipogenesis, 
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while over expression of PFK had the additional effect of causing suppression of food 
intake and a decrease in the hypothalamic expression of neuropeptide Y – this 
contributed to a profound reduction in body weight and decreased hepatic lipogenesis.  
Hence, the step at which glycolysis is enhanced has a dramatic influence on whole 
body energy expenditure and lipid profiles.  On this background the effect of 11β-
HSD1 driven perivenous glucocorticoid generation would promote glycolysis 
independently to the effects of insulin.  This would be particularly important with 
increasing insulin resistance or insulin deficiency where local glucocorticoid 
generation could drive a compensatory increase in glycolysis both at the level of GK 
and PFK.   Any differential effects of glucocorticoids on GK or PFK stimulation 
would further modulate hepatic lipogenesis in addition to the direct effects of 
glucocorticoid upon hepatic de novo lipogenesis. 
The effect of glucocorticoids on promoting hepatic lipogenesis would also be 
compatible with the perivenous zonation of 11β-HSD1.  A number of studies have 
shown that hepatic lipogenesis is promoted by physiological concentrations of 
glucocorticoids (Amatruda et al. 1983). While insulin influences lipogenic enzyme 
translation (Sun and Holten 1978), glucocorticoids influence lipogenic enzyme 
transcription (Fritz et al. 1986). Indeed, any beneficial effect of glucocorticoid 
mediated glycolysis as described above would be offset by the negative effect of 
glucocorticoids upon hepatic lipid accumulation. The co-localisation of mRNA 
expression of hepatic A-ring reductases with 11β-HSD1 in perivenous hepatocytes 
may reflect the importance of the fine tuning of pre-receptor glucocorticoid 
metabolism in the preservation of a normal hepatic metabolic phenotype, such that 
regulation of the set point of 11β-HSD1 activity as well as glucocorticoid clearance 
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by A-ring reductases would optimise the glucocorticoid response to changes in the 
hepatic metabolic milieu. It would be of considerable interest to explore the zonation 
of hepatic 11β-HSD1 activity and expression in disease states such as type 2 diabetes, 
hepatic steatosis and other insulin resistant states, in particular to determine whether 
there is a dynamic component to zonation of hepatic glucocorticoid metabolism.  
Indeed studies described in chapter 7 showed generally increased staining for 11β-
HSD1 in the histologically disrupted NAFLD cirrhotic liver with periseptal 
localisation.  This would indicate that 11β-HSD1 expression in the liver is indeed 
dynamic and may alter in response to multiple factors in various hepatic disease 
states. 
3.4.2. Comparative mRNA expression of glucocorticoid and 
carbohydrate metabolism related genes in normal and diseased 
liver states 
The mRNA expression data from normal and diseased livers showed increased 
hepatic 11β-HSD1 expression in all types of chronic liver disease studied. These 
included non alcoholic fatty liver disease, alcoholic liver disease, other non alcoholic 
chronic liver diseases and glycogen storage disease 1a.  mRNA expression of  both 
11β-HSD1 and GRα were extremely high in the GSD1a liver samples compared with 
normal and all other diseased liver groups (discussed further in chapter 4).  An 
important difference of the GSD1a sample compared with other diseased livers was 
the absence of cirrhosis.  While most of the other diseased livers showed histological 
evidence of cirrhosis, there were adequate histological features to suggest the 
underlying aetiology in all samples chosen for analysis.   
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If hepatic HSD11B1 gene expression is commonly increased across all chronic liver 
diseases regardless of underlying aetiology, the physiological relevance of this 
process is likely to be strongly implicated as cause or effect of common factors 
unifying chronic liver disease states.  With regard to glucocorticoid status in chronic 
liver disease, it has long been recognised that there is impairment of adrenal 
glucocorticoid production and often impairment of the HPA axis. For example, 
chronic hepatic damage due to cholestasis in rats results in decreased hypothalamic 
CRF (corticotrophin releasing hormone) mRNA and protein expression of 
corticotrophin – releasing hormone (Swain et al. 1993). In chronic liver disease there 
is a dissociation of two important functions of the adrenal cortex.  A widening of the 
zona glomerulosa associated with increased aldosterone secretion, and atrophy of the 
zona fasciculata with a decreased cortisol production rate occurs (Gerdes 1979).  This 
could explain the increased hepatic expression of GRα and 11β-HSD1 mRNA as a 
compensatory up regulation to maximise hepatic glucocorticoid exposure. In addition 
inhibition of A-ring reductase activity resulting in decreased glucocorticoid clearance 
further enhances hepatic glucocorticoid availability, a mechanism seen in non 
alcoholic steatohepatitis (chapter 7) and cholestasis. In fact bile acids are potent 
competitive inhibitors and transcriptional regulators of 5β-reduction of 
glucocorticoids (Mc Neilly and McKenzie2 2005). It is likely that hepatic 11β-HSD1 
expression and activity is modulated in conjunction with disease severity as seen in 
NAFLD where there is evidence of increased glucocorticoid clearance and decreased 
11β-HSD1 driven glucocorticoid generation (chapter 7) in hepatic steatosis, with the 
opposite effect occurring with progression to steatohepatitis.  Increased hepatic 
glucocorticoid generation may occur both at the level of gene expression and protein 
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expression as well as regulation of the set point of activity of 11β-HSD1.  The 
mechanism may well depend on the underlying aetiology of the chronic liver disease.   
The role of oxidative stress and ER stress on 11β-HSD1 activity in chronic liver 
disease merits further investigation.  Certainly, chronic liver diseases such as NASH, 
ALD and even GSD1a all have oxidative stress and ER stress is strongly implicated in 
pathogenesis. H6PDH mRNA expression was interestingly higher in the ALD group 
compared with other chronic liver diseases.  This may reflect an additional effect of 
altered ER redox impacting upon 11β-HSD1 in alcoholic liver disease, with H6PDH 
serving a key role linking steroid metabolism and nutrient sensing (chapter 4). Indeed, 
ER stress is clearly an important mechanism in the pathogenesis of NAFLD and this 
may in part be related to its relationship with CYP2E1. CYP2E1 is capable of 
inducing significant ER protein damage and stress via its catalytic activation of pro-
oxidants (Lewis and Roberts 2005) and was increased in the NASH group.  This 
would support the link between non alcoholic fatty liver disease and CYP 2E1, which 
is associated with insulin resistance and mechanistically with the development of 
NAFLD (Schattenberg et al. 2005). Insulin resistance and CYP2E1 expression may be 
interrelated through the ability of CYP2E1-induced oxidant stress to impair hepatic 
insulin signalling.  This may represent another mechanism to worsen the insulin 
resistance in NAFLD.  It may be that the increase in 11β-HSD1 activity seen in 
NASH (chapter 7) is associated with an NADP+/NADPH ratio in the ER lumen, 
influenced by the effect of CYP2E1 on ER redox that would favour reductase activity.  
In ALD, with abstinence from alcohol, hepatic disease progression is associated with 
a decrease in CYP2E1 (Dilger et al. 1997). Alcohol dehydrogenase (ADH) expression 
was increased in all groups, and most significantly so in NASH.  This too may be 
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implicated in ER stress. Studies on cardiac myocytes over expressing ADH showed a 
key role of ADH in cardiac dysfunction, hypertrophy, insulin sensitivity and ER stress 
(Li and Ren 2008). 
Up to 96% of patients with cirrhosis may be glucose intolerant and 30% will have 
diabetes (Hickman and Macdonald 2007). Diabetes that develops as a consequence of 
cirrhosis is termed „hepatogenous diabetes‟, and is not yet recognised by the World 
Health Organisation or the American Diabetic Association as a separate entity, 
although it is distinct from obesity-related type 2 diabetes in that it is much less 
frequently associated with microangiopathy, and fasting glucose levels are usually 
normal. Patients with cirrhosis and diabetes have much higher morbidity and 
mortality from the complications of cirrhosis (El-Serag, Tran, & Everhart 2004;El-
Serag and Everhart 2002).  The underlying aetiology of chronic liver disease has a 
strong bearing on the likelihood of the development of „hepataogenous diabetes‟.  In 
particular, NAFLD, alcoholic liver disease, haemachromatosis and hepatitis C are 
frequently associated with diabetes, which may reflect direct damage to pancreatic β 
cells (as in alcoholism, and haemachromatosis) or associated with increasing hepatic 
steatosis and hepatic insulin resistance.  Consistent with these observations were the 
results of the mRNA expression studies on key enzymes and transporter proteins 
governing hepatic glucose output.  Both the NAFLD group and the ALD group had 
high expression of these genes.  Unfortunately data regarding the presence or absence 
of diabetes in the patients from whom the diseased livers were explanted were not 
readily available, but these results may reflect a possible higher incidence of diabetes 
in the NAFLD and ALD groups compared with chronic liver diseases of other causes. 
G6Pase and the G6P transporter are ER membrane proteins that facilitate the final 
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step of the gluconeogenic pathway. G6Paseα mRNA was significantly increased in 
the NASH samples and also to a lesser extent in the ALD samples.  In addition there 
was significantly increased expression of the G6P transporter in the ALD samples.  
These are important results that may occur secondary to increased hepatic 
glucocorticoid availability from increased 11β-HSD1 expression and activity, as well 
as a mechanism to increase G6P substrate availability for H6PDH in ALD where 
there is increased G6P transporter as well as H6PDH gene expression.  This would 
implicate increased 11β-HSD1 oxoreductase activity as well as increased 11β-HSD1 
gene expression in alcoholic liver disease (as demonstrated in the clinical and in vitro 
studies described in chapter 5), which would have a knock on effect on hepatic 
glucose output through glucocorticoid stimulated gluconeogenic enzymes.  The 
increase in PEPCK and G6Pase mRNA expression in NASH and ALD compared with 
both normal and CLD groups may reflect the added effects of glucocorticoid 
induction on gene transcription of gluconeogenic enzymes in addition to other 
common mechanisms to increase hepatic glucose output in NASH and CLD.  The 
glucose transporter GLUT 2 mRNA expression was significantly higher in all 
diseased liver groups and may reflect a compensatory up regulation due to the 
increased insulin resistance associated with severe chronic liver disease. 
Microsomes were prepared from all the liver samples used in these studies, and the 
conditions for 11β-HSD1 activity assays on these microsomes optimised.  Further 
work will include the comparisons of 11β-HSD1 activity in vitro between groups.  
The in vitro studies described in this chapter provide strong support for the finding 
described in the translational studies exploring hepatic glucocorticoid metabolism in 
glycogen storage disease (chapter 4), alcoholic liver disease (chapter 5) and non 
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alcoholic fatty liver disease (chapter 7).  It would also be of great interest to explore 
the impact of ER stress upon hepatic glucose and glucocorticoid metabolism in 
chronic liver disease, particularly those with a close association with hepatic steatosis 
and insulin resistance such as NASH, ALD and chronic hepatitis C. 
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4. The impact of endoluminal Glucose 6-Phosphate upon 
11β-Hydroxysteroid Dehydrogenase Type 1 mediated 
glucocorticoid generation and Hypothalamo-Pituitary-
Adrenal Axis function 
4.1. Introduction 
A vital function of the liver is to provide glucose during fasting.
 
This occurs through 
two principal pathways, gluconeogenesis
 
and glycogenolysis, in each case yielding 
glucose 6-phosphate
 
(G6P) (reviewed in sections 1.3.2.1 - 1.3.2.4), which is then 
hydrolyzed by glucose-6-phosphatase (G6Pase),
 
more recently described as G6Pase-α 
(Shieh et al. 2003), to glucose (Chou et al. 2002a). G6Pase-α is a transmembrane 
protein in the endoplasmic
 
reticulum (ER) with the active enzyme site directed toward 
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the
 
ER lumen (Chou et al 2002a;Van & Gerin 2002). G6P must be translocated from 
cytosol to ER
 
via a ubiquitously expressed G6P transporter (G6PT) before hydrolysis
 
can occur.  
4.1.1. Glycogen storage disease type 1 
Patients and rodent models lacking components of
 
the G6Pase-α, G6PT system 
emphasize the crucial role of this
 
pathway in maintaining glucose homeostasis in the 
fasting state.
  
This results in accumulation of glycogen and lipids in gluconeogenic 
organs including liver, kidney and intestine. The disease is inherited in an autosomal 
recessive manner. Von Gierke described the first patient with glycogen storage 
disease type 1 (GSD1) in 1929 from the autopsy reports of two children who had 
excessive glycogen in their livers and kidneys (Von Gierke 1929). Thirty three years 
later Cori described six further patients and detected G6Pase deficiency, identifying 
for the first time a single enzyme defect causing an inborn error of metabolism (CORI 
and CORI 1952). While they recognised that hepatic GSD causes a heterogenous 
group of disorders, it remained a mystery why some of these patients had normal 
G6Pase activity until 1978, when a defect in the intracellular transport of the G6P was 
identified (Narisawa et al. 1978).  In recognition of the original description of the 
disease the Cori classification was preserved with von Gierke's disease, type 1a 
caused by G6Pase-α deficiency; and type 1b caused by a G6PT defect (Chen et al. 
2003;Van & Gerin 2002).  As the product of the G6Pase reaction is free glucose, both 
type 1a and 1b cause fasting hypoglycaemia, and hepatomegaly as a consequence of 
glycogen accumulation.  The liver in GSD type 1 therefore loses its fundamental 
function as a glucose homeostatic organ. 
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GSD 1 is one of the few causes of profound hypoglycaemia in newborns, with a rapid 
drop in blood glucose soon after birth, following the withdrawal of maternal glucose.  
Seizures, and cyanosis, irritability and life threatening lactic acidosis occur and 
repeated hypoglycaemia can cause brain damage. Dietary manipulation remains a 
„palliative‟ treatment, but it does reverse the acute complications of hypoglycaemia 
and lactic acidosis. A number of abnormalities persist despite metabolic control 
(Moses 2002).  The limitations of dietary treatment have become clearer with 
increased survival of GSD 1 patients.  These include growth retardation, 
hepatomegaly, lactic acidosis, hyperlipidaemia, hyperuricaemia related gout, 
nephrolithiasis and proteinuria causing renal failure. In adult patients, there is a high 
risk of pulmonary hypertension, hepatic adenomas with risk of malignant change, 
progressive renal failure and hypothyroidism (Franco et al. 2005;Moses 2002).  There 
is an increased risk of osteoporosis and fractures, which is unexplained but may be 
due the restrictive dietary regime, renal calcium loss and high bone turnover (Moses 
2002). In addition GSD 1b is has the added complications of neutropenia, and 
impaired neutrophil function causing recurrent bacterial infections and gut mucosa 
ulceration and eventually GSD enterocolitis. Also, GSD1b is associated with a higher 
prevalence of thyroid autoimmunity and hypothyroidism which is rarely seen in 
GSD1a.  The cause of this is also largely unexplained but has been associated with 
increased amyloidosis in GSD1b patients on chronic therapy with granulocyte-
colony-stimulating factor (GCSF).  An understanding of the complexities of 
disruption in cellular homeostasis that results from a single enzyme defect in GSD 
provides a valuable insight in the interaction between carbohydrate metabolism and 
other systems.  The biochemical and molecular defects underlying GSD 1 are 
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illustrated in Figure 4-1.  As glucose cannot be produced through glycogenolysis, 
glucose cycling is disrupted in GSD 1 and glycogen accumulates in the liver and 
kidney. The effects of G6P accumulation on causing increased lactate triglyceride and 
cholesterol production are reflected in Figure 4-1.   
Increased metabolic stress has recently been implicated as a cause of the neutropenia 
in GSD1b.  Neutrophils from G6PT-null (GSD Ib) mice show evidence of increased 
ER stress, demonstrated by increases in ER chaperones and oxidative stress (Kim et 
al. 2008).  Recent data also suggested that the unique lack of the G6P transporter that 
blocks glucose production in neutrophils may specifically cause neutropenia in 
GSD1b. An additional catalytic unit of G6Pase exists, G6Pase-β with properties 
similar to G6Pase-α.  Hence glucose production still occurs in neutrophils of patients 
with GSD1a albeit at a lower level, and hence netropenia is prevented. In GSD1b, 
glucose production in neutrophils is absent due to the coupling of the G6P transporter 
with G6Pase-β (Cheung et al. 2007). 
Recombinant mice
 
with global deletion of G6Pase-α (Lei et al. 1996) and G6PT (Van 
& Gerin 2002) have similar
  
phenotypes with profound hypoglycemia. 
Characterisation studies showed that G6Pase-/-  mice manifest the same phenotype as 
GSD1a humans with hypoglycemia, growth retardation, hepatomegaly, kidney 
enlargement, hyperlipidemia, and hyperuricemia. Similar to humans, if an effective 
dietary therapy is not implemented, the mice die within 4-5 weeks due to severe 
hepatic and renal disease and metabolic acidosis. The G6PT knockout mouse also 
mimics human GSD1b including disordered myeloid function and impaired 
neutrophil trafficking and function (Chen et al 2003). Infusion of an adenoviral vector 
containing the murine G6Pase gene into a G6Pase deficient mouse resulted in 
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restoration of 19% of hepatic G6Pase function and, normalisation of glucose, lipid 
and urate with a decrease in liver and kidney glycogen accumulation to normal levels, 
improved growth and 100% survival rate (Chou et al. 2002b). 
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Figure 4-1 Biochemical and molecular defects underlying GSD I. Glucose cycling 
is disrupted in glycogen storage disease (GSD I) because glucose 
cannot be produced through glycogenolysis. Dietary glucose is stored 
as glycogen, which accumulates in the liver and kidney in GSD I. (a) 
Biochemical effects of GSD Ia. In the hepatocyte, G6Pase-α deficiency 
(X) blocks hydrolysis of glucose-6-phosphate (G6P) in the liver, 
resulting in decreased glucose production and increased lactate, 
cholesterol and triglyceride production. However, G6Pase-β activity in 
neutrophils prevents neutropenia in GSD Ia (not shown). (b) 
Biochemical effects of GSD Ib. In the hepatocyte, G6PT deficiency (X) 
prevents hydrolysis of G6P with biochemical effects identical to those 
of GSD Ia. Furthermore, in the neutrophil, G6PT deficiency decreases 
glucose production, leading to ER stress and neutrophil death. (c) 
Common missense and nonsense mutations affecting G6Pase (left, 
blue) and G6PT (right, red) in GSD I (Koeberl et al. 2009) . 
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4.1.2. The G6Pase - H6PDH - 11β-HSD1 system 
G6Pase- shares its substrate (G6P) with another enzyme within
 
the ER, hexose-6-
phosphate-dehydrogenase (H6PDH), that catalyzes
 
the first two steps of an ER-
specific "pentose phosphate pathway,"
 
i.e. both G6P dehydrogenase and 6-
phosphogluconolactonase reactions (Hewitt, Walker, & Stewart 2005;Mason et al 
1999), illustrated in Figure 4-2 and described in detail in section 1.6.  
 
Chapter 4  11β-HSD1 regulation by G6P 
144 
 
 
Figure 4-2 The microsomal G6Pase-α, H6PDH and 11β-HSD1 systems and the 
hypothalamo-pituitary-adrenal axis. 
Recent studies have indicated a pivotal
 
link between H6PDH activity in the ER and 
the control of set
 
point of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), 
described fully in section 1.5.2. 11β-HSD1 is an ER-bound enzyme (Ozols 1995) 
catalyzing the interconversion of
 
inactive glucocorticoids (cortisone in humans and 
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11-dehydrocorticosterone
 
in rodents) and hormonally active glucocorticoids (cortisol
 
and corticosterone) (Tomlinson et al 2004b). The reaction direction, which 11β-HSD1 
catalyzes, is determined by the relative abundance of NADP+
 
and NADPH (Lakshmi 
& Monder 1988). In its native purified state, 11β-HSD1 acts as a dehydrogenase-
inactivating cortisol/corticosterone to cortisone/11-dehydrocorticosterone
 
(11-DHC) 
(Lakshmi & Monder 1988;Walker et al 2001). However, in the presence of reducing 
NADPH,
 
generated through H6PDH activity (Clarke & Mason 2003),11β-HSD1 
switches to reductase
 
with the generation of active glucocorticoid in key tissues
 
such 
as liver and adipose (Banhegyi et al. 2004;Bujalska et al 2005;Czegle et al. 2006). In 
these tissues, this
 
reductase activity has been shown to enhance hepatic glucose
 
output 
(Kotelevtsev et al 1997) and adipogenesis (Clarke & Mason 2003), respectively. 
11β-HSD1 is thus an exciting candidate to explain features of obesity and the 
metabolic syndrome with selective inhibitors under active
 
development that may 
prevent and/or reverse diabetes mellitus
 
in obese subjects (Boyle & Kowalski 
2009;Tomlinson 2005), described fully in section 1.5.2.1. Previously, it has been 
shown
 
that H6PDH is an essential requirement for 11β-HSD1 reductase activity; here 
it was explored whether G6P availability to
 
H6PDH could directly modulate 11β-
HSD1 activity, thereby representing
 
a novel pathway linking the metabolism of 
glucose and glucocorticoids. 
4.1.3. Hypothesis 
It was hypothesised that inhibition of G6Pase, with resultant reduction in G6P to 
glucose would increase substrate availability to H6PDH, which in turn would result in 
increased generation of the cofactor NADPH, driving 11β-HSD1 oxoreductase 
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activity and generation of active glucocorticoid.  The murine 11β-HSD1 enzyme 
catalyses the conversion of inactive 11-dehydrocorticosterone, to active 
corticosterone.  To test this hypothesis, studies were carried out on normal mouse 
liver microsomes to elucidate the effects of biochemical inhibition of the G6Pase 
enzyme on 11β-HSD1 activity. Sodium vanadate was used as a G6Pase inhibitor 
(Green 1986).   
Mouse liver microsomes were prepared from snap frozen livers from 3 normal c57Bl6 
male mice aged 10-12 weeks by differential centrifugation as detailed in chapter 2. 
11β-HSD1 enzyme activity assays were carried out as described in section 0  
Microsomes were assayed in duplicate and incubated for 4 hours either with or 
without 20μM sodium vanadate. 
4.2. Materials and methods 
4.2.1. Preparation of Mouse Liver Microsomes 
Mouse liver microsomes
 
were prepared from recombinant male mice (n = 3) with 
global
 
deletion of G6Pase-α, or separately, deletion of G6PT by differential 
centrifugation as described in detail in section 2.7.  The phenotype and
 
background 
strain of these mice have been previously reported (Chen et al 2003;Lei et al 1996)
 
. 
All animal experiments had the approval of the Institutional
 
Animal Care and Use 
Committee and were performed according to
 
procedures approved by that committee.  
4.2.2. 11β-HSD1 Enzyme Activity Assays 
Microsomes (30 µg)
 
were preincubated at 37 °C for 20 min in Mops buffer with
 
1 nM 
of the H6PDH substrate G6P. 11β-HSD enzyme reactions were started by the addition 
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of 200 nM 11-dehydrocorticosterone/500
 
nM corticosterone spiked with 20,000 cpm of 
tritiated 11-dehydrocorticosterone/corticosterone.
 
All experiments were performed in 
triplicate. After incubation
 
at 37 °C for 30 min, steroids were extracted with 
dichloromethane,
 
separated by thin layer chromatography using a mobile phase
 
of 
ethanol and chloroform (8:92), and quantified using a Bioscan
 
2000 image analyzer 
(Lablogic, Sheffield, UK) (Lavery et al 2006). The percentage
 
of substrate 
metabolized in each experiment was 10% or less,
 
ensuring that initial rates of 
metabolism were being measured. The method used has been described in detail in 
section 2.4.2.
 
4.2.3. Immunoblotting 
SDS-PAGE was performed by the method of
 
Laemmli (Laemmli 1970) with 10 µg of 
mouse liver microsomal protein
 
on 11% acrylamide minigels using a Bio-Rad Mini-
PROTEAN II apparatus
 
(Bio-Rad). Following electrophoresis, proteins were 
transferred
 
to Immobilon-P membrane (Millipore Corp., Bedford, MA). Nonspecific
 
protein binding was blocked by incubating membranes in 20% non-fat
 
milk, 0.1% 
Tween 20 in phosphate-buffered saline at 25 °C
 
for 1 h. Membranes were then 
incubated with an in-house raised
 
polyclonal antibody to human H6PDH at a dilution 
of 1:1000 for
 
16 h at 4 °C. Following 3 x 10-min washes in phosphate-buffered
 
saline, 
0.1% Tween 20, membranes were incubated with secondary
 
antibody (goat anti-rabbit 
IgG peroxidase-conjugate) at a dilution
 
of 1:25,000 for 1.5 h at room temperature. 
Bound peroxidase-conjugated
 
IgG was visualized using ECL detection kit (Amersham 
Biosciences,
 
Buckinghamshire, UK) by exposing membranes to x-ray film (Kodak,
 
France). Following stripping, membranes were reprobed with a
 
polyclonal antibody to 
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human 11β-HSD1 (1:1000) (Ricketts et al 1998b) in a similar method as above and 
incubated with goat anti-sheep IgG peroxidase
 
secondary antibody.  The method is 
described in further detail in section 2.6. The immunoblotting was carried out under 
supervision of Dr Gareth Lavery and Dr Elizabeth Walker. 
4.2.4. Analysis of Urine from GSD1a and GSD1b Mice 
Urine samples from GSD mice were kindly provided by Dr Janice Chou,
 
National 
Institute of Health, Bethesda, Maryland. 
Urine was
 
collected on filter paper following bladder massage, and samples
 
were 
pooled from three of each group: wild type (WT), GSD1b,
 
and GSD1a. Three 
individual pooled samples were collected from
 
WT and GSD1b, and a single pooled 
sample was analyzed from the
 
GSD1a mice. The filter papers were cut up and eluted 
with water
 
while vortexing and sonicating. Extracts were subjected to steroid
 
analysis 
by gas chromatography/mass spectrometry as described
 
previously (Lavery et al 
2006;Shackleton 1993;Shackleton 1990) and detailed in section 0. Multiple 
corticosterone metabolites
 
were found in these analyses. Major metabolites were 6β-
hydroxy
 
and 20-dihydro metabolites of corticosterone. Prominent saturated
 
components were hydroxylated (6α - or 11β -) derivatives of "tetrahydro" (3α-, 5α-, or 
3α,5β-) or "hexahydro" (additionally reduced at 20α- or 20β-) corticosterone or 11-
DHC. The basic structure of each
 
compound and elucidation as a corticosterone or 11-
DHC
 
metabolite was easily determined by mass spectral fragmentation,
 
although 
stereochemistry of the 5-hydrogen and the 20-hydroxyl
 
could not be determined in the 
absence of authentic compounds.
 
Quantitation was achieved by measuring the total-
ion-current
 
response for each peak and relating this to a known amount of
 
internal 
Chapter 4  11β-HSD1 regulation by G6P 
149 
 
standard, assuming an equal mass spectrometry response.
 
For the purpose of this 
study, excretions of individual 11-oxo
 
and 11β-hydroxy metabolites were separately 
summed, and the percentage
 
of excretion of each group was calculated.  
4.2.5. Patient Studies 
Five patients with GSD1a were investigated
 
(two males, three females; mean age ± 
S.D., 28 ±
 
1 years). All patients gave formal written consent for the study,
 
which was 
approved by the local hospital ethics committee and
 
carried out according to the 
recommendations of the declaration
 
of Helsinki. All patients were diagnosed in early 
infancy by
 
liver biopsy and G6Pase-α enzyme assay after presenting with severe 
hypoglycemia.
  
Urine steroid metabolite analysis was carried out on 24-h urine
 
collections from 
patients with GSD1a. In addition, we were
 
able to obtain single spot urine samples 
from two children with
 
GSD1b. All samples were analyzed by gas 
chromatography/mass
 
spectrometry, as reported previously (Palermo et al 
1996;Shackleton 1993), measuring free
 
and conjugated cortisol metabolites (described 
in further detail in section 2.9.2). Urinary steroid metabolite
 
ratios and total 24-h 
cortisol metabolite production rates are
 
presented in Table 4-1. GSD1a patients have 
been compared with
 
36 healthy controls (mean age ± S.D., 33 ± 8 years;
 
mean body 
mass index ± S.D., 28.4 ± 5.6 kg/m2).
 
Individual values are presented for the two 
GSD1b patients,
 
alongside the age-adjusted reference ranges Table 4-1.  
At 2300 h, GSD1a subjects were given 1 mg of dexamethasone orally
 
to suppress 
endogenous cortisol production. All subjects attended
 
the Clinical Research Facility at 
0900 h the following morning,
 
and after baseline 0900 h measurements of cortisol and 
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adrenocorticotropic
 
hormone, a further 0.5 mg of dexamethasone and cortisone 
acetate
 
(25 mg) were given orally. Serum cortisol and cortisone concentrations
 
were 
then measured at 30-min intervals for 240 min. Further details of the method are 
described in section 2.9.1. Results were compared with data
 
from 34 age and body 
mass index-matched controls from an existing
 
data base of normal controls.
 
 
4.2.6. Statistical Analysis 
Statistical analysis of comparisons
 
among groups was undertaken using the one-way 
analysis of variance
 
with Tukey's post hoc testing (for normal distribution) or Mann-
Whitney
 
rank sum test (for non-normal distribution). Area under the
 
curve (AUC) 
analysis was performed using the trapezoidal method.
 
All analyses were performed 
using the SigmaStat 3.1 software
 
package (Systat Software, Inc. Point Richmond, 
CA). 
4.3. Results 
4.3.1. Preliminary studies 
Liver microsomal preparations
 
have been extensively used to assess the kinetics of all 
the
 
enzyme systems analyzed in this study and are considered a representative
 
model 
system of the ER (Banhegyi et al. 1997;Banhegyi et al 2004;van de Werve et al. 
2000;Van & Gerin 2002). In hepatic microsomes from normal mice there was a 
significant increase in 11β-HSD1 reductase activity in the presence of the G6Pase 
inhibitor, sodium vanadate (without G6Pase inhibitor: 242 +/- 11, with G6Pase 
inhibitor 411 +/- 25 pmol/mg/h, mean +/- SEM) Figure 4-3, suggesting that increased 
microsomal G6P, the substrate for H6PDH does indeed drive increased 11β-HSD1 
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mediated generation of active glucocorticoid.  These results prompted the further 
clinical studies in patients with GSD1a and 1b and GSD knockout mice. 
 
Figure 4-3 Mean  conversion of 11-DHC to corticosterone (+/- SEM) in normal 
mouse liver microsomes in the presence and absence of G6Pase 
inhibition with sodium vanadate (pmol/mg/h). The representative TLC 
radiochromatograms are also shown. 
4.3.2. In Vitro Analysis of 11β-HSD1 Activity and Protein Expression in 
GSD1b and GSD1a Mice 
11β-HSD1 enzyme activity was assessed by examining the 11-reductase (11-DHC to 
corticosterone)
 
and dehydrogenase (corticosterone to 11-DHC) activity in mouse
 
liver 
microsomes from WT, GSD1b, and GSD1a animals.
  
Representative
TLC radiochromatograms
0
2
4
6
8
10
12
14
16
18
20
Control
%
 c
o
n
ve
rs
io
n
 1
1-
D
H
C
  t
o
 C
o
rt
p < 0.001
+ G6Pase inhibitor
11-DHC
Cort
0
50
100
150
200
250
300
350
400
450
500
Control +G6Pase inhibitor
p
m
o
l c
o
rt
ic
o
st
e
ro
n
e
/m
g/
h
p < 0.001
Chapter 4  11β-HSD1 regulation by G6P 
152 
 
In hepatic microsomes from the WT animals, reductase activity
 
predominated (Figure 
4-4A). In liver microsomes of GSD1b
 
animals, lacking G6P,
 
reductase activity was 
significantly reduced compared with WT
 
animals (p < 0.001;Figure 4-4A). H6PDH 
and
 
11β-HSD1 immunoreactive protein was similar in WT and GSD1b animals 
(Figure 4-4B),
 
indicating that changes in the levels of protein expression could
 
not 
account for the differences in activity.
  
In the GSD1a mice, both reductase and dehydrogenase activities
 
were reduced when 
compared with WT animals. This unexpected
 
finding was explained by a reduction in 
expression of 11β-HSD1 protein in these animals, despite no change in the expression 
of
 
H6PDH (Figure 4-4B).   
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Figure 4-4 11β-HSD1 reductase and dehydrogenase activity and protein 
expression from liver microsomes of WT, GSD1b, and GSD1a mice. A, 
in the WT microsomes, reductase activity (black bars) was significantly 
higher than dehydrogenase activity (white bars). Reductase activity 
from GSD1b microsomes was significantly lower when compared with 
WT and at a similar level to dehydrogenase activity. Microsomes 
prepared from livers of GSD1a had much lower levels of reductase and 
dehydrogenase activity when compared with WT, but within these 
animals, reductase activity still predominates. Values indicate mean 
activity ± S.E.; n = 3 for each group. 
***
, p < 0.001. B, SDS-PAGE 
Western blot analysis revealed similar expression levels of H6PDH 
protein across all animals; however, levels of 11β-HSD1 protein were 
lower in the GSD1a. 
4.3.3. In Vivo Analysis of Corticosterone Metabolism in GSD1b and 
GSD1a Mice 
In vivo assessment of 11β-HSD1 activity in mice was carried out using gas 
chromatography/mass spectrometry analysis
 
of pooled urine collections (n = 3) from 
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each group. WT mice
 
were found to excrete almost exclusively 11β-hydroxy 
metabolites
 
(92.3 ± 3.4%; mean ± S.E.) with only minor amounts
 
of 11-oxo 
metabolites (Figure 4-5A). The converse was true for the
 
GSD1b mice, where the 
dominant steroids excreted in the urine
 
were 11-oxo metabolites (92.3 ± 3.4% WT 
versus 60.2 ±
 
4.6%; GSD1b p < 0.001;Figure 4-5A). This pattern of metabolism
 
was 
mirrored in vitro, where the ratio of reductase to dehydrogenase
 
activity obtained from 
liver microsomal preparations of GSD1b
 
mice was significantly lower than WT (5.21 
± 0.64 WT
 
versus 1.13 ± 0.28 GSD1b p < 0.01;Figure 4-5B). Results
 
from a single 
pooled urine sample from GSD1a mice indicated
 
a similar level of 11β-hydroxy 
metabolites to WT (87.5%;Figure 4-5B).
 
This was consistent with the relative ratio of 
reductase: dehydrogenase
 
activity seen in vitro, being comparable with that of WT 
animals
 
(5.21 ± 0.64 WT versus 5.7 ± 0.7 GSD1a;Figure 4-5B). 
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Figure 4-5 In vivo and in vitro assessment of 11β-HSD1 activity in WT, GSD1b 
and GSD1a mice. A, comparison of the percentage of urinary 
metabolites in WT mice with GSD1b and GSD1a revealed that the 
percentage of 11β-hydroxy metabolites (black bars) were significantly 
decreased in the GSD1b group when compared with WT. Results from 
a single pooled sample of GSD1a urine showed a similar profile of 
metabolites as WT. B, the relative ratio of reductase:dehydrogenase 
activity from microsomal assays of WT, GSD1b, and GSD1a mice was 
significantly higher in both the WT and the GSD1a animals when 
compared with GSD1b. Values indicate mean ± S.E.; 
**
, p < 0.01; 
***
, p 
< 0.001; n = 3. 
Chapter 4  11β-HSD1 regulation by G6P 
156 
 
4.3.4. Analysis of Cortisol Metabolism in patients with GSD1a and 
GSD1b  
In GSD1a patients,
 
total cortisol production rate, as determined from the summation
 
of 
the metabolite excretion in a 24-h urine collection (Tomlinson et al. 2004a),
 
was 
significantly decreased Table 4-1. In addition, the THF+5αTHF/THE, the 
cortols/cortolones, and the 11OH-androsterone+11OH-etiocholanolone/11-oxo-
etiocholanolone
 
ratios, all of which reflect global 11β-HSD1 activity, were 
significantly
 
increased, in keeping with an increased cortisone to cortisol
 
conversion. 
Absolute levels of THF and THE were significantly
 
lower than in control subjects; 
however, there was little change
 
in the relative activity of either 5-α reductase or 5β-
reductase
 
as measured by the THF/5αTHF and etiocholanolone/androsterone ratios 
(Figure 4-6),  although it is still possible that there is a reduction
 
in both 5α-reductase 
and 5β-reductase activity. Small numbers of GSD1b patients precluded statistical 
analysis, but
 
in contrast to patients with GSD1a, a relative decrease in 5α and/or 
increase in 5β-reductase activity (increased THF/5αTHF ratio) was observed in 
GSD1b. However, the etiocholanolone/androsterone
 
ratio was within the normal 
reference range. Importantly, 11β-HSD1 activity, as measured by the THF+5α 
THF/THE and the cortols/cortolones
 
ratios, was decreased (Table 4-1). These were 
spot urines from
 
overnight collections, and we were unable therefore to assess
 
24-h 
cortisol metabolite secretion rates. 
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Table 4-1 Urinary steroid metabolite analysis: Urine was analyzed for levels of 
corticosteroid metabolites by GC/MS. 24-h collections were obtained 
from 36 healthy controls and 5 patients with GSD1a. Data are mean 
values ± S.E. Only spot urines were available from two children with 
GSD1b; thus, only individual values are presented. 
*
, p < 0.05; 
**
, p < 
0.01; 
***
, p < 0.0001 vs. control). andro, androsterone; etio, 
etiocholanolone. 
Total cortisol metabolites (µg/24 h) 5191 ± 1330** 12502 ± 1106
THF (µg/24 h) 742 ± 175* 2015 ± 189
5α-THF (µg/24 h) 724 ± 166 1978 ± 251
THE (µg/24 h) 856 ± 278
** 4303 ± 429
(THF+5α-THF)/THE 1.94 ± 0.2
*** 0.96 ± 0.04 0.28, 0.27 0.62–1.71
Cortols/cortolones 0.64 ± 0.1
*** 0.39 ± 0.02 0.12, 0.11 0.18–0.42
(11OH-andro+11OHetio)/11oxo-etio 13.8 ± 1.0*** 3.2 ± 0.2 3.3, 1.9 0.7–6.0
THF/5α-THF 1.08 ± 0.2 1.43 ± 0.19 2.6, 4.47 0.32–1.35
GSD1a (n  = 5) Sex and age 
matched 
controls (n  = 
36)
GSD1b (n  = 
2)
Sex and age 
matched 
controls (n  = 
15)
Etio/andro 0.75 ± 0.14 0.94 ± 0.09 0.48, 0.59 0.37–1.08
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Figure 4-6 Urinary steroid metabolite ratios from patients with GSD1a when 
compared with controls. Markers of 11β-HSD1 activity 
(cortols/cortolones, THF+5αTHF/THE, 11OH-and+11OH-etio/11-
oxo-etio; mean ratio ± S.E.) were significantly increased in the GSD1a 
patients, whereas indicators of 5α and 5β-reductase activity were 
unchanged. and, androsterone; etio, etiocholanolone. 
4.3.5. In Vivo Analysis of Cortisol Metabolism in GSD1a Patients, 
Cortisol Regeneration from an Exogenous Cortisone Challenge 
Hepatic
 
11β-HSD 1 activity, measured as the conversion of orally administered 
cortisone (25 mg) to cortisol after overnight dexamethasone
 
suppression (Stewart et al 
1999), was elevated in the GSD1a group
 
when compared with controls (n = 34) (mean 
cortisol AUC ±
 
S.E. 248 ± 3 versus 75 ± 4 µmol/liter.min,
 
p < 0.001;Figure 4-7A). 
Serial cortisone measurements over the
 
same time course were similar in both control 
and GSD1a patients
 
(mean AUC 15 ± 3 versus 13 ± 5 µmol/liter.min,
 
p = 0.4) (Figure 
4-7B), suggesting no impact upon renal 11β-HSD2 activity. 
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Figure 4-7 Serum cortisol and cortisone levels in dexamethasone-suppressed 
patients with GSD1a following 25 mg of oral cortisone acetate. The 
data represent the mean ± S.E. of three individuals with GSD1a (two 
premenopausal females and one male) and compared with data from 
34 age and body mass index-matched controls. A, the GSD1a group 
showed a significant increase in serum cortisol concentrations (mean 
cortisol 248 ± 3 versus 75 ± 4 µmol/liter.min, p < 0.001), indicating 
enhanced production of cortisol and therefore increased 11β-HSD1 
reductase activity. B, there were no significant changes in serum 
cortisone concentrations between the controls and the GSD1a group 
(mean cortisone 15 ± 3 versus 13 ± 5 µmol/liter.min, p = 0.4). 
(*p < 0.001) 
(p < 0.4) 
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4.4. Discussion 
This work provides compelling evidence for the critical importance
 
of G6P 
concentrations in the ER lumen in determining the "set
 
point" of 11β-HSD1 activity. 
It further endorses recent findings
 
of a close functional cooperativity between 11β-
HSD1 and H6PDH (Atanasov et al 2008;Banhegyi et al 2004;Bujalska et al 2005) and 
the existence of a separate pool of NADP/H
 
within the ER (Czegle et al 
2006;McCormick et al. 2006;Piccirella et al. 2006).
  
The studies on humans lacking G6Pase-α (GSD1a) show for the first time an 
impressive increase in 11β-HSD1 reductase activity in vivo, resulting in increased 
local generation of active glucocorticoid.
 
In these patients, G6P availability to H6PDH 
is increased, resulting
 
in enhanced NADPH generation for 11β-HSD1. Activity was 
inferred
 
in humans through an increase in the urinary THF+5αTHF/THE, 
cortols/cortolones,
 
and 11OH-androsterone+11OH-etiocholanolone/11-oxo-
etiocholanolone
 
ratios and increased generation of circulating cortisol following
 
an 
oral dose of cortisone acetate, with unchanged markers of
 
5α-reductase and 5α-
reductase activity. We and others have extensively
 
utilized the cortisol generation test 
post-cortisone as a marker
 
of liver 11β-HSD1 activity; a reduced generation of 
cortisol
 
has been observed in patients with obesity (Stewart et al 1999) and in subjects
 
with apparent cortisone reductase deficiency (Tomlinson et al. 2002a). However,
 
this 
is the first time an increase in cortisol concentrations
 
following cortisone has been 
observed. The normal ratio of urinary
 
C11β-hydroxy:C11-oxo metabolites of 
glucocorticoids in humans
 
is ~1:1, but in mice, this ratio is ~20:1, reflecting a more 
efficient
 
reductase enzyme (Lavery et al 2006). As a consequence, a further increase
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in the percentage of urinary 11β-hydroxy metabolites was not observed in mice 
lacking G6Pase-α. However, in hepatic microsomes from mice lacking G6Pase-α, 
absolute levels of both reductase
 
and dehydrogenase activities were lower than WT 
controls. Since
 
both reductase and dehydrogenase activities were reduced by
 
the same 
extent, the ratio of these activities remained unchanged.
 
This was explained by an 
overall reduction in expression of
 
11β-HSD1 protein in the GSD1a liver microsomes. 
The down-regulation
 
of 11β-HSD1 in the liver of these animals may represent a 
negative
 
feedback mechanism whereby an attempt is made to increase G6P
 
hydrolysis 
by limiting the requirement for G6P by H6PDH, although
 
this hypothesis requires 
further investigation.
  
Conversely, when delivery of G6P to the ER is compromised, as
 
seen in mice and 
humans lacking G6PT (GSD1b), a significant
 
impairment of 11β-HSD1 reductase 
activity was observed. It was
 
not possible to undertake cortisol generation profiles 
following
 
oral cortisone in two patients with GSD1b, but the urinary 
THF+5αTHF/THE ratio was reduced by 71% when compared with controls. Similar 
changes were seen in mice, where the percentage of 11-oxo metabolites
 
fell from 92.3 
to 39.8%. Our in vitro data indicated that this
 
was a direct result of impaired reductase 
activity. These data
 
compare favourably with those obtained from our H6PDH 
knockout
 
mouse. In these animals, we also found that the set point of
 
11β-HSD1 
activity switched from reductase to dehydrogenase with
 
greater dehydrogenase 
activity evident from liver microsomal
 
preparations and a higher percentage of 11-oxo 
metabolites present
 
in the urine (Lavery et al 2006).
 
Glycogen storage disease type 1 is a complex liver disorder,
 
and both GSD1a and 
GSD1b patients manifest the symptoms of failed
 
G6P hydrolysis, characterized by 
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growth retardation, hypoglycemia,
 
hepatomegaly, nephromegaly, hyperlipidemia, 
hyperuricemia, and
 
lactic academia (Chou et al 2002a). However, there are distinct 
phenotypic
 
differences between GSD type 1a and 1b, which are not obviously
 
related 
to G6P metabolism in gluconeogenic tissues, and local
 
alterations in 11β-HSD1 
activity may explain some of these differences.
 
The pathogenesis of osteoporosis in 
GSD1a, which is not present
 
in GSD1b, has been studied in some detail and 
demonstrates many
 
similarities with glucocorticoid-induced bone loss (Cabrera-Abreu 
et al. 2004;Rake et al. 2003).
 
Additionally, one unique feature of GSD1b that is not 
seen in
 
GSD1a is neutropenia (Beaudet et al. 1980;Garty et al. 1996;Gitzelmann and 
Bosshard 1993;Visser et al. 2002). G6PT is widely distributed,
 
but G6Pase-α is not 
present in neutrophils (Chou et al 2002a), suggesting that
 
the neutropenia is in some 
way dependent upon loss of substrate
 
for H6PDH. It remains to be seen whether this 
is secondary to
 
a reduction in glucocorticoid generation in bone marrow precursors. 
An important finding that explains why neutropenia specifically occurs in GSD1b is 
the discovery of an additional catalytic subunit of G6Pase, G6Paseβ, described in 
detail in section 4.1.1. 
  
However, perhaps the most important clinical implications of
 
these findings relates to 
the putative role of 11β-HSD1 in the pathogenesis and treatment of patients with 
obesity-metabolic
 
syndrome. Inhibition of 11β-HSD1 lowers glucocorticoid levels in 
liver and adipose, thereby reducing hepatic gluconeogenesis
 
and hepatic glucose 
output and adipogenesis (Bujalska, Kumar, & Stewart 1997;Paterson et al 2004). In 
each
 
case, the assumption is that 11β-HSD1 reductase activity is inhibited; our data 
highlight the key role of G6P delivery and H6PDH activity
 
within the ER to direct this 
activity.
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These studies also offer an exciting link between cellular glucose
 
disposal, local 
glucocorticoid metabolism, and the function
 
of the hypothalamo-pituitary-adrenal 
axis. During hyperglycemia,
 
cytosolic G6P concentrations increase (Krebs et al. 
2001). In addition, under
 
these conditions, free fatty acids limit the availability of
 
G6P 
(Krebs et al 2001). As a consequence, this would increase G6P availability
 
to the ER 
lumen, providing substrate for H6PDH, which would,
 
in turn, drive 11β-HSD1 
reductase activity and increase local
 
glucocorticoid regeneration. In support of this 
hypothesis,
 
within 3 h of a mixed meal, both 11β-HSD1 reductase activity (Basu et al. 
2006) and total cortisol production rates increase (Basu et al 2006;Brandenberger et 
al. 1982;Knoll et al. 1984).
 
Furthermore, at a cellular level, the concentration of 
glucose
 
within cell culture medium has a profound effect on the directionality
 
of 11β-
HSD1, omission of glucose leading to decreased 11β-HSD1 reductase activity 
(Ferguson et al. 1999). This hypothesis may also offer an explanation
 
for observations 
made in other clinical studies. We have previously
 
observed a failure to down-regulate 
11β-HSD1activity (as measured by the urinary THF+5α THF/THE ratio) in obese 
patients with type
 
2 diabetes (Valsamakis et al. 2004). In these patients, 
hyperglycemia, resulting
 
in an increase in cytosolic and endoluminal G6P 
concentrations,
 
would drive 11β-HSD1 reductase activity and explain the relative 
increase in the urinary THF+5α THF/THE ratio seen. In addition, it has been reported 
that selective 11β-HSD1 inhibitors are more efficacious in rodent models of 
hyperglycemia. This could be
 
explained by the hyperglycemia in these animals 
increasing reductase
 
activity in key target tissues, thereby making them more 
responsive
 
to selective 11β-HSD1 inhibition (Alberts et al. 2003). Further studies are 
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now
 
required to determine the impact of short term fasting and feeding
 
upon glucose 
trafficking, cortisol metabolism, and specifically,
 
the impact upon 11β-HSD1activity.  
In summary, human and mouse models of GSD elicit dramatic changes
 
in 11β-HSD1 
activity with induction observed in GSD1a and loss
 
of reductase activity in GSD1b. 
These studies highlight the
 
importance of a novel metabolic pathway involving G6P 
metabolism
 
via H6PDH and the regulation of redox potential within the ER,
 
linking 
cellular glucose metabolism to the function of the hypothalamo-pituitary-adrenal
 
axis. 
4.5.  Further work – in vitro analysis of human GSD1a whole liver 
Since the publication of the work described in this chapter (Walker et al. 2007), a 
female patient who had participated in the clinical study with GSD1a received a liver 
transplant.  Samples of the explanted liver were retained with consent and ethical 
approval. 
4.5.1. Methods 
It was planned to investigate 11β-HSD1 gene and protein expression and activity in 
human GSD1a liver tissue using immunoblotting and enzyme activity assays as 
described in section 4.2.3. 
4.5.1.1. Preparation of human liver microsomes 
Microsomes were prepared from normal human whole liver and human GSD1a liver 
as described in section 4.2.1, and in detail in chapter 2. 
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4.5.1.2. 11β-HSD1 enzyme activity assays 
Microsomes (100 µg)
 
were preincubated at 37 °C for 20 min in Mops buffer with
 
1 
mM of the H6PDH substrate G6P. 11β-HSD enzyme reactions were started by the 
addition of 50 nM cortisone /50
 
nM cortisol spiked with 20,000 cpm of tritiated 
cortisone/cortisol.
 
All experiments were performed in triplicate. After incubation
 
at 
37°C for 60 min, steroids were extracted as described in section 4.3.2.  These reaction 
conditions were determined from experiments to optimize reaction conditions using 
snap frozen whole human liver described in section 3.2.6. 
4.5.1.3. Immunoblotting 
SDS-PAGE was performed by the method of
 
Laemmli (Laemmli 1970) with 10 µg of 
human normal liver microsomal protein/ human GSD1a liver microsomal protein
 
described in section 2.6. 
4.5.1.4. Real time PCR 
11β-HSD1, glucocorticoid receptor and 5α-reductase 2 mRNA expression from 5 
normal human liver samples and one GSD1a human liver sample, as described in 
section 2.3.3. 
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4.5.2. Results 
4.5.2.1. In Vitro Analysis of 11β-HSD1 Activity and Protein Expression in 
normal human liver and GSD1a human liver 
Enzyme activity
 
was assessed by examining reductase (cortisone to cortisol)
 
and 
dehydrogenase (cortisol to cortisone) activities of 11β-HSD1 in human liver 
microsomes from normal donor liver and a GSD1a liver.
  
In hepatic microsomes from normal liver, reductase activity
 
predominated (Figure 
4-8A). In the GSD1a liver, both reductase and dehydrogenase activities
 
were reduced 
when compared with normal, possibly explained by a reduction in expression of 11β-
HSD1
 
protein in GSD1a liver Figure 4-8B.  
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Figure 4-8 11β-HSD1 reductase and dehydrogenase activity and protein 
expression from liver microsomes of normal human liver and liver of 
GSD1a patient. A, in the normal liver microsomes, reductase activity 
(black bars) was significantly higher than dehydrogenase activity 
(white bars). Reductase activity from GSD1a microsomes was 
significantly lower when compared with normal and at a similar level 
to dehydrogenase activity. Microsomes prepared from livers of GSD1a 
had much lower levels of reductase and dehydrogenase activity when 
compared with normal, but reductase activity still predominates. 
Values indicate mean activity ± S.E.; n = 3 for each group. 
*
, p < 
0.001. B, SDS-PAGE Western blot analysis lower levels of 11β-HSD1 
protein in the GSD1a compared with normal.  Bands were seen for the 
34kDa protein and less intense bands for the 68kDa protien. 
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4.5.2.2. Gene expression studies of steroid metabolism in GSD1a human liver 
To put the results in context of changes in gene expression seen in other types of 
diseased liver, results have been displayed alongside those for NASH diseased liver 
expression data, chapter 7.  Real time PCR analysis on GSD1a human liver showed a 
dramatic increase in HSD11B1 gene expression when compared with normals and 
NASH (dCt Normal 25.6+/-0.03, NAFLD 24.6+/-0.05, GSD1a 21.6+/-0.04. GSD1a 
vs normal p<0.001), Figure 4-9A. There was also a significant increase in 
glucocorticoid receptor gene expression in GSD1a that was significantly greater then 
normals and the increased expression seen in NASH livers, (dCt Normal 11.67+/-
0.36, NAFLD 10.37+/-0.37, GSD1a 8.05+/-0.07. GSD1a vs normal p<0.001), Figure 
4-8B.  This was associated with a very marked decrease in 5α-reductase gene 
expression in GSD1a that was much greater than the decrease in expression seen in 
NASH livers, (dCt Normal 10.01+/-0.13, NAFLD 13.3+/-0.01, GSD1a 16.4+/-0.01. 
GSD1a vs normal p<0.001), Figure 4-9C. 
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Figure 4-9 11β-HSD1 (A), Glucorcorticoid receptor (B) and 5α-reductase (C)  
mRNA expression in human normal liver, NASH liver and GSD1a liver 
samples expressed in arbitrary units +/- SE. *p<0.01 vs normal, ** 
p<0.001 vs normal. 
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4.5.3. Discussion 
These exciting results provide a valuable insight into unravelling the glucocorticoid 
response in the liver of patients affected with GSD1a.  The clinical data for this 
patient showed increased 11β-HSD1 activity when assessed after an exogenous 
cortisone challenge as well as on 24 hour urine steroid metabolite analysis.  However, 
western blot analysis showed reduced 11β-HSD1 protein expression in GSD1a liver 
compared with normal. With the knowledge that G6Pase deficiency increases 
substrate supply for H6PDH which in turn drives 11β-HSD1 reductase activity, this 
major shift in the set point of 11β-HSD1 activity may cause negative feedback to 
down regulate 11β-HSD1 protein expression.  However, the change in redox, 
combined with the increase GR expression may be sufficient to maximise local 
hepatic glucocorticoid generation as reflected in the clinical data.   
Any down regulation of protein expression does not occur at the level of transcription 
since gene expression data from GSD1a diseased liver showed a marked increase in 
11β-HSD1 mRNA expression.  This is a curious finding but may be explained on the 
basis on a number of pathophysiological facts in GSD1a.  GSD1a liver disease 
involves a serious error of metabolism that eliminates the ability of the liver to 
produce free glucose, hence any compensatory mechanism in an attempt to maximise 
glucose output will be promoted.  This would include increased GR expression and 
11β-HSD1 expression and activity, as increased glucocorticoid action would promote 
expression of gluconeogenic enzymes as well as secondary mechanisms to promote 
glucose output (section 1.4.6.1), as well as providing a low threshold for local 
glucocorticoid response during times of severe hypoglycaemia. On the other hand, at 
the molecular level the effects on substrate supply to H6PDH and resulting increased 
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glucocorticoid generation via 11β-HSD1 would promote a down regulation in 11β-
HSD1 protein expression and activity.  Indeed the increased hepatic glucocorticoid 
activity in GSD1a may contribute to the hepatic lipid accumulation seen in the 
condition.  A third important point is that in adult GSD1a patients there is generally a 
progressive worsening of chronic liver disease, lipid deposition, with a propensity to 
develop hepatocellular carcinoma, an observation that bears close similarity to the 
disease spectrum of NAFLD.  Increased hepatic glucocorticoid generation would be 
favourable to limit hepatic injury in severe GSD1a liver disease as has been argued 
for non alcoholic steatohepatitis in chapter 7. This observation is supported by the 
impressive down regulation of 5α-reductase 2 gene expression seen in GSD 1a livers. 
Indeed, the gene expression data for glucocorticoid action and metabolism in GSD1a 
follows the same trend as NASH but is much more marked. Urine data from GSD1a 
patients showed a trend for lower A ring reductase activity in GSD1a but this was not 
significant.  Again this can be argued as part of a protective mechanism to maximise 
hepatic glucocorticoid availability to limit hepatic injury and perhaps more 
importantly to allow a better response during periods of hypoglycaemia. 
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5. Hepatic glucocorticoid metabolism in alcoholic liver 
disease and other non alcoholic chronic liver diseases 
5.1. Introduction 
Alcoholic pseudo-Cushing‟s syndrome is an important differential in a patient being 
investigated for Cushing‟s syndrome, and poses a significant challenge to the 
physician.  These patients usually have phenotypic and biochemical evidence of 
hypercortisolism, with failure to suppress cortisol following dexamethasone, and loss 
of the normal circadian rhythm of cortisol secretion. The hypercortisolism resolves 
within a few days to weeks of stopping alcohol consumption.  The aetiology of this 
condition has remained unknown.   
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It is difficult to estimate the prevalence of this syndrome for a number of reasons.  
Firstly, individual case reports and studies have made the diagnosis based on different 
clinical and biochemical criteria. Secondly, the duration of alcoholism as well as the 
period of abstinence have both been notoriously difficult to assess and have differing 
effects on the HPA axis.  Acute ethanol loading in healthy non alcoholic and alcoholic 
subjects has been shown to have a stimulating effect on the HPA axis, increasing 
ACTH.  Chronic alcohol abuse has also been shown to increase ACTH in some but 
not all patients studied, and usually in the context of alcohol withdrawal. Acute 
withdrawal from alcohol causes the HPA axis to be stimulated (most likely due to 
stress), an effect which decreases with the period of maintained abstinence.  
Interestingly periods as long as 2 - 4 months were required for the clinical signs and 
symptoms to disappear in some cases. Other factors which commonly affect 
alcoholics can also stimulate the HPA axis, namely malnutrition and depression.  
Hence, prevalence figures for alcoholic pseudo-cushing‟s have ranged from 6 to 40%.  
In addition, a number of reports have failed to demonstrate any correlation between 
serum and urine hormone levels, liver function tests and clinical signs - even in 
alcoholic patients with Cushingoid appearance, normal results have been obtained 
when the HPA axis was tested (Groote & Meinders 1996). 
We have suggested a role for aberrant cortisol metabolism in this process.  A normal 
circulating cortisol level is maintained by a balance between cortisol clearance and 
secretion.  Changes in clearance are very sensitively detected at the hypothalamus-
pituitary with up regulation or down regulation of CRF-ACTH secretion accordingly, 
Figure 5-1.  
Chapter 5  11β-HSD1 in alcoholic liver disease 
174 
 
 
Figure 5-1 Circulating cortisol concentrations reflect a balance between cortisol 
production and clearance.  Cortisol metabolism is predominantly 
regulated by 11HSD’s, type 1 in liver converting E to F and type 2 
in kidney converting F to E. 
In a previous study we have shown higher urinary cortisol : cortisone metabolite 
ratios in patients with alcoholic liver disease (ALD) compared to patients with chronic 
liver disease (CLD) of other aetiologies (Stewart et al 1993a). These findings 
suggested either an increase in 11β-HSD1-mediated oxo-reductase activity or a 
reduction in 11β-HSD2-mediated dehydrogenase activity. However, impaired 
metabolism of cortisol in its own right would not cause hypercortisolaemia due to the 
negative feedback effect on the hypothalamic-pituitary-adrenal axis resulting in 
decreased ACTH secretion. The study provided evidence that the glucocorticoid 
excess in patients with alcoholic pseudocushing‟s reflected a “two-hit” process, i.e. 
continuing normal cortisol secretion in the face of aberrant cortisol metabolism.  In 
terms of ALD, the obvious target to evaluate is hepatic 11β-HSD1. Hence, in this 
study the aim was to further evaluate hepatic glucocorticoid metabolism in patients 
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with ALD and CLD by measuring F and E concentrations through selective venous 
sampling of the hepatic, portal, renal and peripheral veins. These studies were 
extended and supported by in vitro studies to determine hepatic 11-HSD1 mRNA 
levels in patients with ALD, CLD and normal controls (Ahmed et al 2008).  
5.2. Materials and methods 
5.2.1. Patients studied and Selective Venous Catheterisation 
The study was performed with the approval of the local Hospital Ethics committee.  
Forty seven patients with chronic liver disease were electively admitted to the Liver 
Unit, Queen Elizabeth Hospital for transjugular liver biopsy or insertion of 
transjugular intrahepatic portosystemic shunt (TIPS) according to clinical indications 
and were included in the study after informed written consent.  Patients with ALD had 
a history of significant alcohol consumption (>20 units per day for a minimum of 5 
years).  Patients with a history of alcohol consumption in the seven days prior to 
admission or those taking medications that could interfere with the function of the 
hypothalamic-pituitary-adrenal axis were excluded from the study.  Eight patients 
were excluded from the final analysis for reasons that clearly set them apart from the 
rest of the group. These included end stage renal failure (n=2), transplant rejection 
(n=2), Budd Chiari Syndrome (n=1), reverse portal venous flow (n=1), sepsis (n=1), 
and incomplete sample collection (n=1).   The collection of these samples was kindly 
carried out by Dr Sushma Saksena. 
The clinical indications for TIPS were, intraperitoneal variceal bleeding, recurrent 
ascites, gastric or oesophageal variceal bleeding.  Of the 39 patients analysed 20 
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patients (age 48.1+1.9 years (mean + SEM), 13 males) had histologically confirmed 
alcoholic liver disease (ALD) and 19 (age 50.3+3.1 years, 13 males) had chronic liver 
disease of other aetiologies (CLD), including cryptogenic cirrhosis (n=5), hepatitis C 
cirrhosis (n=3), hepatitis B cirrhosis (n=2), primary biliary cirrhosis (n=2), chronic 
hepatitis (n=3), and α -1 anti trypsin deficiency (n=1).   
6 otherwise healthy adult patients (3 males) undergoing adrenal sampling for 
presumed primary aldosteronism were also studied and served as “normal” controls. 
All had normal liver and renal function tests and no history of liver disease, or 
evidence of Cushing‟s syndrome. In each case, selective venous sampling from 
hepatic, peripheral and right renal vein was undertaken between 10.00h and 12.00h. 
Peripheral vein samples were used to determine routine biochemistry including liver 
and renal function tests.  There was no significant difference in drug history between 
patients in the ALD and CLD groups.  These samples were kindly provided by Gian 
Paolo Rossi, University Hospital, Padova, Italy. 
5.2.2. Liver Samples used for RNA extraction and Real Time 
Quantification 
Separately, liver samples were obtained from the Liver tissue bank at the Queen 
Elizabeth Hospital with ethical approval from the local hospital ethics committee.  
Diseased liver samples were obtained from liver transplant recipients and normal liver 
samples from donor liver at transplant; 7 patients with alcoholic liver disease, 9 
patients with non alcoholic chronic liver disease and 6 normal livers were analysed.  
Full details of the samples used are described in chapter 3.2.1. All alcoholic patients 
were abstinent from alcohol for at least 6 months as an eligibility criterion for 
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transplantation. The underlying diagnosis was verified by histopathology reports.  
Histological diagnoses in the non alcoholic chronic liver disease group included 
primary biliary cirrhosis, cryptogenic cirrhosis, primary sclerosing cholangitis, and 
haemochromatosis. 
5.2.3. Measurement of Plasma Cortisol and Cortisone Concentration 
Blood was collected in tubes without additive and stored at -20ºC until analysis.  
Serum cortisol concentrations were measured using an in house direct 
radioimmunoassay using Guildhay antiserum HPS 631-1G and a cortisol-3-CMO-
histamine-(125-I) tracer (Moore et al. 1985). Serum cortisone was measured 
following the extraction of chloroform using antiserum N-137 and 21 – acetyl – 
cortisone – 3 CMO- histamine- (125-I) tracer (Wood et al. 1996).  Interassay 
coefficients of variation were less than 8% for serum cortisol values over 30 nmol/L 
and less than 10% for serum cortisone concentrations over 15 nmol/L.  The method is 
described in further detail in chapter 2. 
5.2.4. Real Time PCR 
11β-HSD1 mRNA levels were measured by real-time PCR. The method is described 
in detail in section 2.3.2. 
5.2.5. Statistical Analysis 
All data were expressed as a comparison of mean absolute serum cortisol or cortisone 
values obtained from selective venous sampling in the two groups. The mean of the 
differences in cortisol or cortisone concentrations across the liver or kidney were also 
compared. Comparisons were made using the Student‟s t test.  Non parametric data 
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(data for hepatic cortisol generation) were analysed using the Mann Whitney Rank 
Sum test.  A p value of < 0.05 was considered significant. 
5.3. Results 
5.3.1. Electrolytes and liver function tests in patients with ALD and CLD 
Patients in both groups were well matched for severity of liver disease, with similar 
levels of bilirubin and albumin. The higher alkaline phosphatase level in the CLD 
group reflected the greater proportion of patients in the CLD group with cholestatic 
liver disease; Table 5-1.   The 6 “normal” patients had normal renal and liver function 
tests. 
Parameter ALD +/- SE CLD +/- SE 
Urea (mmol/L) 5.2 +/- 0.7 7.2 +/- 1.4 
Creatinine (mmol/L) 102 +/- 7.3 111 +/- 28.6 
Sodium (mmol/L) 136.8 +/- 1.3 135.3 +/- 1.9 
Potassium (mmol/L) 4.1 +/- 0.1 4.1 +/- 0.2 
Bilirubin (μmol/L) 107 +/- 29.0 86.0 +/- 20.7 
Albumin (g/L) 31.8+/- 1.5 31.3 +/- 5.8 
Aspartate Transaminase (U/L) 54 +/- 6.6 172
A 
+/- 50.2 
Alkaline Phosphatase (U/L) 218 +/- 25.0 496
B 
+/- 72.5 
 
Table 5-1 Electrolytes and liver function tests in patients with ALD and CLD 
(shown as mean with standard error). 
A
 P = 0.01 vs. ALD, 
B
 P = 
0.0002 vs. ALD
 
 
5.3.2. Cortisone and Cortisol Values from Selective Venous Sampling 
Two of the patients in the ALD group, and one of the patients in the CLD group had 
insufficient samples taken from the renal vein.  As anticipated cortisone 
concentrations in the renal vein were higher than any other vascular bed but no 
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significant differences were observed between ALD, CLD or normals (ALD 78.4 + 
4.4, CLD 81.5 + 6.3, normal 79.6 + 14.3 nmol/L).  Peripheral vein cortisone levels 
were also similar in all three groups indicating that there was no change in cortisone 
delivery to the liver from the peripheral circulation between groups.  There was a 
trend for lower hepatic vein cortisone levels in the ALD group when compared with 
CLD but this was not statistically significant (ALD 32.5 + 3.6, CLD 39.7 + 4.0 
nmol/L, p = 0.09).   
Hepatic vein cortisol concentrations were higher in the ALD group (391 + 42 nmol/L) 
when compared with CLD (295 + 35nmol/L, p < 0.05), Figure 5-2.  There was a trend 
for higher hepatic vein cortisol concentrations in the ALD group compared with 
normals, although this was not statistically significant (317 + 32 nmol/L, p = 0.08), 
Figure 5-2. 
 
Figure 5-2 Absolute serum cortisol from hepatic and peripheral veins expressed as 
mean +/- SE for each group. *ALD vs CLD p < 0.05; ** ALD vs 
normals p = 0.08. 
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When expressed as the difference between the hepatic and peripheral vein cortisol 
concentration as a surrogate marker for hepatic cortisol production, significantly 
increased values were observed in ALD (+34.5 + 21.7 nmol/L) compared to CLD (-
21.0 +18.5 nmol/L, p<0.05) and normals (-19.6 + 17.2 nmol/L p <0.05 ), Figure 5-3. 
Figure 5-3 Net hepatic cortisol gradient in ALD vs CLD expressed as Hepatic 
mean F generation (hepatic vein F – Peripheral vein F) +/- SE. * ALD 
vs CLD and normal p > 0.05. 
Similarly when the net hepatic cortisone gradient was calculated, as the difference 
between the hepatic and peripheral vein cortisone concentration, a negative gradient 
was observed in all three groups with no statistical difference between any group 
(ALD : -32.4 +/- 4.5, CLD : -23.84 +/- 5.7, Normal : -38.8 +/- 6.89), Figure 5-4.
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Figure 5-4 Net hepatic cortisone gradient in ALD, CLD and normals expressed as 
mean hepatic E generation (hepatic vein E – peripheral vein E) +/- SE. 
No statistically significant difference observed between groups. 
5.3.3. Gene expression data 
Real time PCR analysis of RNA extracted from liver samples showed a 5 fold 
increase in 11HSD1 mRNA expression in liver tissue from patients with alcoholic 
liver disease compared with normals (ALD : dCt 9.84 +/- 0.27,  Normals : dCt 13.48 
+/- 1.12,  p < 0.01) using 18s as an internal reference. There was a lesser though 
significant 4 fold increase in 11HSD1 mRNA expression in patients with non 
alcoholic chronic liver disease, Figure 5-5. Compared with normal livers there was 
no significantly increased mRNA expression of H6PDH mRNA expression in the 
ALD group but not the CLD group (ALD: dCt 11.37 +/- 0.4, CLD: dCt 12.36 +/- 0.4, 
Normals : dCt 12.15 +/- 0.4, ALD vs normals p < 0.05).
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Figure 5-5 11β-HSD1 mRNA expression (fold change)in ALD and CLD vs normal.  
dCt values +/- SE : Normal 12.0 +/- 0.5; ALD 9.6 +/- 0.3; CLD 9.9 +/- 
0.2. ALD vs normal p<0.01, CLD vs normal p<0.01) 
5.4. Discussion 
This study assessed hepatic 11-HSD1 and renal 11β-HSD2 activities in patients with 
and without liver disease by directly measuring E and F in the veins draining these 
organs. Cortisol concentrations were significantly increased in the hepatic vein of 
patients with alcoholic chronic liver disease (ALD) compared with non alcoholic 
chronic liver disease (CLD) and a “normal” control group. In a separate cohort of 
patients, our in vitro work demonstrated increased 11-HSD1 mRNA expression in 
patients with ALD.  
As previously reported (Walker et al 1992a;Whitworth et al. 1989), cortisone 
concentrations were highest in the renal vein in keeping with the abundant expression 
of 11-HSD2 in the kidney. However, there were no significant differences in renal 
function or renal vein cortisone concentrations between the groups, suggesting that 
11β-HSD2 activity was similar in both diseased and normal groups; any changes in 
hepatic vein cortisol levels are unlikely to be due to altered cortisone delivery to the 
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liver. Although cortisol binding globulin (CBG) was not measured, serum albumin 
values were normal and similar in both ALD and CLD groups (Table 5-1), suggesting 
that hepatic synthetic function was not significantly reduced in the diseased groups.  
Hence, differences in CBG would be an unlikely explanation for the detected 
difference in cortisol between ALD and CLD groups. Collectively these data suggest 
that our previous findings of higher urinary cortisol : cortisone metabolites in patients 
with ALD (Stewart et al 1993a) reflect induction of 11-HSD1 in the liver rather than 
inhibition of 11-HSD2 in the kidney.  
This increase in local hepatic generation of cortisol may be explained by a shift in the 
set point of 11β-HSD1 activity towards greater oxoreductase activity.  However, our 
in vitro expression studies data provide compelling evidence for specific induction of 
hepatic 11HSD1 gene expression in alcoholic liver disease.  H6PD has been shown 
to regulate the dehydrogenase / oxoreductase set point of 11HSD1 activity 
(Bujalska et al 2005;Lavery et al 2006), but no changes in the levels of expression of 
H6PDH mRNA were observed.  We observed a negative hepatic cortisol gradient in 
both the CLD and normal groups (Figure 5-3) and a negative hepatic cortisone 
gradient in all three groups (Figure 5-4). This may reflect the hepatic metabolism of 
cortisol and cortisone by enzymes other then 11HSD1, such as the A-ring 
reductases (Morita et al. 2004).  While this may be contributing to the present results, 
the positive hepatic cortisol gradient specifically in the ALD group supported by our 
in vitro data reflects predominant 11HSD1 induction in the ALD group. 
We did however also note a significant induction of 11HSD1 gene expression in 
patients with CLD, though to a lesser extent than that observed in the ALD group, yet 
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no apparent increase in hepatic cortisol production was observed in CLD. It is 
important to stress that these liver samples were obtained from an alternative patient 
population; unfortunately ethical constraints prevented liver biopsies being performed 
in our ALD, CLD and “normal” cohort undergoing catheterisation. There were clear 
histological differences between the ALD group and the CLD group in the transplant 
livers studied, but as a whole both groups consisted of patients with end stage liver 
disease (hence the reason for transplantation), unlike our patients recruited to the 
clinical study.  If 11HSD1 gene expression is induced with increasing liver injury, 
the difference in gene expression between ALD and CLD groups (as clearly seen in 
the selective venous sampling data and our previous urine results) may become less 
marked as liver disease progresses and this may account for the lesser difference 
between the ALD and CLD groups in tissue 11HSD1 gene expression when 
compared to the clinical steroid data.  Other possibilities might include a direct effect 
of alcohol itself. Alcohol has been shown in some studies to directly inhibit 11β-
HSD2 (Valentino et al. 1995),  but it is unknown whether alcohol directly induces 
11β-HSD1 expression.  Both isoenzymes of 11β-HSD evolutionally belong to the 
short chain alcohol dehydrogenase superfamily, so regulation of expression by 
alcohol would be a reasonable possibility (Krozowski 1994). Alcohol does however, 
dramatically alter the redox potential within hepatocytes (Jauhonen et al. 1982) and 
this in itself may influence the expression and enzymatic set point of 11β-HSD1.  As 
a requirement for transplantation, patients in the ALD liver transplant group had been 
abstinent from alcohol for at least six months, unlike those in the catheterised ALD 
group who had been abstinent for at least 7 days. It may therefore be possible that the 
direct effects of alcohol were partially reduced in both groups.  Unfortunately we do 
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not have urinary steroid metabolite data to compare excretion during alcohol intake 
and at the time of catheterisation. 
A number of studies have also shown dysregulation of the HPA axis in patients with 
CLD.  In particular, chronic hepatic damage due to cholestasis in rats results in 
decreased hypothalamic CRF (corticotrophin releasing hormone) mRNA and protein 
expression of corticotrophin – releasing hormone (Swain et al 1993).  Furthermore, 
when cholestatic animals are exposed to psychological stress, there is defective 
activation of the HPA axis with a significant attenuation of circulating glucocorticoid 
levels (Swain et al 1993).  As a group, our CLD patients had significantly increased 
markers of cholestasis compared with the ALD group. It may be that the increased 
11β-HSD1 expression and activity in these patients is offset by the decrease in 
glucocorticoid release via the HPA axis, unlike the ALD patients where there is 
ongoing stimulation of the HPA axis (Groote & Meinders 1996). 
The induction of 11-HSD1 in the face of liver injury and inflammation is a novel 
finding that may well represent a protective effect, with the local generation of 
cortisol dampening the inflammatory response and hence limiting tissue damage.  The 
hepatoprotective effect of endogenously released glucocorticoids have been 
previously reported and appear to be caused in part  by glucocorticoid-mediated 
synthesis and release of IL-10 in the liver (Swain et al. 1999).  IL-10 is produced by 
the Kupffer cells in the liver, and has been seen to have a hepatoprotective effect in a 
number of animal models of acute inflammation.  These cells also produce a number 
of proinflammatory cytokines including IL-6, TNF-α, leukotrienes, PGE2 and nitric 
oxide. The production of these cytokines are directly inhibited by glucocorticoids at 
the level of mRNA stability and gene transcription, as well as through inhibition of 
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the production of proinflammatory transcription factors such as (NF)-κB and (AP)-1 
(Cooper et al. 2001).  Previous work on primary cultures of human osteoblasts and 
human osteosarcoma cell line showed that IL-1β and TNF-α potently induced the 
expression of 11β-HSD1 (cortisone-cortisol conversion) (Cooper et al 2001).  Also of 
interest in this context, is the enzyme alcohol dehydrogenase (ADH).  ADH is an 
important enzyme in alcohol metabolism having a high affinity for alcohol (low Km 
0.2-2 mM) and accounts for essentially all alcohol metabolism when blood and tissue 
concentrations are low.  It is an important first step in alcohol metabolism, in limiting 
the hepatic injury directly caused by alcohol and appears to be positively regulated by 
glucocorticoids  (Dong et al. 1988). Further studies are required to explore the 
relationship between hepatic injury, 11-HSD1 induction and the anti-inflammatory 
effects of glucocorticoids locally within the liver. Once it is determined whether the 
harmful effects of 11-HSD1 induction, both locally in the liver and systemically 
outweigh any possible protective effect in the liver, the role of selective 11-HSD1 
inhibition may be considered in the treatment of Alcoholic pseudocushings syndrome. 
In summary, we have previously suggested that alcoholic pseudo-Cushings might be 
mediated by a “two-hit” process, firstly impaired cortisol clearance and secondly and 
specific to alcoholic versus non alcoholic patients, ongoing activation of the HPA axis 
(Lee et al. 2001;Lee and Rivier 1997;Stewart et al. 1993b) (Figure 5-1).  Here we 
confirm that the impaired cortisol to cortisone metabolism is mediated via the type 1 
isozyme of 11-HSD1 – induction in expression resulting in increased hepatic cortisol 
production.   
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In the context of additional studies carried out on non alcoholic liver disease 
(NAFLD) as part of this thesis in chapter 7, these results are of interest.  Alcoholic 
and non NAFLD are often difficult to distinguish histologically  with emphasis placed 
on history of alcohol intake.  It would be plausible to suggest that hepatic pre-receptor 
glucocorticoid metabolism by 11β-HSD1 is a key player in the pathogenesis of both 
conditions.  While increased cortisol availability may primarily be a protective 
mechanism to limit hepatic inflammation and injury, it occurs at the expense of 
hepatic lipid accumulation, and further dysregulation of glucose homeostasis and in 
turn peripheral insulin resistance in both ALD and NAFLD.  It would clearly be of 
interest to investigate whether hepatic 11β-HSD1 is induced in other types of hepatitis 
above the induction seen in non inflammatory chronic liver diseases described in this 
chapter.   
11β-HSD1 has emerged as a novel therapeutic target to treat patients with the diabetes 
mellitus-obesity-metabolic syndrome spectrum, the hypothesis being that inhibition of 
the enzyme will reduce glucocorticoid concentration locally in liver and fat thereby 
inhibiting hepatic glucose output and adiposity respectively. As and when inhibitors 
come on line, it will be of great interest to extend these studies further to hepatic 
inflammation and specifically as a possible treatment for patients with alcoholic 
pseudocushing‟s syndrome. 
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6. Clinical Study: Expression and activity of 11β-HSD1 and 
hepatic glucose sensitivity in normal physiology, obesity, 
type 2 diabetes and non alcoholic fatty liver disease 
6.1. Introduction and broad aims 
Obesity, in particular central obesity has been closely associated with the 
development of type 2 diabetes mellitus. The important role played by cortisol in the 
pathogenesis of obesity and the metabolic complications of insulin resistance has been 
reviewed (sections 1.4.6.1 and 1.5.3.2.).  To summarise, there have been a number of 
animal and human studies – in obese animals, 11β-HSD1 expression is altered in a 
tissue specific pattern, with increased expression in adipose tissue and decreased 
expression in liver (Alberts et al. 2005;Liu et al. 2003;Livingstone et al. 
Chapter 6  Hepatic 11β-HSD1 in normal physiology, obesity and T2D 
189 
 
2000;Masuzaki et al 2001).  These findings are not however consistent in all animal 
models of obesity (Morton et al. 2005).  In humans, studies which have relied on 
measurements of urine ratios of cortisol and cortisone metabolites, have yielded 
inconsistent results (Fraser et al. 1999;Rask et al. 2001;Rask et al 2002;Stewart et al 
1999).  This may be due to these results being affected by the activity of other 
enzymes, including 5α and 5β- reductase.  It has also been shown using stable isotope 
studies that the whole body rate of cortisol regeneration is not altered in obesity 
(Sandeep et al. 2005).  Hence altered metabolism in one tissue may be cancelled out 
by the differences observed in another.  Tissue specific studies on cortisol metabolism 
in humans have detected differences in 11β-HSD1 in obesity.  Measurement of 
hepatic first pass metabolism of cortisone to cortisol in dexamethasone suppressed 
individuals has consistently shown a decrease in 11β-HSD1 in obesity (Fraser et al 
1999;Rask et al 2001;Stewart et al 1999).  However, primary cultures from 
subcutaneous tissue biopsies have consistently showed increased 11β-HSD1 activity 
and mRNA expression (Kannisto et al. 2004;Lindsay et al. 2003;Paulmyer-Lacroix et 
al. 2002;Rask et al 2001;Rask et al 2002;Wake et al. 2003;Westerbacka et al 2003).  
Regulation of 11β-HSD1 in visceral adipose tissue is less clear.  In one study where 
paired fresh omental and subcutaneous fat biopsies were studied, no relationship 
between 11β-HSD1 and obesity was found (Tomlinson et al 2002b). Stable isotope 
studies led to the discovery that rates of splanchnic cortisol production in healthy non 
diabetic individuals exceeded that produced by non splanchnic tissues (e.g. the 
adrenals), strongly implicating splanchnic cortisone to cortisol conversion via the 
11β-HSD1 pathway.  However, as there was also a concomitant uptake of cortisol in 
the splanchnic bed, only a small amount is released by the liver into the systemic 
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circulation.  This observation, that in vivo splanchnic cortisol generation is not 
increased in obesity is a significant one. (Basu et al. 2005).  It would suggest that 
increased cortisol generation in visceral adipose tissue may offset the known decrease 
in hepatic cortisol generation in obesity.  Alternatively, even if there is not a 
significant increase in visceral adipose cortisol generation, the increase in total 
visceral adipose volume may be sufficient to increase cortisol delivery to the liver 
through the portal vein.  However, a recent stable isotope study using selective venous 
sampling showed significant cortisol release from subcutaneous adipose tissue, but 
cortisol release from visceral tissues in to the portal vein was not detected (Stimson et 
al 2009), section 1.5.3.2.  Despite this, the local production of cortisol in visceral 
adipose tissue may be significant at an autocrine level, by impacting upon lipolysis 
portal FFA delivery and hence influencing hepatic metabolic phenotype. Further 
discussion of the role of 11β-HSD1 in regulating intrahepatic fat in patients with non 
alcoholic fatty liver disease are described in detail in chapter 7.   
An important question is whether increased adipose tissue cortisol generation has an 
influence on the metabolic abnormalities of obesity and to what extent.  While 
subcutaneous adipose 11β-HSD1 does predict insulin resistance (Lindsay et al 
2003;Wake et al 2003), it is difficult to elucidate how much of this is an effect of 11β-
HSD1 driven cortisol generation rather than an effect of obesity alone.  Studies have 
assessed endogenous cortisol production and clearance, abdominal fat depots, insulin 
sensitivity, and adipocyte gene expression before and after weight loss.  The data 
generated supported a model in which increased HPA axis activity in men promotes 
selective visceral fat accumulation and insulin resistance, with 11β-HSD1 gene 
expression in subcutaneous fat being a consequence rather than the cause of adiposity 
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(Purnell et al. 2009). Human studies using selective 11β-HSD1 inhibitors will be a 
useful test in further establishing the contribution of adipose 11β-HSD1 to the 
metabolic derangements of obesity.  In-vitro studies using selective 11β-HSD1 
inhibitors in a transformed human subcutaneous preadipocyte cell line as well as 
primary cultures of human preadipocytes, documented an increase in 11β-HSD1 
activity and expression across adipocyte differentiation. Adipogenesis was blocked in 
the presence of selective 11β-HSD1 inhibition, implying that 11β-HSD1 is essential 
for the induction of human adipogenesis (Bujalska et al. 2008a). In vivo studies in 
mice, high-fat diet-induced obesity was accompanied by increased visceral fat 
preadipocyte differentiation in wild-type but not 11β-HSD1 (-/-) mice. In addition, 
despite there being comparable levels of mRNA expression in preadipocytes from 
visceral fat and subcutaneous fat, glucocorticoid reactivation was higher in visceral 
preadipocytes (De Sousa Peixoto et al. 2008).  This would suggest that 11β-HSD1 
reductase activity is augmented in mouse visceral preadipocytes where it would 
promote preadipocyte differentiation contributing to the accumulation of visceral fat 
in obesity.  
 The putative role of pre receptor glucocorticoid metabolism in type 2 diabetes is less 
well established.  Detailed discussion of the effects of glucocorticoids on glucose 
metabolism can be found in section 1.4.6.1 and the background work on the role of 
11β-HSD1 in insulin sensitivity (particularly in animal models) in section 1.5.3.2.  
Studies on human Type 2 diabetics have had varied results but suggest a defect in the  
down regulation of 11β-HSD1 activity in type 2 diabetes (as seen in obesity), which 
may potentiate dyslipidaemia, insulin resistance and obesity. No difference in 11β-
HSD1 activity measured by urine corticosteroid metabolite ratios was seen in one 
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study (Kerstens et al 2000) and possibly impaired hepatic cortisol generation using the 
cortisone to cortisol generation curve analysis when compared with BMI matched 
controls in another (Andrews et al. 2002). This study also found increased sensitivity 
to glucocorticoids in type 2 diabetics with lower 9am cortisol levels after 
dexamethasone suppression, hence it was concluded that although cortisol secretion is 
normal in type 2 diabetic subjects, it was inappropriately high given the enhanced 
central and peripheral sensitivity to glucocorticoids. In support of this suggestion, a 
failure to down-regulate 11β-HSD1 activity compared with BMI matched obese 
controls (as measured
 
by the urinary THF+5α THF/THE ratio) has been observed in 
obese patients with type
 
2 diabetes (Valsamakis et al 2004).  In addition isotope 
studies have shown that splanchnic cortisol production rates did not differ between 
lean, obese and type 2 diabetic subjects, although splanchnic cortisol uptake was 
increased in both obese and Type 2 diabetic subjects compared with normals (Basu et 
al 2005).  
Results from studies using 11β-HSD1 inhibition have yielded important results. 
Carbenoxolone, a non specific 11β-HSD1 inhibitor was found to enhance insulin 
sensitivity measured during a euglycaemic hyperinsulinaemic clamp in healthy 
volunteers (Walker et al 1995) Figure 6-1.  In type 2 diabetic patients this effect was 
specific to the liver where glucagon stimulated glucose release was inhibited 
(Andrews, Rooyackers, & Walker 2003), Figure 6-1. However no beneficial effect 
was seen in obese non diabetic patients and it was suggested that this may be due to 
hepatic 11β-HSD1 being already down regulated in obesity (Sandeep et al 2005).  
This correlated with findings in obese zucker rats where carbenoxolone was 
ineffective (Livingstone and Walker 2003).  
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Figure 6-1 Effects of the 11β-hydroxysteroid dehydrogenase inhibitor 
carbenoxolone on insulin sensitivity in men with type 2 diabetes and 
obesity. Data are mean ± SEM for glucose disposal and production 
during a hyperinsulinaemic euglycaemic clamp measured by glucose 
tracer infusion in six lean patients with type 2 diabetes mellitus and six 
obese euglycaemic patients treated for 7 days with placebo (Plac) or 
carbenoxolone (CBX) in randomized double-blind crossover studies 
(Andrews, Rooyackers, & Walker 2003;Sandeep et al 2005). 
Carbenoxolone did not enhance peripheral glucose disposal in either 
group but did decrease hepatic glucose production in lean diabetic 
patients, consistent with enhanced hepatic insulin sensitivity. This 
effect in the liver is lost in obese subjects, in whom 11 β-HSD1 is 
known to be downregulated (Walker and Andrew 2006). 
Recent data have also been presented using selective 11β-HSD1 inhibitors.  Using the 
selective 11β-HSD1 inhibitor INCB13739 in over 300 obese Type 2 diabetic subjects, 
a significant reduction in haemoglobin A1C (HbA1C), fasting plasma glucose, 
measures of insulin sensitivity and total cholesterol levels was observed, (section 
1.5.2.1.) (ROSENSTOCK J 2009b).  These data support numerous animal studies 
investigating the antidiabetic effects of 11β-HSD1 inhibition, diabetes, dyslipidaemia 
and atherosclerosis all improved.   
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6.1.1. Aim 
On this background a clinical study was carried out to determine the role of 11β-
HSD1 on hepatic gluconeogenesis and total glucose output and correlating measures 
of 11β-HSD1 activity with body composition, visceral adipose tissue, hepatic 
gluconeogenesis, and other markers of metabolic dysregulation. Patients with obesity 
(without diabetes), type 2 diabetes mellitus and non alcoholic fatty liver disease 
(NAFLD) were compared to normal controls.  
The results of these studies form an excellent research platform for the further 
development of 11β-HSD1 inhibitors. 
6.2. Study Group Criteria, Study design and clinical protocols 
6.2.1. Inclusion Criteria 
Group 1: 20 normal weight healthy volunteers (10 males, 10 females) 
Group 2: 20 patients with simple obesity (10 male, 10 females) 
Group 3: 20 patients (10 male, 10 females) matched for BMI with group 2 with 
type 2 diabetes treated with diet or low dose metformin.   
AIM of 1,2 and 3: to correlate measures of 11-HSD1 activity with body 
composition, body fat distribution and hepatic gluconeogenesis. 
 
Group 4: In collaboration with the regional liver unit, 20 patients admitted for 
investigation of non alcoholic fatty liver disease (NAFLD). 
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AIM of group 4: to directly define expression of hepatic 11-HSD1 and H6PDH in 
liver biopsy material (compared to normal liver) and correlate with clinical study 
results from this group. (Results and discussion from this group are described in 
chapter 7). 
No other significant past medical history except as specified in patient groups above 
Age 20 – 60 years. 
6.2.2. Exclusion Criteria 
Poorly controlled hypertension 
Cerebrovascular disease 
Ischaemic heart disease 
Epilepsy 
Diabetes (unless specified in patient group) 
Liver disease (unless specified within patient group) 
Asthma or chronic respiratory disease 
Severe Renal impairment 
Glucocorticoid therapy in any form within the last 12 months 
HRT or hormonal contraception in any form 
6.2.3. Sample size calculation 
Sample size calculations were performed using the SigmaStat computer package and 
powered to examine changes in cortisol metabolites (THF, 5α-THF, THE, UFF, UFE) 
(t-test, power 0.9, alpha 0.05). Using preliminary and published data to anticipate the 
difference (and its standard deviation) between groups, (obese, lean and obese type 2 
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diabetics), calculations predicted that we would need 16 patients in each group. To 
allow for unforeseen drop-outs from the study we planned to recruit 20 patients to 
each group wherever possible. In reality, the dropout rate was highest in the obese 
group reflecting the greater total number of patients in that group. 
 
6.2.4. Patient recruitment and ethical approval 
Patients were recruited to the study through local sources.  These included 
advertisements in the University and Queen Elizabeth Hospital, Birmingham online 
newsletters. NAFLD patients were recruited from dedicated outpatient clinics. Letters 
were sent to all General Practitioners in Birmingham and type 2 diabetics were 
recruited mainly from them. 
Ethical approval for the all aspects of the study including in vitro work was obtained 
from the Solihull local research ethics committee, reference number: 05/Q2706/27. 
6.2.5. Patient information sheet 
All patients received an information sheet, (Appendix 1), and gave written informed 
consent prior to their participation in the study.  On completion of the study they 
received detailed lifestyle advice and all the clinically relevant results from their 
participation. 
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6.2.6. Clinical protocol and plan of investigation 
Each patient attended the Clinical Research Unit for two separate visits, a brief 
overview is provided below further details of each test are described in section 6.3. 
6.2.6.1. Visit 1  
Tests performed:  Anthropomorphic measurements, baseline BP, Pulse and serum 
samples for renal, liver, cholesterol and FBC profile, oral glucose tolerance test 
(OGTT), deuterated water test. 
 
Day 1  0830 volunteers arrived fasted  
Day 1  0845 Patient oriented to ward, general observations (anthropomorphic 
measurements, baseline BP and pulse) 
Day 1  0900 Oral glucose tolerance test and collection of baseline serum 
samples at time 0. 
After OGTT volunteers were allowed to eat and drink normally.   
Whole body DEXA scan and CT scan on this day. 
Day 1  1800 Volunteers given standardised meal and followed by fast (except 
water). 
Day 1  2300 Baseline venous blood samples and start of Deuterated water test  
Day 2  1600 End of investigation on visit 1.  
24-hour urine collection for urine steroid metabolite analysis provided to patient to 
return at next visit. 
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6.2.6.2. Visit 2 (cortisol generation profile) 
Previous night: 1mg dexamethasone taken orally at 2300 previous night (at home) 
followed by fast. 
Day 1  0830 25mg oral cortisone acetate administered  
Day 1  0900 serial serum cortisol and cortisone samples for 4 hours 
Day 1  1300 Test Complete. 
Nursing protocols included in Appendix 2 
6.3. Methods 
6.3.1. Anthropomorphic measurements and blood pressure 
Weight in kilograms was measured to the nearest 0.1kg on a beam balance in subjects 
without shoes and only light clothing.  Height in meters was measured to the nearest 
1mm using a stadiometer, and the BMI in kg per square meter was calculated. Waist 
circumference in centimetres was taken in duplicate with a 6mm wide flexible tape 
and was measured as the maximum abdominal circumference between the costal 
margin and the iliac crest.  Hip circumference was measured as the distance around 
the largest area of the hips, usually the widest part of the buttocks. Waist and hip 
measurements were taken with the subject standing.  Sagittal height with the subject 
supine on a firm examination bed and was measured in centimetres as the maximal 
distance between the top of the examination table and a spirit level placed 
horizontally.  Supine blood pressure was recorded with an automatic 
sphygmomanometer using the mean of three measurements. 
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6.3.2. Whole body composition using dual energy x-ray absorptiometry 
(DEXA) 
Body composition analysis was performed using dual-energy X-ray absorptiometry 
(DEXA) with a total body scanner (QDR 45OO; Hologic, Bedford, MA). Coefficients 
of variation for multiple scans were <3%.  Total and percentage fat and lean mass 
were analysed and lean body mass values were used to calculate total body water.  
The formula of  Pace and Rathbun was used to estimate the total body water from lean 
body mass, where water was found to constitute 72.4% of the fat-free (lean) body 
mass (Pace and Rathburn 1945). 
6.3.3. Computed tomography (CT) scanning to assess intraabdominal 
fat distribution 
6.3.3.1. Scan technique and measurement of liver attenuation 
Patients removed any tight abdominal clothing and were scanned in the supine 
position using a GE Lightspeed scanner (General Electric, Milwaukee, USA).  A 
single slice through the right lobe of the liver of 5mm thickness was obtained.  Scout 
views were used to identify the appropriate slice.   
The slice was viewed on liver window settings. A 100mm
2
 region of interest (ROI) 
was placed over five areas of this section, and the Hounsfield unit of each ROI were 
recorded.  Care was taken not to include any obvious vessels in the chosen ROIs.  The 
mean liver attenuation was calculated from the five liver ROIs.  The attenuation of the 
spleen was measured in the same way using three ROIs per scan (reflecting the 
smaller area of the spleen on the scan).  The CT attenuation characteristics were 
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recorded as: 1) the mean liver attenuation (liver attenuation <50 HU seen in hepatic 
steatosis, (Roldan-Valadez et al. 2008)) , 2) the liver-to-spleen (L/S ratio) and 3) as 
categorical data, being either fatty (L/S ratio of <1) or not fatty (with an L/S ratio of 
greater the or equal to 1) (Bydder et al. 1981;Piekarski et al. 1980). 
6.3.3.2. Abdominal fat distribution analysis 
A single 5mm thick slice at the L3 vertebral level was used for the analysis.  Care was 
taken to include the entire skin surface in the field of view.  Patients who did not have 
the entire skin surface included in the field of view were excluded from the fat 
distribution analysis.  At the time of the analysis GE software to carry out the desired 
function for the analysis had been discontinued, so an alternative commercial software 
was used that was currently being used for similar purposes for other studies in the 
radiology department (MeVis PULMO 3D 3.11, MeVIS Research GmbH, Bremen, 
Germany).  A three dimensional analysis was carried out on the scan from which the 
area was calculated by dividing the volume results by the scan thickness.  Total fat 
area and visceral fat area ROIs were delineated by manually tracing a contour of each 
region.  Fat pixels and therefore fat area were identified with threshold attenuation 
values between -50 to -250 hounsfield units as described previously  (Borkan et al. 
1982).  The subcutaneous fat area was calculated by subtracting the visceral from total 
fat area.  Data was expressed as 1) total, subcutaneous and visceral fat area, 2) the 
ratio of visceral to total fat (% visceral fat), 3) the ratio of subcutaneous to total fat (% 
subcutaneous fat) and 4) the ratio of visceral to subcutaneous fat (V:S ratio). 
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Figure 6-2 Screenshot of CT scan slice at level of L3 with region of interest drawn 
around the entire slice to measure total fat including visceral and 
subcutaneous (blue line around perimeter of slice).  The software 
automatically selects out areas on the scan that are outside the range 
of threshold values of -50 to -250. 
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Figure 6-3 Screenshot of same slice as seen in Figure 6-2 with only visceral fat 
areas selected automatically by the software after a manual ROI was 
drawn aound the areas to include visceral fat only (blue markings). 
Subcutaneous fat area was calculated by subtracting visceral fat area 
from the total fat area. 
6.3.4. Biochemistry 
Patients were studied after an overnight fast and had blood drawn at 0900am on the 
first day of visit 1 for serum F and E, plasma ACTH, fasting glucose, fasting insulin 
lipids, free fatty acids (FFA) renal and liver function tests including aspartate 
aminotransferase (AST), alanine aminotransferase (ALT),  and gamma-glutamyl 
transferase (γGT). Glycosylated haemoglobin (HbA1C) was measured in diabetic 
subjects.  Glucose, HbA1C, lipid renal and liver profile and full blood count were 
measured using standard laboratory methods.   
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Serum F
 
was assayed using a coat-a-count radioimmunoassay (Diagnostic Products, 
Los Angeles, CA) as per the manufacturer's guidelines.  Interassay coefficient of 
variation was 3-6% (detailed in full in section 2.9.4). 
Insulin was measured using a commercially available colorimetric ELISA (Mercodia, 
Uppsala, Sweden), section 2.9.3.  Plasma FFA were analysed as described in section 
2.9.5.   
Insulin sensitivity was derived from fasting glucose and insulin data, using the 
homeostasis model assessment (HOMA) mathematical model (Matthews et al. 1985). 
Serum ACTH values had not yet been analysed at the time of writing this thesis. 
6.3.5. Clinical assessment of 11β-HSD1 activity 
All subjects collected a 24 hour urine collection for urinary steroid metabolite profiles 
using GC/MS spectrometry as previously reported and described in further detail in 
section 2.9.2. (Palermo et al 1996;Shackleton 1993).  The THF+5α-THF/THE, the 
cortols/cortolones, and the 11OH-androsterone+11OH-etiocholanolone/11-
oxoetiocholanolone
 
ratios represent acknowledged markers of global 11β-HSD1 
activity,
 
with a high ratio indicating increased 11β-HSD1 reductase activity. Ratios 
are presented as well as for total F metabolites and urine F/E ratio (representing renal 
11β-HSD2 activity (Palermo et al 1996). The 5αTHF/THF was used as a marker of 
5α-reductase activity with a high ratio in the setting of increased absolute levels of 
urinary 5α-THF indicating increased activity. The urine androsterone/etiocholanolone 
(An/Et) ratio was also used as a marker of 5α-reductase activity.  
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Measurement of hepatic first pass metabolism of cortisone to cortisol in 
dexamethasone suppressed individuals was made by determining the cortisol 
generation profile (CGC) (described in further detail in section 2.9.1). 
6.3.6. Oral glucose tolerance test 
Patients underwent a standard 75-g oral glucose tolerance test, with samples taken at 
30-min intervals for 120 min for measurement of insulin and glucose. 
6.3.7. Deuterated water test 
6.3.7.1. Principle 
In order to fully define total hepatic glucose production and gluconeogenesis the 
following quantification methods were used based on published methodologies, 
(Chandramouli et al. 1997;Landau et al. 1996).  
The method depends on the incorporation of hydrogen-2 from 
2
H2O into glucose. 
When di-deuterated water (
2
H2O) is given to a fasting subject, once steady state is 
achieved, the ratio of enrichment of deuterium bound to C-5 of blood glucose to 
enrichment in body water is equal to the fraction that gluconeogenesis contributes to 
glucose production (Landau et al 1996).  This happens because the conversion of each  
molecule of pyruvate to glucose involves the addition of one molecule of hydrogen 
from body water to C2 of the intermediate phosphoenolpyruvate. This carbon 
becomes C5 of glucose.  The conversion of glycerol to glucose also involves one 
molecule of hydrogen from body water to be added to C2 of glyceraldehyde-3-
phosphate during isomerisation with dihydroxyacetone-3-phosphate.  That carbon 
also becomes C5 of glucose.  Therefore, the enrichment in C5 of glucose represents 
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glucose production from pyruvate and glycerol i.e. from all gluconeogenic precursors 
(see section 1.3.2.2: glycolytic flux and gluconeogenesis), Figure 6-4. 
A hydrogen atom from body water bound to the C-2 reflects glucose production via 
both gluconeogenesis and glycogenolysis.  This is because a single molecule of 
hydrogen is added to C2 of glucose-6-phosphate when fructose-6-phosphate (F6P) is 
converted to glucose-6-phosphate (G6P) during gluconeogenesis.  G6P is also 
produced as an intermediate during glycogenolysis and equilibrates with F6P, 
resulting with the H bound to the C2 of G6P being exchanged with that in body water.  
Enrichment at C5 of glucose does not occur in glycogenolysis; hence the ratio of 
enrichment at C-5 to that at C-2 provides a measure to the fractional contribution of 
gluconeogenesis to endogenous glucose production. 
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Figure 6-4 Glycerol conversion to glucose and the site of labelling at carbon 2 
and 5 of the glucose by deuterium (bold hydrogen) from deuterated 
water (Landau et al 1996). 
To allow the experiments to be performed with a safe and well tolerated dose of 
2
H2O, 
hydrogen enrichment at C2 and C5 were determined by isolating them in 
formaldehyde and assaying the formaldehyde mass spectrometry using 
hexamethylenetetramine (HMT) (Landau et al. 1995;Landau et al 1996).  HMT is an 
adduct of four molecules of ammonia with six molecules of formaldehyde, hence the 
hydrogen enrichment of glucose is magnified six fold for the assay, Figure 6-5. 
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Figure 6-5 Conversion of glucose to xylose and the formation of HMT from 
formaldehyde from xylose (Landau et al 1996). 
The purpose of this part of the study was to determine the fractional contribution of 
gluconeogenesis to endogenous glucose production in the different patient groups and 
to relate these to markers of cortisol metabolism, in particular via 11β-HSD1, and 
known markers of metabolic dysregulation in the metabolic syndrome.  This would 
provide a critical insight into global and hepatic cortisol metabolism with relation to 
hepatic glucose output in the fasting state. 
6.3.7.2. Method 
A primed constant intravenous glucose tracer was given to measure total endogenous 
glucose production, primarily reflecting hepatic glucose production in the overnight 
fasted state. On the day of the study all subjects were admitted to CRF and a standard 
meal was ingested at 18.00h – each subject received the same meal (a vegetarian 
lasagne with salad and bread roll). The meal was followed by a 22 h fast with ad 
libitum access to drinking water. At 23.00h two mixed venous baseline bloods were 
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taken. The subjects were then given 2.5g/kg body water of 
2
H2O to drink. Total body 
water was calculated from lean body mass as detailed in section 6.2. Water ingested 
ad libitum after 23.00h was enriched 0.05% with 
2
H2O to maintain isotopic steady 
state in the body water pool. At 06.00h a catheter was placed retrogradely in a hand 
vein and the hand kept in a hot box at 56°C to arterialize the blood samples. After 
placement of an antecubital intravenous catheter in the contralateral arm for infusion, 
a primed (9 µmol per kg) continuous (0.15 µmol per kg per min) infusion of 
6,6
2
H2glucose (Cambridge Isotopes Laboratories, Andover, MA) was started and 
continued for 10 hours (06:00h to 16.00h) for determination of rates of glucose 
production. After 120 min of infusion, blood samples are taken every 60 min for 
determination of 6,6
2
H2 glucose enrichment under basal conditions. Bloods were also 
taken to be analysed for determination of 
2
H enrichment of the H-atoms bound to C2 
and C5 of blood glucose and for determination of 
2
H enrichment in body water, and 
free fatty acids at each time point. The tracer infusion and study were stopped after 
the last blood sample has been obtained at 16.00h. This technique involved 
collaboration with Professor Anton Wagenmakers (School of Sport and Exercise 
Sciences, University of Birmingham). A timeline of the sampling protocol for this test 
is illustrated in Figure 6-6. 
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Figure 6-6 Timeline of sample collection for deuterated water test 
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6.3.8. Statistical analysis 
Results are expressed as mean +/- SE in the case of normally distributed data or 
median (interquartile range) in the case of non-Gaussian distribution.  Statistical 
analyses comparing groups of subjects were undertaken using the Student‟s t test and 
Mann-Whitney U test in the case of non Gaussian distribution of the variables.  To 
test the association between different variables, Spearman correlation analyses were 
performed. A P-value of < 0.05 was considered to be significant.  The SPSS 17.0 
statistical software was used for statistical analysis (SPSS, Inc., Chicago, IL). 
6.4. Results 
6.4.1. Study population descriptive statistics 
Parameters from the complete groups of normal weight healthy volunteers, obese, and 
type 2 diabetic cohorts are shown in Table 6-1.  The obese cohort was closely BMI 
matched with the diabetic group. 
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Table 6-1 Study population descriptive statistics for normal, obese and diabetic 
groups (values expressed as mean +/- SEM or median (interquartile 
range)). Significant P values in bold. 
mean SEM mean SEM mean SEM 2 vs 1 3 vs 1 3 vs 2
N 
BMI (kg/m2) 21.9 0.7 32.1 0.9 33.5 1.5 <0.001 <0.001 0.4
Waist:Hip ratio 0.88 0.02 0.91 0.01 0.96 0.01 0.2 0.002 0.01
pulse (bpm) 66 2 70 2 72 3 0.2 0.1 0.7
Systolic blood pressure (mmHg) 118 3 133 4 145 3 0.009 <0.001 0.04
Diastolic blood pressure (mmHg) 73 2 76 2 84 2 0.5 0.002 0.04
Total % body Fat (from DEXA) 24 1.7 37 1.3 34 1.6 <0.001 <0.001 0.2
Lean body mass (kg) 47 2 53 2 55 5 0.09 0.1 0.7
sag height (cm) 18.9 0.4 22.9 0.6 24.2 0.9 <0.001 <0.001 0.2
Glucose tolerance test and HOMA-IR
fasting glucose (mmol/L) 5.0 0.4 4.8 0.1 8.5 0.7 0.5 <0.001 <0.001
OGTT glucose AUC (mmol/L.120min) 709 41 761 26 1591 98 0.3 <0.001 <0.001
Fasting insulin (mIU/L) 5.9 1.5 9.5 1.8 13.4 1.9 0.2 0.004 0.1
OGTT Insulin AUC (mIU/L.120min) 4125 455 7734 814 5542 793 0.003 0.1 0.07
HOMA-IR 1.3 0.3 2.0 0.4 4.8 0.7 0.2 <0.001 <0.001
Baseline serum biochemistry
HBA1C (%) . . . . 7.5 0.4
Na (mmol/L) 141 0.4 140 0.4 140 0.6 0.05 0.1 0.9
K (mmol/L) 4.1 0.1 6.2 2.0 4.2 0.0 0.4 0.4 0.4
Urea (mmol/L) 4.7 0.3 5.4 0.3 5.1 0.3 0.1 0.4 0.4
Creat (μmol/L) 86 3.2 89 2.6 82 5.4 0.4 0.5 0.2
Ca (mmol/L) 2.3 0.0 2.2 0.0 2.2 0.0 0.7 0.8 0.9
Alb (g/L) 44 1.2 44 0.5 43 0.5 1.0 0.6 0.4
TP (g/L) 72 1.1 72 0.6 72 0.9 0.7 0.6 0.7
ALP (u/L) 148 6.3 163 8.0 162 13.1 0.2 0.3 1.0
AST (iU/L) 23 1.6 22 0.9 25 1.5 0.5 0.3 0.047
Bilirubin (μmol/L) 11 1.2 9 0.7 9 0.6 0.1 0.2 0.7
γGT (iu/L) 23 6.9 22 2.2 41 7.1 0.8 0.1 0.004
Total cholesterol (mmol/L) 4.5 0.2 6.7 1.3 4.6 0.2 0.2 0.8 0.2
HDL cholesterol (mmol/L) 1.6 0.1 1.4 0.1 1.2 0.1 0.2 0.008 0.03
Triglycerides (mmol/L) 0.8 0.1 1.3 0.1 2.1 0.5 0.002 0.02 0.08
ALT (iu/L) 21.6 2.2 23.7 2.3 28.8 2.8 0.5 0.05 0.2
Hb (g/dL) 13.2 0.3 13.6 0.3 13.8 0.3 0.4 0.2 0.7
WCC (x109/L) 21.7 16.2 6.1 0.3 6.7 0.5 0.2 0.4 0.3
Plts (x109/L) 225 20 242 10 222 17 0.4 0.9 0.3
fasting FFA (μmol/L) 286 38 328 17 506 51 0.2 0.004 0
CT measured body fat distribution
Liver attenuation (HU) 64.3 1.63 63.3 1.40 54.2 2.37 0.6 0.001 0.001
Spleen attenuation (HU) 54.8 0.71 55.4 0.54 55.3 0.61 0.5 0.6 0.9
L/S ratio 1.18 0.03 1.15 0.03 0.97 0.04 0.4 0.001 0.001
% visceral fat 33.7 3.70 33.2 3.21 49.7 3.10 0.9 0.002 0.001
% s/c fat 66.0 3.67 66.7 3.21 50.3 3.10 0.9 0.003 0.001
V:S ratio 0.66 0.17 0.64 0.13 1.09 0.14 0.9 0.06 0.02
Normal (1) Obese (2) Diabetic (3) P  value
21 36 22
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6.4.2. Cortisol metabolism in normal, obese and type 2 diabetic subjects 
 
Table 6-2 Data reflecting cortisol metabolism in normal, obese and type 2 
diabetic cohorts.  Significant differences are displayed in bold. Notable 
differences that did not quite achieve significance are displayed in bold 
italics. [values expressed as mean +/- SEM or (in italics) median 
(interquartile range)] 
Data reflecting cortisol metabolism in the normal, obese and type 2 diabetic subjects 
is shown in Table 6-2.  9am baseline serum cortisol levels were significantly lower in 
the obese group when compared with both normal and diabetic groups.  There was no 
difference in 9am cortisol between diabetic and normal weight subjects. 
mean/
median SEM
mean/
median SEM
mean/
median SEM 2 vs 1 3 vs 1 3 vs 2
N 
Baseline serum 9am Cortisol 
(nmol/L) 359 72 239 30 346 37 0.08 0.86 0.04
Serum cortisol generation 
profile (CGC)
Baseline cortisol post dex 
suppression (nmol/L) 12.8 2 23.3 5 16.1 2 0.17 0.29 0.28
Peak cortisol (nmol/L) 603 56 602 33 632 34 0.99 0.64 0.55
Area under the curve 
(nmol/L.240min) 105469 51986 84469 38994 100323 30003 0.73 0.92 0.59
24 hr urine steroid anaysis
Urine Total F metabolites 
(μg/24hrs) 7741 817 9042 854 10385 892 0.34 0.04 0.31
THF 1149 806 1571 166 1752 157 0.17 0.01 0.47
5α-THF 1084 1504 1444 1433 1570 300 0.89 0.17 0.29
THE 2578 1715 4123 4283 2649 2215 0.44 0.07 0.29
α-cortol 256 27 328 196 369 33 0.24 0.01 0.15
β-cortol 465 356 454 373 460 350 0.34 0.70 0.54
α-cortolone 958 85 1273 108 1466 135 0.07 0.00 0.28
β-cortolone 555 54 612 57 701 50 0.53 0.06 0.30
F:E 0.60 0.04 0.65 0.15 0.62 0.21 0.74 0.14 0.16
(THF+5αTHF):THE 0.85 0.31 0.96 0.34 0.94 0.44 0.82 0.93 0.61
cortols:cortolones 0.49 0.02 0.40 0.09 0.38 0.06 0.04 0.00 0.44
11βOHEt+11βOHAn:11OXOEt 2.91 2.04 2.57 1.47 2.50 1.52 0.03 0.17 0.42
5αTHF:THF 1.02 1.16 0.79 0.46 0.83 0.61 0.26 0.81 0.45
An:ET 1.63 1.35 1.20 0.50 0.94 0.84 0.13 0.48 0.54
Normal (1) Obese (2) Diabetic (3) P  value
21 36 22
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Area under the curve calculations from serum cortisol generation profiles after 25mg 
of cortisone acetate and dexamethasone suppression were used as an in-vivo marker of 
hepatic 11β-HSD1 activity.  There was no significant difference observed between 
groups although the cortisol generation AUC was highest in the normal group and 
lowest in the obese group, a trend which matched the urine cortisol metabolite ratios 
for 11β-HSD1 activity. The peak cortisol level was highest in the diabetic group, and 
higher in obese subjects compared with normals, but these differences also did not 
achieve significance. Values for the final two time points (180 min and 240 min) 
showed a significant difference between normal and obese groups Table 6-2, Figure 
6-7. 
 
Figure 6-7 Serum cortisol generation profiles follwoing 25mg cortisone acetate in 
dexamethasone suppressed subjects in normal, obese and diabetic 
cohorts (mean +/- SEM).(* p<0.05 normal vs obese). 
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24 hour urine steroid metabolite analysis did reveal some interesting differences 
between groups. Urine total F metabolites were highest in the diabetic group.  This 
difference was significant when compared with the normal cohort, but not when 
compared with BMI matched controls (the obese group). Total F metabolites were 
higher in the obese group compared with normals, although the difference was not 
statistically significant.  These results show evidence of HPA axis activation in Type 
2 diabetes, Figure 6-8. 
 
 
Figure 6-8 24 hour urine total cortisol metabolites (mean +/- SEM) in normal, 
obese and diabetic cohorts. (* p < 0.05 diabetic vs normal). 
Urine F:E ratios were not different between groups implying that renal 11β-HSD2 
activity was similar and hence did not impact any results reflecting 11β-HSD1  driven 
cortisol metabolism between groups (as cortisone (substrate) availability for 11β-
HSD1  would be assumed to be unchanged between groups), Figure 6-9. 
Urinary markers of 11β-HSD1 driven cortisol generation were the urinary steroid 
metabolite ratios: THF+5α-THF/THE, cortols/cortolones, and 11OH-androsterone 
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+11OH-etiocholanolone/11-oxoetiocholanolone.  As displayed in Figure 6-9, the 
widely used urinary marker for 11β-HSD1 activity - the THF+5α-THF/THE ratio, 
was similar for all three groups.  
  
  
Figure 6-9 Urine steroid metabolite ratios displayed as boxplots with median and 
interquartile range.  (*obese vs normal p<0.05,** diabetics vs normal 
p<0.01). 
* 
* 
** 
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When compared with normal, the urine cortols/cortolones ratio was significantly 
lower in both the obese and the diabetic groups.  The 11OH-androsterone+11OH-
etiocholanolone/11-oxoetiocholanolone ratio was significantly lower in the obese 
group compared with the normal group Figure 6-9. There was no significant 
difference in these ratios between diabetic and the obese group, who were BMI 
matched.  
Markers of cortisol clearance via the A-ring reductases include the urinary 
5αTHF/THF and An/Et ratios.  While there was a trend for these ratios to be lower in 
the obese and diabetic groups compared with normal, these were not statistically 
significant. 
The observed differences were unaltered after matching for sex between groups. 
Two important observations from this analysis were, 1) HPA axis activation in the 
type 2 diabetic group with significantly increased total cortisol metabolites and 
significantly higher 9am cortisol compared with the BMI matched obese group; 2) 
some evidence of suppression of 11β-HSD1 driven glucocorticoid metabolism in the 
obese cohort compared with normal. There was also a suggestion of loss of 
suppression of 11β-HSD1 activity with the highest peak cortisol in the cortisol 
generation profile compared and higher total AUC of the cortisol generation profile in 
the type 2 diabetic group compared with obese non diabetic (neither of these 
differences however achieved statistical significance). 
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6.4.3. Body fat distribution analysis and lean body mass 
The markers of body fat distribution used in the study were waist:hip circumference 
ratio, sagittal height, total % body fat measured by DEXA and CT measured 
intrahepatic fat, visceral and subcutaneous fat area Table 6-1. 
 
Figure 6-10 Fat distribution analysis using CT measured liver attenuation (lower 
attenuation implying increased intrahepatic fat), % visceral and 
subcutaneous fat (measured by CT), and % total body fat measured by 
DEXA +/- SEM, (* p<0.01 diabetic vs obese and normal, ** p<0.01 
obese vs normal and diabetic vs normal). 
Despite having similar BMI compared with obese non diabetic patients, and total % 
body fat (calculated from DEXA), patients with diabetes had a significantly higher 
waist:hip ratio, and CT measured  %visceral and lower % subcutaneous fat.  This was 
accompanied by significantly increased CT measured intrahepatic fat in diabetics 
compared with obese (BMI matched) controls.   Interestingly, when obese and normal 
weight healthy volunteers were compared there were no significant differences in 
waist:hip ratio or CT measured  % visceral, % subcutaneous and intrahepatic fat, 
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despite significantly increased BMI, total % body fat and sagittal height in the obese 
group, Figure 6-10.  
With non contrast enhanced CT, as used in this analysis, a liver attenuation of less 
than 50 is seen in overt steatosis and a reduction of 1.6HU is observed for 
approximately each milligram of triglycerides deposited per gram of liver tissue 
(Roldan-Valadez et al 2008).  In quantitative evaluations, a liver-to-spleen attenuation 
ratio with a cut-off value of 1.1 has been proposed to exclude moderate steatosis 
(Roldan-Valadez et al 2008). Based on this criterion, the diabetic group had 
radiological evidence of hepatic steatosis.   
6.4.3.1. Lean body mass 
The link between lean body mass and insulin resistance has been described previously 
(Brochu 2008).  While the lean body mass (calculated from DEXA) was highest in the 
diabetic group compared with obese and normal groups, the difference between 
groups did not achieve statistical significance.  However a strong relationship between 
lean body mass and cortisol metabolism and HPA axis function was observed in all 
three groups, section 6.4.7.2.   
6.4.4. Baseline serum biochemistry 
In comparison with the BMI matched obese group, diabetics had significantly lower 
HDL cholesterol, and higher triglycerides and free fatty acids (FFA).  A difference in 
total cholesterol was not seen which would reflect statin treatment in the diabetic 
group (which was stopped three days before participation in the study). When the 
obese and normal cohorts were compared, there was no difference in total cholesterol, 
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HDL cholesterol and fasting FFA, although fasting serum triglycerides were 
significantly higher in the obese group Table 6-1.   
Baseline renal function and full blood count were similar in all three cohorts.  
However from the liver function tests, serum AST and γGT were significantly higher 
in the diabetics compared with obese patients.  Serum ALT was also higher in the 
diabetic group but this did not achieve statistical significance. Of importance in this 
observation was that the mean serum AST, ALT and γGT were still within normal 
reference range values for all groups, including diabetics.  None of the patients with 
diabetes had any suggestion on liver function tests of the possibility of hepatic 
steatosis or other liver abnormality, although there was radiological evidence of early 
hepatic steatosis in this group, section 6.4.7.1.  
6.4.5. Glucose homeostasis (oral glucose tolerance test) and HOMA-IR 
As expected, fasting glucose was highest in the diabetic group, and also at each 
subsequent time point during the OGTT.  The OGTT glucose AUC was highest in the 
diabetic group and lowest in the normal group although the increase in the obese 
group compared with normal did not achieve statistical significance, Table 6-1, Figure 
6-11. 
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Figure 6-11 75g Oral glucose tolerance test glucose profiles in normal, obese and 
diabetic cohorts.  Mean serum glucose +/- SEM at each time point 
Fasting insulin levels were also highest in the diabetic group (normals 5.9 +/- 1.5, 
obese 9.5 +/- 1.8, diabetic 13.4 +/- 1.9 miU/L +/- SEM) Table 6-1.  Obese patients 
also had a higher fasting insulin level compared with normal subjects but this was not 
statistically significant.  The OGTT insulin AUC however, was highest in the obese 
group and this was significantly higher than in the normal and diabetic cohorts, Figure 
6-12 and Figure 6-13. 
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Figure 6-12 Insulin profile during oral glucose tolerance test in normal, obese and 
type 2 diabetic cohorts.  Data expressed as mean serum insulin at each 
time point +/- SEM. 
 
Figure 6-13 Total area under the curve of insulin profile following 75g oral glucose 
tolerance test in normal, obese and type 2 diabetic cohorts +/- SEM (* 
p < 0.01 obese vs normal and obese vs diabetics). 
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6.4.6. Endogenous glucose production (EGP) with prolonged fasting in 
normal, obese and diabetic cohorts 
Glucose production, i.e., the rate of appearance (Ra) of glucose in μmol/kg body 
wt/min was set equal to the enrichment of the [6,6-
2
H2]glucose divided by the moles 
percent excess enrichment at C6 of blood glucose and the rate of infusion of the [6,6-
2
H2]glucose and then minus that rate.  While it was possible to obtain samples from 
most of the subjects in each cohort, it was only possible to obtain results for total 
glucose production.  The fraction of glucose produced by gluconeogenesis was to be 
obtained by calculating the enrichment of the hydrogen bound to C-5 to that of C-2.  
This part of the analysis has not yet been possible due technical difficulties with 
analysis using the equipment currently available.  It is hoped that these results may be 
obtainable in the near future. 
 
Figure 6-14 Mean rate of appearance of glucose (μmol/kg/min +/- SEM) at selected 
timepoints during fast during the [6,6-2H2] glucose infusion which 
was started at the 12h timepoint of the fast. *diabetic vs obese p <0.01, 
diabetic vs normal p<0.05, **diabetic vs obese p<0.05. 
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EGP results were obtained from 3 normal patients, 18 obese, and 8 type 2 diabetic 
patients, illustrated in Figure 6-14.  The samples from the rest of the patients were yet 
to be analysed at the time of writing this thesis. 
As displayed in Figure 6-14 endogenous glucose production i.e. the rate of appearance 
(Ra) of glucose was significantly higher in the diabetic groups at the 14h 
(μmol/kg/min +/- SEM: normal 0.37 +/- 0.1, obese 0.65 +/- 0.09, diabetic 1.92 +/- 
0.8; diabetic vs obese p<0.01, diabetic vs normal p<0.05)  and 16h time points 
(μmol/kg/min +/- SEM: normal 0.38 +/- 0.09, obese 0.31 +/- 0.025, diabetic 0.48 +/- 
0.08; diabetic vs obese p<0.05).  This was followed by a steady state of glucose 
production that was not significantly different between groups.   
The Ra of glucose at the 14h time point was tightly correlated with hepatic 11β-HSD1 
activity (AUC of cortisol generation profile (R=0.92, p<0.05) specifically in the 
diabetic group. 
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6.4.7. Correlation of body composition and biochemical parameters with 
markers of glucocorticoid metabolism 
6.4.7.1. Body fat distribution 
  
Figure 6-15 Association between body mass index (R=0.6, p < 0.01), and hepatic 
11β-HSD1 activity in type 2 diabetic subjects. 
In the diabetic cohort, BMI was strongly negatively correlated with hepatic 11β-
HSD1 activity (AUC from cortisol generation profile), Figure 6-15.  
Despite the significant differences in subcutaneous and visceral fat distribution in the 
diabetic group, there was no consistent relationship of CT measured visceral fat and 
subcutaneous fat with glucocorticoid markers in any group. Surprisingly, waist:hip 
ratio, which is considered a more crude measure of visceral fat then when measured 
by CT correlated negatively with hepatic 11β-HSD1 activity (AUC from cortisol 
generation profile) (R=0.5, p <0.05). 
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6.4.7.2. Lean body mass 
For the entire study population, (excluding the NAFLD cohort from the analysis), 
there was a strong negative correlation of lean body mass with hepatic 11β-HSD1 
activity (AUC from cortisol generation profile) (R = -0.5, p <0.001), Figure 6-16. 
There was also a strong positive correlation of lean body mass with total urinary 
cortisol metabolites (R = 0.6, p <0.001), Figure 6-17. 
 
Figure 6-16 Correlation of lean body mass with hepatic 11β-HSD1 activity in 
normal, obese and diabetic patients, R= -0.5, p <0.001. 
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Figure 6-17 Correlation of lean body mass with 24hr urine total cortisol 
metabolites, R = 0.6, p <0.001. 
On further analysis of these relationships at subgroup level, it was discovered that the 
correlation between lean body mass and hepatic 11β-HSD1 activity was not present in 
the normal group, but was present in the obese and diabetic groups, with the 
correlation being stronger in the diabetic group compared with the obese group, Table 
6-3. The correlation between lean body mass and urine total cortisol metabolites held 
true for all three groups when analysed at subgroup level. 
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Table 6-3 Correlation of lean body mass with hepatic 11β-HSD1 in normal, 
obese and diabetic groups. 
6.4.7.3. Serum fasting free fatty acids 
Fasting FFA in normal subjects negatively correlated with hepatic 11β-HSD1 activity 
(AUC from cortisol generation profile) (R= -0.8, p<0.05).  In obese subjects, fasting 
FFA were strongly associated with 5α-reductase driven cortisol clearance, being 
positively associated with the urine 5αTHF/THF and An/ET ratios (R=0.4, p<0.05 
and R= 0.5, p<0.01 respectively) as well as total cortisol metabolites (R=0.5, p<0.01), 
which were higher in the obese group compared with normals.  In contrast fasting free 
FFA in the diabetic group were positively correlated with hepatic 11β-HSD1 activity.  
These results showed a change in hepatic glucocorticoid metabolism in relation to 
FFA with increasing states of insulin resistance. Hence, in normal subjects higher 
fasting serum FFA was associated with a down regulation of hepatic 11β-HSD1 
activity, whereas in obese subjects the association was with increased glucocorticoid 
Lean body mass vs 
hepatic 11β-HSD1 activity 
Normal Pearson Correlation -0.21
Sig. (2-tailed) 0.43
N 16
Obese Pearson Correlation -.585**
Sig. (2-tailed) 0.001
N 29
Diabetic Pearson Correlation -.723**
Sig. (2-tailed) 0.001
N 18
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clearance, and in the diabetics there was a switch in the association with higher serum 
FFA being associated with increased hepatic 11β-HSD1 activity. 
6.4.7.4. Correlation of glucose and insulin markers with glucocorticoid 
metabolism 
The observed differences between groups for fasting and post oral glucose insulin and 
glucose profiles were associated with markers of adrenal glucocorticoid production 
and glucocorticoid metabolism.  In the diabetic group there was a strong negative 
correlation between fasting insulin and hepatic 11β-HSD1 activity measured by serum 
cortisone generation profile (R= -0.6, p<0.01), Figure 6-18, as well as the peak serum 
cortisol achieved during the test (R= -0.5, p<0.05). 
 
Figure 6-18 Association between serum fasting insulin and hepatic 11β-HSD1 
activity measured by serum cortisol generation profile after 25mg oral 
cortisone acetate in type 2 diabetic subjects (R=0.6, p<0.01). 
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Furthermore, the insulin values at all other time points significantly correlated 
negatively with the peak cortisol in the cortisol generation curve in the diabetic group. 
The total insulin AUC from the OGTT insulin profile also correlated negatively with 
hepatic 11β-HSD1 activity measured by serum cortisol generation profile (R= -0.5, 
p<0.05) in the diabetic group. 
Endogenous glucose production in the diabetic group was significantly associated 
with increased 11β-HSD1 activity at the time points significantly higher than normal 
and obese groups, (section 6.4.6). 
HOMA-IR was, as expected, highest in the diabetic group and lowest in the normal 
group.  Compared with the BMI matched obese group HOMA-IR was significantly 
higher in the diabetic group (mean HOMA-IR +/- SEM): normal 1.3 +/- 0.3, obese 2.0 
+/- 0.4, diabetic 4.8 +/- 0.7; diabetic vs obese and diabetic vs normal p<0.01). In the 
diabetic group, HOMA-IR was negatively associated with hepatic 11β-HSD1 activity 
measured by serum cortisol generation profile (R= -0.5, p<0.05), as would be 
expected from the association of fasting insulin with 11β-HSD1 activity in the 
diabetic group. 
6.4.8. Multivariate regression analysis 
On the background of the strong univariate negative correlation between fasting 
insulin (in diabetics) and lean body mass (in obese patients) with hepatic 11β-HSD1, 
and the relationship between fasting FFA and glucocorticoid metabolism,  
multivariate linear regression modelling was undertaken to further explore the 
contribution of cortisol metabolism to these variables. Multivariate forward regression 
models were created using the following as measures: fasting insulin, fasting glucose, 
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CT measured liver attenuation (indicative of liver fat content), and lean body mass, 
each as the dependant variable in separate models. The possible explanatory variables 
used were: markers of HPA axis function and cortisol metabolism, total cholesterol, 
triglycerides, fasting FFA, intrahepatic fat (CT liver attenuation and liver:spleen ratio, 
not used in the model with liver fat as the dependant variable), liver enzymes (γGT, 
AST, ALT, bilirubin), total % fat (from DEXA), %visceral fat, %subcutaneous fat, 
and lean body mass (except in the model with lean mass as the dependant variable). 
6.4.8.1. Regression models with fasting insulin as the dependent outcome 
variable 
Variation in fasting FFA, HDL cholesterol, and urine F/E ratio explained 72% (R
2 
= 
0.72) of the variance in fasting insulin, Table 6-4.  
 
Table 6-4 Regression model with fasting insulin as the outcome measure for all 
subjects in normal, obese and diabetic groups. 
To further explore the relationship between fasting insulin and cortisol metabolism, 
fasting FFA were omitted from the analysis.  In this situation a number of other 
variables became independently associated with fasting insulin: γGT, urine 
cortol/cortolones (a marker of 11β-HSD1 activity), % body fat and lean body mass, 
the variation of which explained 70% (R
2 
= 0.70) of the variation in fasting insulin 
Table 6-5. 
Unstandardized 
B Coefficients Std. Error P value
fasting FFA 0.03 0.006 0
HDL cholesterol -9.27 2.52 0.002
urine F/E ratio 11.28 4.44 0.023
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Table 6-5 Regression model with fasting insulin as the outcome measure for all 
subjects in normal, obese and diabetic groups, with fasting FFA 
removed from the analysis. 
These two models suggest that the close relationship seen between fasting insulin and 
11β-HSD1 activity is influenced by a contribution from serum FFA and is associated 
with body composition, in particular total % fat and lean body mass. 
6.4.8.2. Regression model with fasting glucose as the outcome variable 
Serum creatinine, urine THF+5α-THF/THE (a urine marker of 11β-HSD1) and post 
dexamethasone suppressed baseline cortisol independently predicted serum fasting 
glucose with variance in these three variables explaining 98% (R
2 
= 0.98) of the 
variation in fasting glucose Table 6-6. 
 
Table 6-6 Regression model with fasting glucose as the outcome measure for all 
subjects in normal, obese and diabetic groups 
These relationships suggest a key role of 11β-HSD1 in fasting glucose homeostasis in 
addition to the known influence of HPA axis function on fasting glucose. 
Unstandardized 
B Coefficients Std. Error P value
γGT 0.13 0.03 0
cortols/cortolones -16.31 6.46 0.018
%Fat 0.25 0.07 0.001
Lean body mass 0.14 0.06 0.022
Unstandardized B 
Coefficients Std. Error P value
Creat 0.11 0.01 0
Urine (THF+5aTHF)/THE 4.52 0.54 0.001
Baseline serum cortisol post dex 
suppression -0.08 0.01 0.005
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6.4.8.3. Regression model with CT measured liver attenuation (a marker of 
intrahepatic fat) as the outcome variable 
The urine 5α-THF/THF, and An/ET ratios (markers of cortisol clearance via A-ring 
reductases), serum triglycerides, total protein and serum potassium independently 
predicted serum liver attenuation with variance in these variables explaining 100% 
(R
2 
= 1) of the variation in liver attenuation with high significance Table 6-7. 
 
Table 6-7 Regression model with liver fat attenuation on CT as the outcome 
measure for all subjects in normal, obese and diabetic groups 
The results of this model strongly support the significance of the finding of increased 
cortisol clearance via A-ring reductases with increasing liver fat as shown in the 
NAFLD studies described in chapter 7, as well as the close association of CT liver 
attenuation with hepatic triglyceride levels. 
6.4.8.4. Regression model with lean body mass as the outcome variable 
The urine cortols/cortolones ratio (a urine marker of 11β-HSD1 independently 
predicted serum liver attenuation with variance in urine cortols/cortolones explaining 
34% (R
2 
= 0.34) of the variation in lean body mass with no other variables from the 
list of explanatory variables used being associated in the relationship. 
Unstandardized B 
Coefficients Std. Error P value
urine 5aTHF/THF -13.58 0.11 0
serum triglycerides -5.54 0.03 0
total protein 0.74 0.01 0
serum potassium 3.49 0.09 0.001
urine An/ET -0.58 0.09 0.023
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Table 6-8 Regression model with lean body mass as the outcome measure for all 
subjects in normal, obese and diabetic groups 
6.5. Discussion 
The similarities between patients with Cushing‟s syndrome and the metabolic 
syndrome have focussed interest in the role of glucocorticoids in the pathophysiology 
of insulin resistance and type 2 diabetes, and 11β-HSD1 has emerged as novel 
candidate both in the pathogenesis and treatment of the metabolic syndrome.   
The results of this detailed analysis have revealed a complex and definite role, both of 
adrenal glucocorticoid production and pre receptor glucocorticoid metabolism as a 
mechanism to promote normal metabolic phenotype, as well as in the 
pathophysiology of insulin resistance.  Many of these results have endorsed previous 
findings, but the relationship of hepatic tissue specific 11β-HSD1 with lean body 
mass, insulin sensitivity, and hepatic glucose output form novel results that provide an 
exciting reflection into the role of 11β-HSD1 in the pathophysiology of type 2 
diabetes and support the putative role of selective 11β-HSD1 inhibition to preserve 
and promote a favourable metabolic phenotype.  
While circulating cortisol concentrations are invariably normal in obesity and type 2 
diabetes, changes in HPA axis activity and sensitivity in these subjects have been 
reported with stress, dexamethasone and other stimuli (Duclos et al. 2001;MIGEON 
et al. 1963;Pasquali et al. 1993).  This work has shown increased sensitivity to 
glucocorticoids in type 2 diabetics with lower 9am cortisol levels after dexamethasone 
suppression compared with BMI matched obese subjects as previously reported 
Unstandardized B Coefficient Std. Error P value
urine cortols/cortolones -61.557 22.304 0.015
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(Andrews et al 2002).  While baseline 9am cortisol remained within the normal range 
in the diabetic cohort it was significantly higher in this group when compared with the 
obese and normal cohorts.  Total urinary cortisol metabolites were also significantly 
elevated in the type 2 diabetics, and together these observations imply HPA axis 
activation despite the increased sensitivity to glucocorticoids. Furthermore, there was 
an overall lack of inhibition of hepatic 11β-HSD1 in diabetics compared with BMI 
matched obese controls, with the highest peak cortisol generated during cortisone 
generation profile following 25mg cortisone acetate and the total area under the curve 
generated being higher than in non diabetic obese subjects.  However while there was 
a lack of inhibition of whole body 11β-HSD1 with increasing BMI in diabetics as 
reported in a previous study based on urine glucocorticoid metabolite ratios reflecting 
whole body 11β-HSD1 activity (Valsamakis et al 2004), there was clear evidence of 
inhibition of hepatic 11β-HSD1 with increasing BMI in diabetics in this study, Figure 
6-15.  Increased hepatic triglyceride content is associated with decreased 11β-HSD1 
activity (Westerbacka et al 2003). Type 2 diabetes is associated with impaired hepatic 
triglyceride clearance (Curtin et al. 1996). Our diabetic subjects had increased serum 
triglycerides compared with normal and obese controls, with radiological evidence of 
increased hepatic fat (CT liver attenuation is directly related to hepatic triglyceride 
content, section 6.4.3).  Hence, increased hepatic triglyceride content may decrease 
hepatic 11β-HSD1 activity.  This is an important observation as it endorses the model 
described in the NAFLD cohort of the study (chapter 7) where hepatic steatosis 
specifically inhibited hepatic glucocorticoid generation and promoted hepatic GC 
clearance.   
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6.5.1. Fat distribution, body composition, and cortisol metabolism  
Visceral fat has been established as a major contributor to the pathogenesis of the 
metabolic syndrome.  A summary of published work related to visceral fat and 11β-
HSD1 and expression are discussed in section 6.1.  Surprisingly the results from the 
study did not uncover associations between CT measured visceral fat and 11β-HSD1 
activity, despite it being significantly higher in the diabetic group.  However there 
were significant associations of cortisol metabolism with waist:hip ratio, a more crude 
index of visceral fat and increased metabolic risk. In the diabetic group it was 
associated with the AUC of the cortisol generation profile and hence hepatic 11β-
HSD1 activity.  This was an interesting observation in light of recent studies which 
have shown that visceral fat cortisol production does not contribute to splanchnic 
glucocorticoid delivery to the liver, section 6.1.   Instead it may be the increased FFA 
delivery to the liver and its potential effect upon liver fat accumulation resulting in 
increased 5α-reductase mediated hepatic glucocorticoid clearance as a protective 
effect as described above. Indeed, intrahepatic fat and not visceral fat has been shown 
to be linked with the metabolic complications of obesity (Fabbrini et al. 2009). 
Perhaps the most exciting and novel finding of this study relate to the association of 
lean body mass with hepatic glucocorticoid metabolism and HPA axis function. Lean 
body mass was highest in the diabetic group of the study but not significantly so. 
Univariate analysis revealed a strong negative correlation between lean body mass 
and hepatic 11β-HSD1 activity and a strong positive correlation with urine total 
cortisol metabolites.  Subgroup level analysis revealed that the relationship with 
hepatic 11β-HSD1 activity was not present in the normal group but was present and 
more significant in the diabetic group compared with obese. Furthermore, multivariate 
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regression model analysis for the entire study population confirmed whole body 11β-
HSD1 activity to be the sole factor, from all the variables analysed that independently 
predicted with lean body mass. These findings would support in vitro studies where, 
at the tissue specific level, 11β-HSD1 has been shown to regulate glucocorticoid 
mediated insulin resistance in skeletal muscle (Morgan et al. 2009). Skeletal muscle in 
type 2 diabetes is resistant to insulin action, with a significant reduction in the ability 
of insulin to increase muscle glucose disposal.  This action is mediated by the GLUT-
4 transporter.  The translocation of GLUT-4 to the cell surface in response to insulin 
and to other stimuli is inhibited in the presence of glucocorticoids (Coderre et al. 
1996;Oda et al. 1995).  The positive association of HPA axis function and lean mass 
in the diabetic group may therefore contribute negatively upon skeletal muscle insulin 
resistance.  The specific relationship between lean body mass and specific hepatic 
11β-HSD1 activity is a curious one – by what mechanism does hepatic 11β-HSD1 
impact skeletal muscle? This may be speculated upon from the inferences drawn from 
the characterisation of zonation of hepatic 11β-HSD1 described in chapter 3.  The 
perivenous zonation of hepatic 11β-HSD1 would promote increased glycolysis with 
up regulation of activity or expression of 11β-HSD1.  Increased hepatic glycolysis has 
been elegantly demonstrated as a mechanism by which skeletal muscle mass and 
insulin resistance may be reduced (described in detail in section 3.4.1) (Wu et al 
2005). This may underly the negative correlation seen between lean body mass and 
hepatic 11β-HSD1 activity, and may reflect a protective mechanism to limit whole 
body insulin resistance.  It would therefore be of interest to investigate the impact of 
selective 11β-HSD1 inhibition upon skeletal muscle insulin resistance. 
Chapter 6  Hepatic 11β-HSD1 in normal physiology, obesity and T2D 
237 
 
6.5.2. Associations of cortisol metabolism with insulin sensitivity and 
glucose output  
Insulin resistance may reflect impaired insulin dependent down-regulation of hepatic 
glucose release (gluconeogenesis) and / or an impairment in the insulin mediated 
increase in peripheral glucose uptake. Which is the more important factor in the 
metabolic syndrome remains controversial, but the effect of glucocorticoids appears 
to include both of these variables (Rizza et al. 1982;Rooney et al. 1993). With respect 
to hepatic pre receptor glucocorticoid activation promoting insulin resistance, from 
the results of this study, dysregulation of hepatic 11β-HSD1 appears to provide 
critical link in the insulin resistance and glucose intolerance associated with type 2 
diabetes. Whole body 11β-HSD1 activity for the entire study population 
independently predicted fasting glucose in multivariate regression model analysis, and 
was unmasked as predictor of fasting insulin under the influence of free fatty acids. 
While fasting insulin levels were highest in the diabetic group, both fasting glucose 
and endogenous glucose production in the fasting state were significantly higher in 
the diabetic group, reflecting the impairment of the insulin-dependent down 
regulation of hepatic glucose release in diabetes. The increase in endogenous glucose 
production in type 2 diabetics was specifically associated with increased hepatic 11β-
HSD1 activity, whereas fasting insulin was strongly linked with decreased hepatic 
11β-HSD1 activity.  The effect of hepatic glucocorticoid generation in promoting 
endogenous glucose production in diabetes can be explained on the basis of the local 
effects of glucocorticoid on hepatic glucose output. The inverse correlation between 
fasting insulin and hepatic 11β-HSD1 activity would be a favourable one during 
fasting hyperinsulinaemia in insulin resistance as the additional contribution to 
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hepatic glucose output via local glucocorticoid stimulation would be reduced as a 
result.  It would be interesting to investigate whether this association is maintained 
with increasing beta cell dysfunction in type 2 diabetes where lower fasting insulin 
levels would be associated with increased hepatic 11β-HSD1 activity with further 
stimulation of hepatic glucose output.  Indeed, glucocorticoids inhibit insulin 
secretion from pancreatic β cells (Delaunay et al. 1997;Ling et al. 1998) and recent 
work has excitingly shown that local regeneration of glucocorticoid via 11beta-HSD1 
within alpha cells regulates glucagon secretion and in addition may act in a paracrine 
manner to limit insulin secretion from β cells (Swali et al 2008). 
Insulin may also indirectly promote hepatic 11β-HSD1 mediated cortisol generation 
via inhibition of glucose-6-phosphatase (G6Pase). Studies have shown selective tonic 
inhibition of G6Pase catalytic subunit, but not G6P transporter, gene expression by 
insulin in vivo (Hornbuckle et al. 2001). Any degree of inhibition of G6Pase, with 
normal G6P transporter activity would in turn lead to increased G6P within the ER 
lumen.  This would cause increased 11β-HSD1 driven cortisol generation from 
cortisone secondary to increased cofactor delivery by the H6PDH enzyme which uses 
G6P as a substrate.  This link between HPA axis function and glucose metabolism has 
been fully explored in the glycogen storage disease type 1 studies described in chapter 
4. On this background it would be of interest to explore whether hepatic 11β-HSD1 
activity is lower in type 2 diabetic patients with evidence of marked beta cell 
dysfunction, where fasting insulin levels would be lower. 
There was some evidence of suppression of hepatic 11β-HSD1 activity in obese non 
diabetic subjects. This may be regarded as a favourable protective response, as has 
been demonstrated previously, including studies on obese animals which have shown 
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increased adipose but reduced hepatic 11β-HSD1 (Alberts et al 2005;Liu et al 
2003;Livingstone et al 2000;Masuzaki et al 2001). The loss of this protective response 
may predict the onset of glucose intolerance and diabetes, and may well relate to body 
fat distribution as detailed below. 
6.5.2.1. Free fatty acids (FFA) and insulin sensitivity with relevance to cortisol 
metabolism 
FFA are an important link between obesity, insulin resistance and type 2 diabetes 
(Boden 1999). As expected, FFA were significantly elevated in obese subjects 
compared with normal controls, and in the diabetic group compared both with obese 
and normal controls.  Multivariate regression modelling confirmed that serum FFA 
independently predicted fasting insulin and the impact of 11β-HSD1 on fasting insulin 
was strongly influenced by FFA.  This finding was associated with clear differences 
in the relationship between fasting serum FFA and hepatic glucocorticoid metabolism 
in the different cohorts.  In the normal group FFA was negatively associated with 
hepatic 11β-HSD1 activity.  Low FFA levels in this group in conjunction with this 
association would serve well to protect hepatic metabolic phenotype.  In the obese 
cohort serum fasting FFA correlated with increased 5α reductase mediated cortisol 
clearance.  Increased FFA delivery to the liver from the splanchnic circulation in 
obesity may have a direct effect upon the liver to increase 5α reductase mediated 
cortisol clearance to preserve hepatic phenotype and limit hepatic lipid accumulation.  
This would be supported by similar findings in hepatic steatosis, an early stage of 
NAFLD, the hepatic phenotype of the metabolic syndrome chapter 7. It is however 
important to note the results of a study which showed that specific aliphatic 
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unsaturated fatty acids inhibited 5α-reductase (Liang and Liao 1992). In diabetic 
subjects fasting free fatty acids correlated with increased hepatic 11β-HSD1 activity.  
This in addition to the HPA axis activation seen in diabetics would have a deleterious 
effect by further promoting glucocorticoid mediated hepatic glucose output and 
hepatic fat accumulation as seen in the diabetic cohort, as well as promoting adipose 
tissue lipolysis, further increasing FFA delivery to the liver. 
The total serum cholesterol in the diabetic group was not easy to interpret perhaps due 
to the lasting effects of statin therapy in that group, despite patients having stopped 
therapy three days before participating in the study.  However, glucocorticoids are 
known to exert and anti-atherosclerotic effect possibly by limiting local inflammation 
in the endothelium (Hadoke et al. 2009), and 11β-HSD1 inhibition has been shown to 
limit the progression of atherosclerosis in mice (Hermanowski-Vosatka et al. 2005). 
Further investigations are required to clarify the link between glucocorticoid excess 
and cardiovascular events and to determine the mechanism through which 
glucocorticoid treatment inhibits atherosclerosis/restenosis. This will provide greater 
insights into the potential benefit of selective 11β-HSD1 inhibitors in treatment of 
cardiovascular disease. 
Collectively, these data support the hypothesis of a reduction in 11β-HSD1 activity 
may act as a protective mechanism to prevent increasing adiposity and increased 
hepatic glucose output with advancing obesity.  This adaptive mechanism is altered in 
obesity associated type 2 diabetes both at the tissue specific level in liver, muscle and 
adipose as well as at the level of HPA axis function, and may therefore be implicated 
in the underlying pathogenesis of the disease.  The importance of glucocorticoid 
metabolism in lean mass and hence skeletal muscle insulin resistance has also been 
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discussed. This work provides support for the observed and predicted effects of 
selective 11β-HSD1 in the treatment of the metabolic syndrome and its multifactorial 
effects.
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7. Cortisol metabolism and hepatic expression of 11β-
hydroxysteroid dehydrogenase type 1 in patients with non 
alcoholic fatty liver disease 
7.1. Introduction 
Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of the 
metabolic syndrome and is now the commonest liver problem of the western world, 
and the leading cause of cryptogenic cirrhosis.  NAFLD represents a spectrum of liver 
disease ranging from simple and reversible hepatic steatosis, to non alcoholic steato-
hepatitis (NASH) where there is evidence of inflammation and liver cell death.  It 
may progress to cirrhosis with liver failure, and hepatocellular carcinoma. NASH 
cirrhosis is rapidly becoming the leading indication for liver transplantation. 
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Critically, the histological diagnosis at presentation predicts prognosis in these 
patients.  Those with simple fatty liver at presentation only have a 2% risk of 
progressing to end stage cirrhosis in a 20 year period.  However when there is 
evidence of steatohepatitis or fibrosis, the risk of developing cirrhosis is up to 50% in 
a 2 year period (de Alwis and Day 2008).  
The pathogenesis of NAFLD is poorly understood but several factors are thought to 
be important, including, insulin resistance, obesity and type 2 diabetes; 90% of 
patients with NAFLD cirrhosis having obesity and/or diabetes mellitus.  
Patients with the metabolic syndrome share many phenotypic features with Cushing‟s 
syndrome (such as hypertension, central obesity, insulin resistance and impaired 
glucose tolerance).  Indeed, 20% of patients with Cushing‟s syndrome have NAFLD 
(Rockall et al 2003), and there are a number of reports that implicate excess 
glucocorticoid (GC)  in hepatic triglyceride accumulation (Dourakis et al. 2002;Nanki 
et al. 1999). Glucocorticoids promote steatosis by directly stimulating hepatic de novo 
lipogenesis and FFA utilization (Dolinsky et al. 2004;Hellerstein 1999;Norrheim et al. 
1990), and by a secondary effect on adipose tissue, promoting lipolysis within 
omental fat, resulting in increased portal free fatty acid (FFA) delivery to the liver 
(Baxter and Forsham 1972). Cushing‟s syndrome is rare and the vast majority of 
patients with the obesity-metabolic syndrome have normal circulating cortisol levels.  
However, local GC concentrations within key metabolic target tissues are controlled 
at the pre-receptor level through a series of enzymes; 11β-hydroxysteroid 
dehydrogenase Type 1 (11β-HSD1), interconverts hormonally inactive cortisone (E) 
to active cortisol (F) and, 5α and 5β reductase which inactivate cortisol.  There is 
increasing evidence for the role of 11β-HSD1 in the pathophysiology of the metabolic 
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syndrome through its amplification of GC responses in key insulin target tissues, 
resulting in visceral obesity and other features of the metabolic syndrome (Bujalska, 
Kumar, & Stewart 1997;Masuzaki et al 2001;Morton et al 2001).   
We have proposed that dysregulation of hepatic GC metabolism may be critical in the 
progression of NAFLD and that increased regeneration (11β-HSD1) or decreased 
clearance (5α-reductase) contributes to the hepatic phenotype.  We have therefore 
performed a detailed characterisation (in vivo and ex vivo) of GC metabolism in 
patients with NAFLD compared with BMI matched controls.  A number of cross 
sectional studies have reported the association of NAFLD with chronic, subclinical 
activation of the hypothalamo-pituitary-adrenal (HPA) axis in humans (Konopelska et 
al 2009;Targher et al. 2006;Westerbacka et al 2003). None of these studies however 
have undertaken a detailed analysis of hepatic pre receptor cortisol metabolism in 
patients with NAFLD. 
7.2. Methods 
7.2.1. Subjects 
Clinical studies were carried out on 16 patients recruited from hospital clinics.  All 
patients had chronically elevated liver enzymes and evidence of hepatic steatosis on 
ultrasound.  The diagnosis of NAFLD was made on histological analysis of biopsies 
after exclusion of other possible aetiological factors (alcohol intake of >20g/day, viral 
and autoimmune hepatitis and hepatototoxic drugs).  Renal function was normal and 
none were taking any drugs known to interfere with the HPA axis (glucocorticoids, 
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anticonvulsants, oestrogen treatment). 5 patients had type 2 diabetes (2 diet 
controlled, 3 treated with metformin) 
32 healthy age, sex and BMI matched control volunteers recruited were by local 
advertisements. All had normal liver function biochemistry (AST, γGT, ALT, ALP 
and bilirubin). 
Separately, liver samples were obtained from the liver tissue archive at the Centre for 
Liver Research, University of Birmingham (section 2.1) and were used for gene and 
protein expression studies.  All diagnoses were verified by histological analysis 
(NASH n=5, normal transplant donor liver n=5). None of the donor organs were 
obtained from institutionalized persons. 
7.2.2. Clinical Studies 
The study and protocol received approval from the local ethics committee and written 
informed consent was obtained from all participants.  The NAFLD subjects formed 
the fourth patient group of the clinical study. 
The clinical methods were as detailed in sections 6.3.1 - 6.3.6. and included 
anthropometric measurements, whole body composition using DEXA, CT 
measurements of fat distribution, whole body  and hepatic 11β-HSD activity and oral 
glucose tolerance testing.  Biochemical analysis was carried out as described in 
section 6.3.4. 
7.2.3. Real Time PCR 
11β-HSD1 mRNA levels were measured by real-time PCR. The method is described 
in section 2.3 in detail. 
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7.2.4. Immunohistochemistry 
Immunohistochemistry for 11β-HSD1 was carried out on five explanted livers with 
severe NASH and five normal donor livers. The method has been described in section 
2.2.5.2 in detail. 
7.2.5. Statistical Analysis 
Data are presented as means ± SE unless otherwise stated. Area under the curve 
(AUC) analysis was performed using the trapezoidal method. For comparison of 
single variables, t tests were used (or nonparametric equivalents where data were not 
normally distributed). Regression analyses were performed using Pearson 
correlations; where more than one variable was considered, multiple linear regression 
analysis was used. Analysis was performed using SPSS Statistics 17.0 software.  
7.3. Results 
7.3.1. Clinical and biochemical characteristics of participants 
Metabolic phenotype and hepatic cortisol metabolism was characterised in patients 
with histologically proven NAFLD (n=16 of whom 7 had steatosis only and 9 had 
NASH) compared to age and BMI-matched controls (n=32). As expected, intra-
hepatic fat (measured by liver:spleen attenuation ratio (L:S) on CT) was higher in the 
NAFLD group compared to controls (L:S 0.81± 0.08 vs. 1.13±0.04, p<0.01).  Fasting 
serum free fatty acids (FFA) were significantly increased in the NAFLD group and 
correlated with intrahepatic fat measured by CT (r = 0.4, p<0.05).  Baseline clinical 
and biochemical characteristics of both groups are presented in Table 7-1.  
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Table 7-1 Baseline clinical characteristics of patients with NAFLD and controls. 
Data are presented as means ± SE.  *CT measured liver:spleen 
attenuation ratio (mean ± SEM).  Lower ratio implies increased 
intrahepatic fat. Whole body fat measured by DEXA. 
7.3.2. Urinary steroid metabolite analysis 
24h urinary steroid metabolite analysis by GC/MS demonstrated increased cortisol 
clearance with higher 5R activity in patients with hepatic steatosis only, 
(5THF/THF ratio, controls 0.80 ± 0.07, steatosis 1.31 ± 0.21, NASH 0.90 ± 0.30; 
steatosis vs obese:  p < 0.05), Figure 7-1A. 5-, and not 5-reduced metabolites were 
increased in the steatosis group, Figure 7-1B.  Absolute values are presented in Table 
7-2. Interestingly, in both NAFLD and control groups there was a correlation between 
FFA and hepatic cortisol clearance as measured by the urinary 5THF/THF ratio (r = 
0.4, p<0.05), Figure 7-2. 
Variable NAFLD patients Control subjects P  values
age (years) 47 ± 2.6 47 ± 2.0 NS
BMI kg/m2 36.0 ± 2.4 32.4 ± 0.9 NS
sag height (cm) 25.2 ± 1.2 23.3 ± 0.6 NS
%Fat 33.1 ± 2.0 38.5 ± 1.1 <0.05
Liver:spleen attenuation ratio 0.81 ± 0.08 1.13 ± 0.04 <0.01
Creat (μmol/L) 91.5 ± 3.0 89.5 ± 3.0 NS
γGT (iu/L) 103 ± 33 24 ± 2.6 <0.01
Total cholesterol (mmol/L) 5.4 ± 0.3 6.8 ± 1.5 NS
HDL cholesterol (mmol/L) 1.2 ± 0.1 1.4 ± 0.1 <0.05
Triglycerides (mmol/L) 2.2 ± 0.3 1.4 ± 0.13 <0.01
ALT (iu/L) 63.0 ± 10.6 25.1 ± 3.0 <0.01
ALP (u/L) 191 ± 19 173 ± 8 NS
AST (iU/L) 45.2 ± 5.7 22.7 ± 1.1 <0.01
fasting FFA (μmol/L) 422 ± 35 336 ± 17 <0.05
fasting glucose (mmol/L) 5.6 ± 0.4 4.7 ± 0.1 <0.05
Systolic blood pressure (mmHg) 134 ± 2.7 136 ± 3.7 NS
Diastolic blood pressure (mmHg) 78 ± 3.0 78 ± 2.5 NS
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Table 7-2 Urinary steroid metabolites and ratios in patients with steatosis, NASH 
and control patients. Mean absolute values are shown (μg/24h) +/- 
SEM. 
a
p < 0.05 vs controls, 
b
p < 0.01 vs controls, 
c
p < 0.05 vs 
steatosis, 
d
p < 0.01 vs steatosis. 
In addition, total cortisol metabolites were significantly increased in patients with 
steatosis consistent with increased glucocorticoid production rate, Table 7-2, Figure 
7-1C.  The urinary THF+5THF/THE ratio was lower in the steatosis group and 
elevated in the steatohepatitis group but this did not reach statistical significance.   
Steroid (μg/24h) controls steatosis NASH 
Cortisol 71 ± 7 78 ± 8 112 ± 20a 
Cortisone 120 ± 11 127 ± 20 162 ± 39 
THE 3426 ± 346 5626 ± 554 3447 ± 326c 
THF 1624 ± 169 1973 ± 199 1759 ± 231 
5α-THF 1324 ± 178 2500 ± 417a 1429 ± 300 
α-cortol 316 ± 27 379 ± 42 496 ± 90a 
β-cortol 457 ± 36 533 ± 102 515 ± 97 
α-cortolone 1303 ± 111 1899 ± 206a 1789 ± 256 
β-cortolone 621 ± 57 834 ± 112 641 ± 91 
Total F metabolites 9266 ± 857 13949 ± 1075a 10351 ± 984d 
Ratios 
   F/E 0.61 ± 0.03 0.65 ± 0.06 0.74 ± 012 
(THF+5αTHF)/THE 0.89 ± 0.04 0.81 ± 0.06 0.96 ± 0.13 
cortols/cortolones 0.43 ± 0.02 0.33 ± 0.02a 0.42 ± 0.04 
5αTHF/THF 0.84 ± 0.07 1.31 ± 0.22a 0.93 ± 0.3 
An/ET 1.11 ± 0.10 1.99 ± 0.31b 1.55 ± 0.6 
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Figure 7-1 5α-reductase activity as depicted by the urinary 5αTHF/THF ratio 
(mean ± SEM) (A), total 24 Urine 5α-reduced metabolites (mean ± 
SEM) (B), total 24hr Urine F metabolites (mean ± SEM) (C), in 
patients with steatosis and steatohepatitis compared with controls.
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Figure 7-2 Serum fasting FFA in NAFLD patients and controls correlates with 5α-
reductase activity (R=0.4, p<0.05). 
However the cortols/cortolones ratio, which also reflects 11β-HSD1 activity, was 
significantly reduced in the steatosis group, Table 7-2, Figure 7-3. Importantly the 
urine UFF/UFE ratio was similar between groups indicating that there was no 
difference in extrahepatic 11β-HSD2 activity, Table 7-2. 
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Figure 7-3 11β-HSD1 activity assessed by 24hr urine cortols/cortolones and 
5αTHF+THF/THE ratios (mean ± SEM) in patients with steatosis and 
steatohepatitis compared with controls.  
7.3.3. Cortisol Generation Profiles 
Endorsing the urinary steroid metabolite data, cortisol generation from oral cortisone 
was decreased in patients with steatosis compared with controls Figure 7-4. In 
contrast, patients with steatohepatitis had significantly increased cortisol generation 
consistent with increased hepatic 11β-HSD 1 activity compared with controls and 
patients with steatosis, (AUC cortisol: controls 382 ± 22, steatosis 304 ± 27, NASH 
496 ± 22 g/L.min; steatosis vs obese p < 0.05, NASH vs obese p < 0.05, NASH vs 
steatosis p < 0.01), Figure 7-4.   
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Figure 7-4 Hepatic cortisol generation measured by cortisol generation profiles 
(mean AUC ± SEM) in patients with steatosis and steatohepatitis 
compared with controls. 
7.3.4. 11β-HSD1 expression studies 
11β-HSD1 mRNA expression in explant livers from patients with NASH was 
significantly higher compared with normal controls (dCT NASH 9.65 ± 0.29 vs 
11.96± 0.29, p < 0.01 NASH vs normal), Figure 7-5.   
0
100
200
300
400
500
600
controls steatosis steatohepatitis
H
ep
at
ic
 1
1
β
-H
SD
1
 A
ct
iv
it
y 
: c
o
rt
is
o
l 
ge
n
er
at
io
n
 μ
m
o
l/
L.
m
in
vs controls p<0.05
vs steatosis p<0.01
Chapter 7  Hepatic 11β-HSD1 in Non alcoholic fatty liver disease 
253 
 
 
Figure 7-5 Real time PCR mRNA expression data for 11β-HSD1 on whole liver 
samples from 5 normal patients and 5 NASH patients expressed as 
arbitrary units +/- SE. 
These results were supported at the protein level by immunohistochemistry; liver 
parenchymal staining for 11β-HSD1 was increased in NASH livers compared with 
normals. Specifically, intense staining was seen in the periseptal areas in particular at 
limiting plate.  There was also staining within the portal/septal inflammatory cells 
with a morphology in keeping with macrophages, Figure 7-6 A-E. 
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Figure 7-6 11β-HSD 1 protein expression in liver sections from patients with 
severe NASH compared to normal controls. There was generally 
increased staining for 11β-HSD1 throughout the liver parenchyma in 
(A) NASH samples compared with (B) Normal liver x20. (C) Increased 
staining at the limiting plate in peri-septal areas in NASH x10 (D) 
Increased staining at the limiting plate in peri-septal areas and in 
portal/septal inflammatory cells with a morphology in keeping with 
macrophages in NASH x20 (E) Peri-central zonation of  11β-HSD1 in 
normal liver x20 (cv – central vein). 
7.4. Discussion 
Results from this study have defined hepatic glucocorticoid metabolism in patients 
with the full spectrum of NAFLD, illustrated in Figure 7-7.  
 
Figure 7-7 Schematic: Hepatic glucocorticoid metabolism and its modulation in 
response to disease progression in NAFLD 
In the early stages of NAFLD, characterized by hepatic steatosis alone, hepatic 
cortisol clearance predominates, driven by increased 5αR activity, decreased cortisol 
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generation by 11β-HSD1 and consequent increased adrenal glucocorticoid production.  
With disease progression and worsening inflammation and liver injury, there is 
induction of hepatic 11β-HSD1 expression and activity with increased hepatic 
glucocorticoid generation, Figure 7-7. Collectively these results provide a crucial 
insight into the pathophysiology of the NAFLD disease spectrum.  
The first suggestion of a role of 11β-HSD1 in NAFLD came with the observation that 
transgenic mice over expressing 11β-HSD1 in adipose tissue develop the full 
phenotype of the metabolic syndrome including hepatic steatosis. Conversely 11β-
HSD1 knockout mice are protected from many of these features including hepatic 
steatosis (Masuzaki et al 2001;Morton et al 2001).    Transgenic mice overexpressing 
the 11β-HSD1 gene selectively in the liver under the transcriptional control of the 
human apoE gene, exhibit fatty liver with increased hepatic triglyceride accumulation 
and impaired hepatic lipid clearance (Paterson et al 2004). Furthermore 11β-HSD1 
inhibition reduced hepatic triglyceride concentration by nearly 30% and increased in 
vivo hepatic fat oxidation and expression of related genes in rats fed an obesogenic 
diet (Berthiaume et al. 2009), reflecting the detrimental effect of glucocorticoids upon 
liver function by impacting on a number of pathogenic mechanisms. 
We postulate that the increase in hepatic cortisol clearance by 5α-reductases, and 
decreased 11β-HSD1 driven hepatic cortisol generation in hepatic steatosis is a 
protective mechanism to preserve hepatic metabolic phenotype by limiting hepatic 
cortisol exposure and reduce glucocorticoid induced deleterious effects. These include 
hepatic de novo lipogenesis, β-oxidation and increased glucose output all of which 
worsen hepatic and peripheral insulin resistance.  Indeed, recent work from our group 
has shown a reduction in 5α-reductase activity with weight loss in otherwise healthy 
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obese subjects (Tomlinson et al. 2008b).  Women with polycystic ovarian syndrome 
who are characterized by a susceptibility to the metabolic syndrome also have 
increased 5α-reductase activity and adrenocortical drive (Vassiliadi et al. 2009).  Both 
these groups of patients have an increased propensity to develop NAFLD, and these 
findings may represent a protective hepatic mechanism to limit hepatic lipid 
accumulation and dysregulation of glucose homeostasis, thus preserving hepatic 
insulin sensitivity, with a knock on effect of limiting extrahepatic insulin resistance.  
Our data support previously published findings of a subtle activation of the HPA axis 
in patients with NAFLD, (Konopelska et al 2009;Targher et al 2006).  This may 
reflect the increased clearance of hepatic glucocorticoid by the 5α-reductase enzymes 
as shown in our steatosis patients. 
By contrast, increased hepatic glucocorticoid availability is a favourable protective 
mechanism to limit further hepatic inflammation and injury. Immunologic responses 
are suppressed by glucocorticoid excess, an observation which provided the stimulus 
to develop potent glucocorticoids for treatment of a wide range of inflammatory and 
autoimmune conditions, and organ transplantation.  Indeed, tissue inflammation is 
known to activate the HPA axis through release of cytokines into the circulation and 
the stimulation of vagal afferents, an interaction that has been termed the 
„neuroimmune axis‟(Turnbull and Rivier 1999).  Elevated plasma cytokines have 
been demonstrated in patients with chronic hepatic inflammation, and chronic 
exposure to these cytokines has been shown to lead to dysregulation of the HPA axis 
(Turnbull & Rivier 1999). Indeed rats with cholestatic liver injury show defective 
HPA axis activation in response to psychological stress, with an attenuation of 
glucocorticoid release into the circulation compared with control animals (Swain et al 
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1993). Our urinary data also reflect decreased HPA axis activation in patients with 
NASH compared with steatosis. Hence, an inherent mechanism to increase local 
glucocorticoid availability by increasing 11β-HSD 1 activity and expression would be 
a crucial response in an attempt to limit further liver inflammation. Specific induction 
of 11β-HSD1 activity was seen but only in patients with steatohepatitis.    In livers 
with NASH increased staining of 11β-HSD1 was seen in the peri septal areas, 
specifically opposed to areas of pathological fibrogenesis and inflammation.  The 
appearances would be consistent with a secreted factor from the inflammatory 
infiltrate inducing 11β-HSD1 in the adjacent hepatocytes. Studies on other tissues, 
including synovium from patients with rheumatoid arthritis (Hardy et al. 2008), 
human and rodent colitis (Zbankova et al. 2007), aortic smooth muscle cells (Dover et 
al. 2007), and granulosa cells in the inflammatory response to ovulation (Rae et al. 
2004), all show a consistent picture of induction of cell specific 11β-HSD1 gene 
expression in response to pro inflammatory cytokines, TNFα and IL-1β being the 
most commonly implicated (Cooper et al 2001).  The molecular mechanism by which 
11β-HSD1 is induced in response to cytokines is not entirely clear, but key 
transcription factors of the C/EBP family play a crucial role (Chapman et al. 
2009;Williams et al 2000). 
There was also intense staining of 11β-HSD1 in portal/septal inflammatory cells with 
morphology in keeping with macrophages in NASH livers.  Clearly local 
amplification of glucocorticoids by macrophages in the chronic inflammatory 
infiltrate would dampen the inflammatory response and promote macrophage 
phagocytosis of inflammatory cells. In vitro models of acute inflammation showed the 
dynamic regulation of 11β-HSD1 in human monocyte macrophages by pro resolution 
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mechanisms - 11β-HSD1 was down regulated following phagocytosis of apoptotic 
neutrophils (Gilmour et al. 2006).   
Simple hepatic steatosis is a relatively benign entity in the NAFLD disease spectrum 
with only a 2% risk of developing progressive disease in a twenty year period.  
However, the presence of fibrosis or inflammation at diagnosis is associated with a 
risk of developing NASH cirrhosis of up to 50% in a two year period (de Alwis & 
Day 2008).  The factors implicated in the crucial switch between simple steatosis and 
NASH are not entirely clear. Increased liver fat is pivotal to inflammation in NAFLD, 
and thus the increased supply of free fatty acids to the liver, associated with adipose 
tissue insulin resistance and obesity is a key factor in the development of hepatic 
inflammation in NAFLD. Our data show significantly increased fasting serum FFA in 
patients with NAFLD compared with BMI matched controls which correlated with 
intrahepatic fat. Adipose tissue insulin resistance may occur in obesity in part through 
the infiltration of macrophages which release pro inflammatory cytokines such as 
TNFα, IL-6 and IL1β (Weisberg et al. 2003).  Once FFA are taken up by the liver, as 
well as being oxidized and stored as triglyceride, they activate the transcription factor 
NFκB, a key regulator of gene transcription of proinflammatory cytokines, adhesion 
molecules, and chemokines (Feldstein et al. 2004).  What results is a cycle of hepatic 
injury and inflammation.  The cytokines released from hepatocytes, in particular 
TNFα activate classic inflammatory cells, as well as Kupffer cells which generate 
more cytokines.  These cytokines further contribute to hepatic oxidative stress by 
promoting FFA oxidation, which enhances the hepatic injury that occurs by cytokine 
driven hepatocyte apoptosis and necrosis (Cai et al. 2005).  
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An important question that arises from this work is whether 11β-HSD1 activity and 
expression is induced in other types of chronic hepatitis.  Our work on alcoholic liver 
disease (ALD) showed significant induction of 11β-HSD1 expression in explanted 
livers with ALD, with a smaller but significant induction in a mixed group of (non 
alcoholic, non fatty, and non infectious) severe liver disease (CLD).  This was 
supported by clinical data from selective venous sampling that showed net cortisol 
generation specifically in patients with ALD but not CLD (Ahmed et al 2008), chapter 
5. The histological appearance of severe NASH, ALD and hepatitis C are relatively 
similar – all involving a degree steatohepatitis.  It would therefore be plausible to 
suggest a role for 11β-HSD1 induced local glucocorticoid production in the 
pathophysiology of severe chronic hepatitis and would certainly merit further 
investigation. 
This work has defined hepatic glucocorticoid metabolism in progressive NAFLD, 
which can be summarized into two distinct phases of altered regulation of hepatic 
cortisol metabolism; increased hepatic cortisol clearance in steatosis, and increased 
hepatic cortisol regeneration in NASH.  Failure to regulate in this way may worsen 
the phenotype of liver disease i.e. drive hepatic steatosis or unchecked progressive 
hepatic inflammation. Hence the therapeutic benefit of 11β-HSD1 inhibition may 
critically depend on the histological stage of NAFLD. 
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8. Conclusions and future studies 
The work described in this thesis has established a pivotal role of hepatic 
glucocorticoid metabolism by 11β-HSD1 in normal physiology, insulin resistant 
states and chronic metabolic liver diseases, with particular relevance to hepatic and 
whole body insulin sensitivity. 
In vitro studies characterized the zonation of hepatic 11β-HSD1 mRNA and protein 
expression in detail, confirming perivenous zonation. By inference, the impact of 
hepatic 11β-HSD1 on hepatic glycolyis, and the resulting impact on whole body 
insulin sensitivity is a novel suggestion of the physiological role of hepatic 11β-
HSD1, and may explain many of the observations from the clinical study comparing 
normal, obese and diabetic cohorts.  This is in contrast to the intense focus of 
numerous published and ongoing studies on the importance and impact of 11β-HSD1 
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on hepatic glucose output via gluconeogenesis and represents an exciting new 
paradigm that warrants further investigation.   
Hepatic pre receptor glucocorticoid metabolism resulting in changes in hepatic 
glucocorticoid activation and/or glucocorticoid clearance was found to be implicated 
in a range of liver diseases and may thus be associated with the dysregulation of 
insulin sensitivity seen in these conditions.  In particular, hepatic glucocorticoid 
metabolism was found to be abnormal in each histological stage of non alcoholic fatty 
liver disease (NAFLD) (the hepatic phenotype of the metabolic syndrome). In 
alcoholic liver disease there was clear evidence of increased hepatic glucocorticoid 
activation and 11β-HSD1 gene expression, that may be important in defining the 
cause of the alcoholic „pseudocushings‟ state.   
Glucose 6 phosphate was defined as a direct link between glucose and glucocorticoid 
metabolism and the HPA axis and formed a seminal publication; the concept of ER 
nutrient sensing with respect to glucose and cortisol metabolism is now a major focus 
of research activity. 
Clinical studies comparing glucose and glucocorticoid metabolism in normal, obese 
and type 2 diabetic subjects revealed new data with relevance to the importance of 
lean body mass and insulin sensitivity and a strong association with HPA axis 
function and hepatic 11β-HSD1 activity. In addition the association of hepatic lipid 
accumulation with suppression of hepatic 11β-HSD1 and stimulation of 5α-reductases 
in insulin resistant states without any clinical suggestion of hepatic steatosis was 
confirmed, strongly endorsing the findings of the NAFLD study. 
Collectively, the data presented in this thesis provide support for the role of selective 
11β-HSD1 inhibition for the treatment of insulin resistant states and type 2 diabetes. 
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However, important questions arise with regard to the use of these agents in the 
presence of inflammatory liver disease, in particular non alcoholic steatohepatitis, 
where increased hepatic glucocorticoid activation, and decreased glucocorticoid 
clearance serve as a protective response to limit worsening hepatic inflammation and 
injury.  In addition the predicted impact of these inhibitors upon hepatic glycolysis 
and skeletal muscle insulin resistance warrants further investigation. 
In addition to the above, this work has led to the possibility of a number of future 
studies. It would be of great importance to fully define the physiological role of the 
perivenous distribution of hepatic 11β-HSD1 and its relevance upon glycolytic 
pathways and the resulting impact upon whole body and in particular skeletal muscle 
insulin sensitivity. An initial study would include the comparison of the activity and 
expression of key glycolytic enzymes in normal and 11β-HSD1 knockout mice. 
It would be of significant interest to characterise hepatic zonation of 11β-HSD1 in 
progressive stages of NAFLD, as well as other chronic liver diseases (such as 
alcoholic liver disease and chronic hepatitis C) that are strongly associated with 
insulin resistance and histologically bear close resemblance with NAFLD.  This 
would be allied with studies to define the localisation of 11β-HSD1 within 
inflammatory cells in hepatitis and the factors involved in the activation of this 
process.  In normal liver it would be of interest carry out in vitro studies to investigate 
the presence of 11β-HSD1 in hepatic stellate cells, and its possible role in stellate cell 
activation.  
In addition, clinical studies to define hepatic glucocorticoid metabolism in vivo, in 
progressive stages of NAFLD would be important.  Animal models of NAFLD would 
be a useful tool to explore the role of selective 11β-HSD1 inhibition in progressive 
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stages of the disease.  On the basis of the results of the NAFLD study, a novel role for 
selective 5α-reductase inhibition would be as a therapy specifically for steatohepatitis 
and other forms of chronic hepatitis. Its aim would be to reduce hepatic glucocorticoid 
clearance, and hence maximise endogenous hepatic glucocorticoid to limit 
inflammation.  Its role if proven would be very significant in its ability to exert a 
tissue specific increase in hepatic glucocorticoid without the multiple undesirable 
effects of systemic glucocorticoid therapy. 
Further clinical studies in type 2 diabetes are warranted to examine hepatic and whole 
body glucocorticoid metabolism in progressive disease.  This study and many others 
previously reported specifically chose diet controlled diabetics or those with early 
disease. It would be important to extend these investigations to diabetic subjects with 
increased states of insulin resistance and type 2 diabetics with evidence of beta cell 
failure.  Technically these studies would be more challenging but would provide 
important information of the detrimental or beneficial effect of 11β-HSD1 driven 
glucocorticoid activation and hepatic glucocorticoid clearance by A-ring reductases. 
Results from the stable isotope studies quantifying gluconeogenesis in normal and 
diseased states, and its relationship with hepatic and whole body glucocorticoid 
metabolism carried out as part of the work for this thesis will provide key results in 
this area.  
The studies defining glucose 6 phosphate as a novel regulator of 11β-HSD1 driven 
glucocorticoid activation lead to many important further studies, many of which have 
already led to early findings being published by other investigators.  These would 
include a detailed definition of the role H6PDH and 11β-HSD1 in ER redox and ER 
nutrient sensing.  Further investigation of glycogen storage diseases type 1a and 1b 
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may implicate 11β-HSD1 in the pathogenesis of a number of unexplained 
complications of these diseases.  In particular the role of excess glucocorticoid 
activation in bone as a contributing cause of osteoporosis in GSD1a, and the absence 
of 11β-HSD1driven local glucocorticoid production in bowel in GSD 1b patients who 
have a specific propensity to develop inflammatory bowel disease.  It would also be 
of interest to investigate the role of the hepatic glucocorticoid excess seen in GSD 
type 1a in the significant hepatic lipid accumulation that occurs in the disease. 
The results described in this thesis form key data with clear clinical importance and 
relevance in the application of 11β-HSD1 inhibition.  Further studies will follow that 
will provide a greater depth of understanding and offer new possibilities for the 
treatment of patients with the metabolic syndrome, a serious global public health 
concern.  
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Novel Targets in the Metabolic Syndrome:   e Role of 11βHSD Type 1 and H6PDH
Information for Study Participants
Investigators : Professor PAUL M STEWART, Consultant Physician and Professor of Medicine and Endocrinology, University of Birmingham                                       
Dr ADEEBA AHMED, Clinical Research Fellow, University of Birmingham
Thank you for taking the time to read this leafl et. We would like to invite you to be part of this study. If 
there is any further information that you would like then 
please don’t hesitate to contact us.
What is the study about?
 e link between obesity and sugar diabetes is well 
established and is recognised as an increasingly common 
health hazard. We have come up with a mechanism 
that might explain this link – an enzyme (11βHSD1) 
present in liver and fat that can generate a hormone 
called cortisol that directly predisposes to obesity and 
diabetes.  is study will address the role of this enzyme 
and additional regulating enzymes specifi cally in the liver 
and their contribution to the development and progression 
of diabetes.  Additional clinical studies will use novel 
methods to measure the release of sugar from the liver in 
patients with obesity, sugar diabetes and fatty liver and to 
compare this with normal volunteers. It will provide the 
key research basis for the development of a new treatment 
for obesity-related diabetes – ‘11βHSD1 inhibitors’.  is 
would potentially have a huge impact in the management 
of diabetes and in particular delay or prevent the 
progression to treatment with insulin.
What will I have to do?
 e study involves two periods of investigations.  e 
fi rst visit involves tests carried out over the course of one 
and a half days (involving an overnight stay), and a second 
visit from 9am to 1pm.  e 2 periods of investigations will 
usually be separated by about a week, but can be suited to 
your convenience.
On the fi rst day of the study, having arrived fasting from 
midnight the previous night, the fi rst investigation  will 
be commenced - a Glucose Tolerance Test.  is test will 
tell us how well your body handles sugar and whether you 
have diabetes.  It involves 3 blood samples taken from the 
cannula ( a tiny plastic tube, which allows blood samples 
to be drawn without the need to use further needles for 
each sample) inserted into a vein in one of your arms – one 
while you are fasting, and two over the course of the next 
hour after having a sugary drink.  After this test you may 
eat and drink normally.   e same cannula will be used to 
take all the blood samples for the day.
 is will be followed by a DEXA scan and CT scan of 
a small region of the abdomen.  ese scans are to help us 
calculate your total amount of body fat and the amount 
of fat in and around your liver.    ese investigations are 
painless and should be complete before 5pm.
At 6pm you will be given a ‘standardised’ meal – where 
we will exactly calculate the amount of carbohydrate, 
fat and protein according to your body weight.  After 
this meal you will be fasting till 4pm (at the very latest) 
the following day – but can drink as  much water as you 
wish.  e fast may end sooner pending the results of our 
preliminary investigations.  e water you will drink will 
contain a ‘marker’ so we can trace the passage of sugar 
and water in your liver.  At 11pm, 2 blood samples will 
be taken from the cannula in your arm.  At 6am the next 
morning, a small cannula will be inserted in back of the 
hand or lower forearm of the other arm, and your hand 
will be placed in a box which will keep it warmer then 
body temperature.  Hourly blood samples will be taken 
from this cannula while a sugar solution is pumped at a 
very slow rate through the cannula in your free arm.  is 
investigation will tell us exactly how your liver handles 
sugar and how much sugar it produces on its own while 
you are fasting.  You may eat and drink normally after the 
test is completed.
Immediately prior to the second part of the study we ask 
you to complete a 24-hour urine collection (alternatively 
this can be done while you are in hospital during the fi rst 
visit), and we will also give you a small dose of a steroid 
tablet that you will have to take at 11pm the evening 
before you attend for the second part of the study. On the 
fi rst morning of the second part of the study we give you 
2 further doses of the steroid tablet. Over the next 4 hours 
we take regular blood samples every 20 minutes from a 
cannula inserted into one of the veins in your arm.  is 
test will tell us how well you activate this steroid in the 
liver. All the doses of steroid used in this study are small 
and have a short duration of action; within 12 hours they 
are completely out of the system. Using these doses there 
are no short or long term side eff ects
With your permission we will inform your GP that you 
are taking part in this study. If we detect any abnormality 
during the study we will inform you straight away and 
refer you to your GP for further treatment.
We will off er fi nancial reimbursement to cover travel 
expenses and inconvenience as we appreciate that this 
study requires a great deal of your time during the 2 
periods of investigation.
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What are the benefi ts?
 is study will help us  to determine how well the body 
and in particular the liver is able to handle sugar and relate 
this to measures of activity of the two enzymes we are 
studying ( 11 beta hydroxysteroid dehydrogenase type 1 
and hexose 6 phosphate dehydrogenase) .   You will receive 
valuable information about your body fat distribution and 
sugar metabolism.  You will also receive valuable lifestyle 
advice, and if you are overweight you will receive advice 
with regards to the lifestyle changes that will aid healthy 
and long term weight loss.
 is is an important study that will tell us the crucial 
details of steroid metabolism. It will also serve as the 
platform and scientifi c basis for the mechanism of 
action and eff ectiveness of drugs that are currently in 
development.  ese drugs are likely to be used in the 
treatment of conditions including diabetes and obesity.
What are the risks?
 e DEXA and CT scans involve the use of X rays.   e 
amount of radiation received is similar to the ‘background 
radiation’ you would normally receive from the atmosphere 
over about 6-8 weeks.   ere are no other signifi cant risks 
associated with taking part in this study.
What if I do not want to take part?
If having read this leafl et you feel you do not want to take 
part then you need take no further action. Importantly 
this will not aff ect your future medical care in any way.
What happens to the information?
All the information is entirely confi dential.  e only 
people who have access to the information are those who 
are directly involved with the study. With your permission 
we would like to inform your GP that you are taking part 
in this study.
Who else is taking part?
We are aiming to recruit 20  volunteers from diff erent 
groups between the ages of 20 and 65. 
Group 1:  20 healthy volunteers (10 males, 10 females), 
non  diabetic, non obese.
Group 2: 20 volunteers with simple obesity (10 male,10 
females).  
Group 3: 20 volunteers (10 male, 10  females) matched for 
body mass index with group 2, with type 2 diabetes (diet 
controlled or on low dose metformin only). 
Group 4: In collaboration with the regional liver unit, 20 
patients admitted for investigation of ‘fatty liver’ with and 
without a history of alcohol ingestion will be studied. 
Group 5: A small number of known patients with 
‘Cortisone Reductase Defi ciency’.
Unfortunately, if you have a history of epilepsy, poorly 
controlled high blood pressure, steroid treatment, stroke, 
or if you are taking the oral contraceptive pill you will not 
be able to take part. In addition, if you are pregnant or 
planning pregnancy you will not be allowed to take part. 
What if something goes wrong?
It is most unlikely that anything will go wrong. We will 
provide you with names and numbers of people who you 
will be able to contact in the unlikely event that anything 
does go wrong.
What happens at the end of the study?
At the end of the study the results will be published in 
medical journals
What if I have more questions or do not          
understand something?
If you do have any further questions or concerns then feel 
free to contact us (see below).
What happens now if I decide to take part?
If you have decided that you would like to take part then 
we will make an appointment for you to come up to our 
research facility where you will need to sign a consent 
form and we can then begin the study.
What happens if I change my mind during the study?
You are free to leave the study at any point for any reason. 
You do not have to tell us why you wish to leave the study 
and importantly it will not aff ect your future medical care 
in any way. 
Contact name and number:
Dr. Adeeba Ahmed, Division of Medical Sciences, 
Institute of Biomedical Research, Queen Elizabeth 
Hospital, Birmingham. B15 2TT. 
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If you would like to be part of this study or if you would like more information then please return this slip in 
the envelope provided or contact Dr Adeeba Ahmed at the email address / telephone number above.
Name ……………………………………………Signature………………………Date……………...
I would like / I would not like [delete as applicable] to be part of the study entitled ‘11β-hydroxysteroid dehydrogenase 
type 1 and Hexose 6 Phosphate Dehydrogenase in the metabolic syndrome’
Address…………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
………………….………………………………………………………………………………………………………………
………………
Daytime Tel. ……………………………………………..Fax. ……………..…………………………..
E-mail………………………………….
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Flow sheet 
 
Visit 1 (overnight stay)       date__________ 
 
Glucose Tolerance Test       Sign 
 
 Dr Ahmed to clerk patient and consent for trial and obtain 
physical examination 
 
 Obtain prescription for, IV labelled glucose, deuterated water, 
(both supplied by Dr Ahmed) heparinised saline 
(dexamethasone, cortisone acetate on out patient prescription 
for visit 2)  and sign dexa form and CT scan form 
 
 Check patient has fasted overnight 
 Order lunch (patient choice) 
 Phone kitchen and ask for Linda McCartney vegetarian lasagne 
from the 24 hour fridge as arranged for dinner 
 
 Complete page 1 and 2 of CRF including  
 BP, pulse, temp and oxygen saturations  
 height, weight and BMI  
 hip and waist measurements  
 Allergies, medical conditions, family history of diabetes 
 medications 
 
 Cannulate and take baseline bloods 1, 2a 6 and 7 (4 purple, 2 
yellow, 1 grey,2 red) 
 
 Give 75g oral glucose   
 Take bloods 2a + 7 (1 grey, 1 red) at 30, 60, 90 and 120 minutes 
post glucose 
 
30 mins time =   
60 mins time =  
90 mins time =  
120 mins time =  
 Feed patient.  DO NOT REMOVE CANNULA, PLEASE 
FLUSH WITH HEPARINISED SALINE 
 
 Patient to have dexa scan in the morning and CT scan if possible  
 Whilst patient is having dexa scan please measure saggital 
height and record on CRF.  This is done once pt is lying flat on 
dexa table by placing spirit level (in box file) on pts stomach and 
measuring the distance from the  table to the spirit level 
 
 Send letter to GP (from study file on computer, adding pt 
details) 
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Deuterated Water Test 
 
 
 17.00 – 17.40 give patient standardised meal.  FAST FROM END OF 
MEAL EXCEPT WATER UNTIL END OF TEST APPROX 22 
HOURS! 
 
 23.00 Baseline 1  
 take bloods 2b, 4, 5 (1 grey, 2 purple, 4 large purple) 
 
 23.00 give deuterated water, all water ingested from this time must 
contain the deuterated additive 
 
 05.40 Cannula inserted into hand which is then placed into hot box 
at 60ºC and left for 20 minutes prior to blood sampling so the 
sample is an arterial sample taken at 06.00 
 
 06.00 Baseline 2  
  2b, 4, (1 grey, 2 purple) 
 
 Cannula to anticubital fossa to be used for IV infusion of 5% glucose 
containing tracer.  To run for 10 hours, start at 06.00 
 
 5 minutes from start of infusion give loading bolus over 30 seconds  
 Time infusion started =   
After 2 hours take hourly bloods from time infusion started 
Remember to put patients’ hand back into the hot box for 20 minutes prior 
to taking blood sample 
 
+ 2 hour time =                 bloods 2b, 3 5 (1 grey, 1 purple, 4 large purple)  
+ 3 hours time =                bloods 2b, 3  (1 grey, 1 purple)  
+ 4 hours time =                bloods 2b, 3   (1 grey, 1 purple)  
+ 5 hours time =                bloods 2b,3   (1 grey, 1 purple)  
+ 6 hours time =                bloods 2b, 3, 5 (1 grey, 1 purple, 4 large purple)  
+ 7 hours time =                bloods 2b, 3   (1 grey, 1 purple)  
+ 8 hours time =                bloods 2b, 3   (1 grey, 1 purple)  
+ 9 hours time =                bloods 2b, 3   (1 grey, 1 purple)  
+ 10 hours time =              bloods 2b, 3, 5 (1 grey, 1 purple, 4 large purple)  
 Stop infusion, remove cannulas, feed patient  
 Give patient TTO for dexamethasone for visit 2  
 Issue patient with plain 24 hour urine bottle to bring back at visit 2  
 Arrange for visit two for within one weeks time if possible at 09.00  
 
 
  Visit 2 Date _____________ 
 
Cortisol Generation Profile 
 
 Make sure patient has taken 1 mg of dexamethasone at 23.00 the 
previous night and 0.5 mg at 09.00 this morning 
 
 Collect urine save and decant as protocol  
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 Patient may have CT scan today if it was not possible at first 
admission 
 
 Check patient fasted from 23.00 the previous night  
 08.30insert cannula into anticubital fossa vein  
 Take baseline bloods 6 (1 red top)  
 09.00 (1 hour after administration of dexamethasone, 25mg of 
cortisone acetate is administered orally) 
 
 Bloods 6 (1 red top) to be obtained after the following times  
20 minutes time =   
40 minutes time =  
60 minutes time =  
80 minutes time =  
100 minutes time =  
120 minutes time =  
140 minutes time =  
180 minutes time =  
240 minutes time =  
 Patient to be given food and drink  
 Remove cannula and discharge  
 Patient given £40 expenses from Dr Ahmed on completion and 
asked to sign receipt form 
 
 
 
This flow sheet accurately represents the study protocol 
 
Signed (research fellow) ______________________ Date____________________ 
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Processing of Samples 
 
Bloods 1 
 
Test Bottle Instructions Distribution 
U & Es, 
LFTs, 
cholesterols 
GGT  
2 yellow tops On biochemistry form tick 
renal, liver, bone, write on 
total chol, HDL, Trigs, 
ALT,GGT and tick fasting 
Send to biochemistry 
FBC 1 purple top On haematology form tick 
FBC 
Send to haematology 
ACTH 1 purple top 
on ice 
Spin within 20 minutes for 
3000 rpm for 10 minutes at 
4ºC 
Aliquot into as many  
microcentrifuge tubes as possible 
Label with study no, subject no, 
date and ACTH, store in -80ºC 
Genotyping 2 purple tops Do not spin Store 2 purple tops in -80ºC 
freezer, label with study no, 
subject no, date and DNA 
 
 
Bloods 2a 
 
Test Bottle Instructions Distribution 
glucose 1 grey top On biochemistry form tick 
glucose and write on GTT   
Add either 0, +30, +60 ,+90 or  
+120 to grey tops 
Send to biochemistry in 1 
form 
 
 
Bloods 2b 
 
Test Bottle Instructions Distribution 
glucose 1 grey 
top 
On biochemistry form tick glucose and 
write on ‘deuterated water test’   
Add date and time from infusion to 
grey tops i.e. baseline1, baseline 2, + 2 
+3 +4 etc 
Send to biochemistry in 1 
form 
 
 
Bloods 3  
 
Test Bottle Instructions Distribution 
Total 
glucose 
production 
1 
purple 
top 
Spin  2200 
rpm for 10 
mins at 4ºC 
Aliquot 500ul in 0518 glass bottle and 250ul in another 
0518 glass bottle  
Label as study no, subject no, date, time from start of 
infusion (i.e. 1 hour, 2 hr etc) + glucose 
Aliquot another 250ul into glass bottle and label as above 
but with FFA 
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Bloods 4 
 
Test Bottle Instructions Distribution 
Total 
glucose 
production 
2 
purple 
tops 
Spin  2200 
rpm for 10 
mins at 4ºC 
Aliquot 500ul in 2 0518 glass bottles and 250ul in 
another 2 0518 glass bottles 
Label as study no, subject no, date, baseline 1 (23.00) or 
baseline 2 (06.00) and glucose 
Aliquot another 250ul into glass bottle and label as above 
but with FFA 
 
 
Bloods 5 
    
Test Bottle Instructions Distribution 
Plasma 4 large purple 
tops (supplied 
by Dr Ahmed) 
Spin  2200 rpm 
for 10 mins at 
4ºC 
Aliquot plasma between large 0518 glass 
bottles 
Label as study no, subject no, date, time from 
start of infusion (i.e. baseline 1(23.00)  + 1 
hour, 6 hr or + 10 hr) + plasma 
 
 
Bloods 6 
 
Test Bottle Instructions Distribution 
Cortisol 
and 
cortisone 
1 red top Clot at room temp for 
30 minutes before 
spinning 
Spin at 3000 rpm for 
10 minutes at 4ºC 
Divide between microcentrifuge tubes 
Label as study no, subject no, date time (i.e. 
0, 20, 40 etc) and cortisone 
 
Bloods 7 
 
Test Bottle Instructions Distribution 
Insulin 1 red top Place in fridge for 30 
minutes before 
spinning 
Spin at 3000 rpm for 
10 minutes at 4ºC 
Divide between microcentrifuge tubes 
Label as study no, subject no, date time (i.e. 
0, 30,60,90,120) and insulin 
 
 
24 hour urine collection – use plain bottle 
 
Instructions  Storage 
Measure total volume and decant into 3 
20ml universal containers 
 
Label with study no, subject no, date, 
Total Volume and freeze at -80ºC 
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Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in 
patients with alcoholic liver disease 
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11 β Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular 
Glucose 6-Phosphate Provides Evidence for a Novel Link between 
Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function 
The Journal of Biological Chemistry Vol. 282, No. 37, pp. 27030–27036, 
September 14, 2007 
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